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Since the identification of a widespread transcriptional dysregulation that occurs in 
Huntington's disease (HD), histone deacetylase (HDAC) inhibition has been explored 
as a possible therapeutic strategy for this devastating disease. Studies using broad-
range acting HDAC inhibitors have shown great promise in HD mouse models. 
Concomitantly, effects of inhibition of individual HDACs have been investigated, 
however, these experiments have been most frequently performed in worm, fly, 
and cell and less so in mouse models of HD. Previous reports have demonstrated 
disease modifying potential for both HDAC6 and SIRT2, which are the only tubulin 
deacetylases known in mammals. Nevertheless, the therapeutic value of these 
enzymes has not yet been explored in a complex mammalian system. This work 
addressed the question of what is the effect of genetically depleting either HDAC6 
or SIRT2 in the R6/2 mouse model of HD on disease progression. After thorough 
characterisation of both Hdac6KO and Sirt2KO mice and expression of either 
mutation in the R6/2 mouse, a battery of physiological, behavioural and molecular 
readouts has clearly demonstrated that previous studies performed in invertebrate 
or cell culture systems do not translate to the mouse and that, therefore, HDAC6 
and SIRT2 inhibition would not be of therapeutic value and should not be prioritised 
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1.1. Huntington’s Disease 
Huntington’s Disease (HD) is a devastating, autosomal dominant, 
neurodegenerative disorder. In North America and Western Europe approximately 
5-10 people in 100,000 are affected (Warby et al., 2011). The mean age of HD onset 
is between 35 and 50 years, however, juvenile HD cases where symptoms develop 
before the age of 20 are also known to occur (Walker, 2007). HD symptoms 
progress for 15-20 years before death, though juvenile HD patients usually have a 
more rapid disease progression that is characterised by bradykinesia rather than 
the typical chorea observed in adult onset HD (Bates et al., 2002; Walker, 2007). 
Other commonly observed HD symptoms include rapid weight loss, dementia, 
depression, and cognitive impairment in reasoning, judgement and memory (Novak 
and Tabrizi, 2010). Therapeutics available to HD patients are directed against 
primary symptoms like chorea or depression, however, those approaches do not 




At the molecular level HD is caused by the expansion of a CAG tri-nucleotide repeat 
within exon 1 of the huntingtin gene (HTT) (The Huntington's Disease Collaborative 
Research Group, 1993). Normally, the number of CAG repeats ranges from 6 to 35, 
however, people who carry 36-39 repeats are at risk of developing HD (Novak and 
Tabrizi, 2010). Individuals that carry over 39 repeats will develop HD while those 
with over 60 repeats will most likely develop juvenile HD (Bates et al., 2002). An 
inverse correlation explaining 40-50% variance exists between the age of onset and 
CAG repeat length, however, other genetic and environmental factors that 
influence disease age of onset are currently under investigation (Andrew et al., 
1993; Walker, 2007).  
Chapter 1  Introduction 
22 
 
HD is primarily a disease of the central nervous system (CNS) as evidenced by the 
fact that HD patients lose as much as 40% of brain volume compared to non-HD 
individuals (Bates et al., 2002; Vonsattel et al., 1985). Perhaps the most striking 
change that takes place in HD is the progressive atrophy of the cerebral cortex and 
the basal ganglia (Fig. 1.1) (Novak and Tabrizi, 2010; Rosas et al., 2003; Vonsattel et 
al., 1985). In particular, the caudate nucleus and putamen show dramatic 
morphological changes, though other regions such as the globulus pallidus, 
subthalamic nucleus, thalamus, hypothalamus, substantia nigra, white matter and 
cerebellum are also affected (Politis et al., 2008; Vonsattel and DiFiglia, 1998). It has 
been reported that atrophy occurs before symptom onset suggesting that the CNS 
is able to cope with some degree of neuronal damage before any behavioural 
changes manifest (Rosas et al., 2005). 
Outside the CNS, two hallmarks of HD are progressive weight loss and skeletal 
muscle wasting (Farrer and Meaney, 1985; Sanberg et al., 1981). Impaired glucose 
tolerance and insulin secretion capacity have also been observed in patients, as well 
as reduced levels of testosterone, reduced numbers of germ cells and abnormal 
seminiferous tubule morphology in men (Bacos et al., 2008; Lalic et al., 2008; 
Markianos et al., 2005; Van Raamsdonk et al., 2007). About 30% of HD patients 
suffer from cardiac failure compared with 2% in age matched unaffected individuals 
making it the leading cause of death in HD (Lanska et al., 1988). Though the 
mechanisms of how these peripheral symptoms arise have not yet been elucidated, 
there is reason to believe they are not a secondary effect of brain pathology (Saleh 
et al., 2009). 




Figure 1.1. Brain atrophy in HD patients.  
Comparison of coronal sections of brains from an end stage disease HD and 
unaffected individual. Note the pronounced atrophy of the cortex, caudate (Cd), 
and putamen (Put), enlargement of ventricles (Vt) and white matter loss. 
Reproduced from (Bates et al., 2002), with permission of Oxford University Press. 
 
1.1.2. Huntingtin 
The Huntingtin gene spans approximately 170 kb, contains 67 exons, and is 
translated into a 348 kDa protein. The CAG stretch located in exon 1 is translated 
into a polyglutamine (polyQ) tract starting at the 18th amino acid and is followed by 
a polyproline stretch that possibly stabilizes the PolyQ tract and maintains its 
solubility (Steffan et al., 2004). Although huntingtin (HTT) has no sequence 
homology to any other protein, it does possess four clusters of functional domains 
called HEAT repeats (from Huntingtin, Elongation factor 3 (EF3), the regulatory A 
subunit of protein phosphatase 2A (PP2A) and Target of rapamycin 1 (TOR1)) that 
are involved in protein-protein interactions (Fig. 1.2) (Andrade and Bork, 1995).  
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1.1.2.1. Post-translational modifications of Huntingtin 
It comes as no surprise that a protein as big as HTT contains multiple post-
translational modification (PTM) sites, which affect localisation, longevity or toxicity 
of HTT (Fig. 1.2). For example, there are three lysine (K) residues at the amino(N)-
terminus (K6, K9 and K15) that can be either ubiquitinated (promoting HTT 
degradation) or sumoylated (resulting in HTT nuclear localisation) (Steffan et al., 
2004). Phosphorylation of HTT occurs at one threonine (T3) and several serine (S13, 
S16, S421, S434, S536, S1181, S1201, S2076, S2653 and S2657) residues and its 
outcome can have variable effects depending on the residue in question, ranging 
from protection from proteolytic cleavage (S421, S434, S536) (Luo et al., 2005; 
Schilling et al., 2006; Warby et al., 2009) through proteasomal targeting (S13 and 
S16)(Thompson et al., 2009) to modulation of vesicle transport (S421) (Zala et al., 
2008). Acetylation sites have been identified at K9, K178, K236, K345 and K444 
(Cong et al., 2011), and it has been demonstrated that acetylation at K444 
promotes targeting of HTT for degradation by autophagy (Jeong et al., 2009). HTT is 
also palmitoylated at cysteine 214 which is in line with its proposed role in vesicle 
trafficking (Yanai et al., 2006). Additionally, HTT can be cleaved by calpains, 
cathepsins, and caspases -2, -3, and -6 and possibly by other proteases such as 
MMP-10; generating a panel of shorter HTT fragments (Miller et al., 2010). When 
generated, these fragments can be more toxic than the full length mHTT protein 
(Graham et al., 2006; Lunkes et al., 2002). As occurrence of these modifications 
varies between mutant and wild type forms of HTT, strategies that block or 
enhance their generation are currently under investigation as possible therapeutics 
for HD.   




Figure 1.2. Huntingtin post translational modifications.  
Huntingtin can become phosphorylated, ubiquitinated, sumoylated, acetylated and 
palmitoylated, as well as cleaved by proteases. The effect of these modifications on 
mHTT toxicity and disease pathology is currently being investigated. Modified from 
(Ehrnhoefer et al., 2011) with permission of SAGE Publications. 
 
1.1.2.2. Huntingtin expression and function 
Expression of HTT is ubiquitous in both humans and rodents, though its levels are 
highest in neurons of the CNS (Li et al., 1993). Inside the cell, HTT can be found in 
the cytoplasm, often associated with microtubules, the Golgi, the endoplasmic 
reticulum (ER), and mitochondria (Bhide et al., 1996; Hilditch-Maguire et al., 2000; 
Panov et al., 2002). HTT can also be found on the membranes of both synaptic and 
clathrin coated vesicles of the endocytic or secretory pathways (Velier et al., 1998). 
Although controversial, HTT has also been reported to localise to some neuronal 
nuclei and nuclear membranes (Hoogeveen et al., 1993; Kegel et al., 2002).  
While the exact function of the HTT protein is not clear, it is known that HTT is 
essential for embryonic development and neurogenesis, as demonstrated by knock-
out and knock-down of the Hdh (Huntington’s Disease Homologue) gene in mice 
(Duyao et al., 1995; Nasir et al., 1995; White et al., 1997; Zeitlin et al., 1995). In 
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addition, HTT is anti-apoptotic and protects neurons against excitotoxicity and 
ischemic injury in adult mouse brains (Leavitt et al., 2006; Rigamonti et al., 2000; 
Zhang et al., 2003). Furthermore, HTT has been shown to play an important role in 
regulating neuronal function (Dragatsis et al., 2000). This is achieved by regulating 
the transcription of neuronal genes via cytoplasmic sequestration of REST/NRSF 
(Repressor Element 1 Silencing Transcription Factor/Neuronal Restrictive Silencing 
Factor), and by controlling synaptic transmission and vesicular transport along 
axons (Gauthier et al., 2004; Zuccato et al., 2003). 
Although there are indications that loss of function of wild type HTT contributes to 
disease progression our current understanding indicates that the pathology 
observed in HD is a result of a toxic gain of function by mHTT. In order to 
understand the mechanisms behind HD pathology, numerous models of HD have 
been created. 
 
1.1.3. HD models 
Since the identification of the HD causing mutation, numerous models have been 
created to study the disease. Though worm, fly and cell culture models are helpful 
in studying the most basic mechanisms of HD pathogenesis or for screening 
potential therapeutic compounds, their similarity to the human disease is limited. 
Placing the mutation in the context of a mammalian organism is essential for 
proper investigation of the complex disease mechanisms and validation of 
therapeutic strategies. As such, HD is most commonly modelled in mice, though rat, 
pig, sheep and monkey models are also used (Crook and Housman, 2011; Jacobsen 
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1.1.3.1. Mouse models of HD 
Mouse models of HD can loosely be divided into 3 categories: transgenic fragment 
models, transgenic full length models and genetically precise – “knock-in” models. 
The most commonly used representatives of each group are summarised in Table 
1.1. 
 
1.1.3.2. Transgenic fragment models 
The first generated and most commonly used mouse model of HD is the R6/2 
mouse (Mangiarini et al., 1996). R6/2 mice express a single copy of the first exon of 
HTT under the control of the human HTT promoter that generates a HTT 
transprotein with 150 – 200 polyQ repeats. These mice develop behavioural 
abnormalities such as rotarod and grip strength impairments, hypo-activity and 
deficiencies in learning and memory tasks by 8 weeks of age (Carter et al., 1999; 
Lione et al., 1999). A concomitant loss of body and brain weight, as well as atrophy 
of the skeletal muscle and testis is also evident (Mangiarini et al., 1996). R6/2 mice 
also develop cytoplasmic aggregates and nuclear inclusions in the brain and 
periphery before symptom onset (Davies et al., 1997; Sathasivam et al., 1999). 
Although disease progression is very quick and R6/2 mice do not survive for longer 
than 15 weeks (at King's College London colony), motor impairment and weight loss 
as well as muscle atrophy and changes to the hypothalamic-endocrine system 
suggest that the sequence of pathogenic events in these mice is very similar to that 
seen in humans (Bjorkqvist et al., 2005; Sanberg et al., 1981; Sathasivam et al., 
1999). 
In addition to R6/2, another commonly used transgenic fragment model is the N171 
mouse, which expresses the first 171 amino acids of HTT with 82Q under the 
control of the mouse prion promoter (Schilling et al., 1999). These mice develop 
similar behavioural and physiological abnormalities to R6/2, although onset and 
disease progression is less aggressive than in R6/2 mice. Weight loss begins around 
2-3 months of age, rotarod impairment is evident from 4 months onwards and 
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disease end point occurs at 6 months of age (Schilling et al., 1999). Cytoplasmic and 
nuclear inclusions are also formed in N171 mice, however, their distribution 
between brain regions differs from that observed in HD patients and R6/2 mice 
(Schilling et al., 1999). This may be due to the fact that HTT transprotein expression 
in N171 mice is under the control of the prion promoter. 
 
1.1.3.3. Transgenic full length models 
The two most commonly used full length HD mouse models are the YAC (Yeast 
Artificial Chromosome) and BAC (Bacterial Artificial Chromosome) HD mice. Both 
express full length human HTT under the control of its own promoter. YAC mice are 
available with a polyQ length of 18, 46, 72 and 128 (Hodgson et al., 1999; Slow et 
al., 2003), and BACHD mice carry 97Q (Gray et al., 2008). In contrast to fragment 
models, transgenic full length HD mice display a slower disease progression with a 
normal life span and even exhibit an increase in body weight (Gray et al., 2008; Van 
Raamsdonk et al., 2005b). However, both YAC128 and BACHD mice develop motor 
impairment, activity abnormalities and cognitive deficiencies (Gray et al., 2008; Van 
Raamsdonk et al., 2005b). Equally, both models also suffer from a decrease in brain 
weight, and cortical and striatal degeneration are evident at 12 months of age (Gray 
et al., 2008; Slow et al., 2003; Van Raamsdonk et al., 2005a).  
Perhaps the greatest difference between fragment and full length transgenic 
models is in the formation of mHTT aggregates. Large mHTT inclusions are only 
detected in BAC and YAC mice at 12 months of age, after the appearance of motor 
symptoms (Gray et al., 2008; Hodgson et al., 1999; Wang et al., 2008a). Equally, 
large intranuclear and cytoplasmic inclusions are less abundant and a diffuse HTT 
specific signal and "micro-aggregates" are more commonly found in brain tissue of 
these full length transgenic mice (Gray et al., 2008; Hodgson et al., 1999; Slow et al., 
2003). While full length transgenic mice are useful for studying the mechanisms of 
HD progression in the context of full length mHTT, they are still not genetically 
precise and can therefore be limiting in modelling HD. 




Table 1.1. Summary of most commonly used HD mouse models. 
Model Genetic basis Promoter Repeat length 
R6/2 Human HTT exon 1 Human HTT 200* 
N171 Human HTT exons 1, 2 and part of 3 
(first 171 amino acids) 
Prion promoter 82 
BACHD Human HTT Human HTT 97 
YAC72 Human HTT Human HTT 72 
YAC128 Human HTT Human HTT 128 
HdhQ111 Mouse HTT homologue (Hdh); chimeric 





CAG140 Mouse HTT homologue (Hdh); chimeric 
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1.1.3.4. "Knock in" HD mice 
The most genetically precise HD models are the “knock in” mice, where the 
endogenous mouse HD gene (Hdh) has been modified to contain an expanded CAG 
repeat number. Most commonly used are the HdhQ111, CAG140 and HdhQ150 mice, 
which carry 111, 140 and 150 CAG repeats respectively (Lin et al., 2001; Menalled et 
al., 2003; Wheeler et al., 1999). Similarly to transgenic full length mice, knock-in 
mice exhibit slow disease progression. However, certain behaviours such as activity 
and rearing can be altered as early as 1 month of age in the CAG140 mice, though 
these mice do not display any overt symptoms such as weight loss, tremor or 
clasping by 1 year of age (Menalled et al., 2003).  HdhQ150 mice do not display 
physiological abnormalities until 12 months of age with rotarod impairment only 
becoming pronounced by 18 months of age (Woodman et al., 2007). Nevertheless, 
these mice form cytoplasmic and nuclear aggregates by 6 months of age and by 21-
22 months their pattern of aggregation in both the CNS and peripheral tissues is 
extremely similar to that of R6/2 mice at 12 weeks of age (Moffitt et al., 2009). At 
the same time, there are numerous molecular abnormalities that correlate well 
between HdhQ150, R6/2 and HD patients; an observation which suggests a possible 
common pathogenic mechanism (Hodges et al., 2006; Kuhn et al., 2007; Labbadia et 
al., 2011; Landles et al., 2010; Sathasivam et al., 2010). Aggregation is also a feature 
of disease in the HdhQ111 and CAG140 mice, where diffuse nuclear staining can be 
observed by 1-2 months of age, and nuclear inclusions appear by 6 (CAG140) and 
10 months of age (HdhQ111) (Menalled et al., 2003; Wheeler et al., 2000).  
The validity and usefulness of HD models has been debated in the context of 
genetic precision, similarity of symptoms between models and patients, and 
molecular pathology (Fig 1.3). The rapid disease progression of R6/2 mice allows for 
efficient compound screening, but the full length or knock in models, with longer 
“pre-manifest” stage could be more useful for elucidation of subtle molecular 
changes that occur before symptom onset in an adult organism. Also, some 
molecular events and their role in HD pathology such as proteolytic cleavage cannot 
be examined without the context of the full length mutant protein. On the other 
hand, if toxicity is caused by N-terminal fragments, there is no reason why fragment 
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models should not be used to study the sequence of pathological events and 
applicability of therapeutic strategies downstream of HTT cleavage.  
 
 
Figure 1.3. Timeline of pathological events in mouse models of HD.  
Transgenic fragment (R6/2 and N171) models develop motor dysfunction and 
molecular pathologies earlier than transgenic full length (BACHD, YAC72 and 
YAC128) and “knock-in” (HdhQ111, CAG140 and HdhQ150) mice. Modified from 
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1.1.4. Molecular pathogenesis of HD 
The events and mechanisms that lead to HD pathology and symptoms have mostly 
been attributed to a toxic gain of function conferred to mHTT by the expanded 
polyQ tract. However, several lines of research have also pointed to a contributory 
effect of a loss of function of HTT through the presence of the HD mutation. The 
toxic gain of function scenario is supported by the fact that similar symptoms and 
molecular abnormalities are also displayed by patients and models of other polyQ 
expansion disorders which are summarized in table 1.2. Although the polyQ 
expansion occurs in functionally and structurally different proteins, these diseases 
share common symptomatic and molecular features as well as an inverse 
correlation between increased polyQ length and disease onset (Williams and 
Paulson, 2008). Equally, all of the polyQ expanded proteins have a strong 
propensity for aggregation. Additional evidence comes from a study where a CAG 
expansion was ectopically inserted into the Hprt (hypoxanthine 
phosphoribosyltransferase) gene. Mice expressing the HPRT protein with an 
expanded polyQ tract develop a neurological phenotype and neuronal intranuclear 
inclusions similar to those observed in the nine known polyQ diseases (Ordway et 
al., 1997).  Finally, the severity of symptoms is similar between patients 
homozygous and heterozygous for the HD mutation (Wexler et al., 1987). At the 
moment the consensus is that the toxic gain of function in HTT is central to disease 
pathogenesis, and loss of function of normal HTT has a contributory, rather than 
causative, toxic effect.  
Huntingtin is a protein of many functions with many interacting partners. The 
expanded polyQ stretch seems to confer additional properties on this already 
versatile protein. With this in mind it is not surprising that almost every pathway, 
cycle, cascade or mechanism investigated in HD seems to be affected by the 
presence of mHTT. The difficulty in elucidating the pathogenic mechanism is 
disentangling the cause from the effect. However, the main areas in which mHTT 
appears to play a pivotal role in disease onset and progression include aggregate 
formation, protein homeostasis, transcriptional dysregulation, neuronal function, 
and energy homeostasis (Fig. 1.4). 
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Table 1.2. Summary of polyQ expansion diseases. 
Disease Protein Size 
(kDa) 
Putative function Mutation 
repeat length 
HD Huntingtin 348 Signaling, scaffold, 
transport, transcription 
>39 
SBMA Androgen receptor 99 Steroid hormone 
receptor 
>40 
DRPLA Atrophin-1 125 Transcription >49 
SCA1 Ataxin-1 87 Transcription >40 
SCA2 Ataxin-2 140 RNA metabolism >32 
SCA3 Ataxin-3 42 De-ubiquitination >52 
SCA6 α1A voltage 
dependent Ca2+ 
channel subunit 
282 Ca2+ signalling >20 
SCA7 Ataxin-7 95 Transcription >37 
SCA17 TBP 38 Transcription >47 
SBMA – spinal and bulbar muscular atrophy; DRPLA – dentatorubral-pallidoluysian 
atrophy; SCA – spinocerebellar ataxia, TBP – TATA binding protein 




Figure 1.4. Depiction of main events contributing to HD pathogenesis.  
Mutant HTT (mHTT) is proteolytically cleaved in the cytoplasm (A). Chaperones 
attempt to re-fold or target mHTT for proteasomal or autophagic degradation, 
however, the system is inefficient and mHTT aggregates in the cytoplasm and 
nucleus. (B) PolyQ expansion enables mHTT and N-terminal fragments to 
abnormally interact with proteins and organelle membranes, causing defects in Ca2+ 
signalling (C) and mitochondrial dysfunction (D). (E) N-terminal mHTT fragments 
translocate to the nucleus where they impair transcription and form intranuclear 
inclusions. (F) mHTT also causes defects in vesicle transport, recycling and neuronal 
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1.1.4.1. Aggregate formation in HD 
The presence of mHTT aggregates has been well documented in patients and 
animal models of HD (Davies et al., 1997; DiFiglia et al., 1997; Gutekunst et al., 
1999). The intracellular localisation of aggregates is dependent on the length of the 
mHTT fragment that is present (Lunkes et al., 2002). The fact that full length mHTT 
has not been detected in aggregates suggests that cytoplasmic, neuropil, and 
intranuclear inclusions are formed by shorter N-terminal fragments of mHTT that 
most likely arise from proteolysis of the full length protein (DiFiglia et al., 1997; 
Martindale et al., 1998).  
Electron microscopy and atomic force microscopy have demonstrated that mHTT 
forms a spectrum of oligomeric annular, spherical, amorphous, and fibrillar species 
in vitro and in vivo in HD mice and HD patients’ post mortem brain samples (Fig. 
1.5) (Legleiter et al., 2010; Sathasivam et al., 2010; Scherzinger et al., 1997; Wacker 
et al., 2004). However, the exact mechanisms and kinetics of aggregate formation 
are still elusive. It is known that the expanded polyQ tract has a propensity to 
interact with itself and other polyQ tracts to form beta sheet structures termed 
polar zippers, which could serve as aggregation nuclei (Perutz et al., 1994). 
Following fast addition of monomers, the oligomers can assemble into protofibrillar 
species which then form a ribbon like structure with many features of an amyloid 
such as detergent insolubility, Congo Red staining, birefringence under polarised 
light and beta sheet structure (Scherzinger et al., 1999).  
Aggregate formation is dependent on time, polyQ length and concentration 
(Scherzinger et al., 1999). It has also been shown that aggregation proceeds faster 
when fibrillar aggregation nuclei are present (Scherzinger et al., 1999). Additionally, 
it has been shown that the first 17 amino acids and the polyproline stretch can also 
influence the aggregation kinetics of HTT exon 1 (Bhattacharyya et al., 2006; Thakur 
et al., 2009). The polyproline stretch has been predicted to decrease the frequency 
with which the polyQ tract of mHTT exon 1 forms a beta rich state in silico and has 
been shown to decrease the formation and stability of mHTT exon 1 amyloid 
formation in vitro (Bhattacharyya et al., 2006; Lakhani et al., 2010). In contrast, the 
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first 17 amino acids of mHTT enhance its propensity for aggregation, as evidenced 
by in vitro and yeast studies (Duennwald et al., 2006; Sivanandam et al., 2011; 
Thakur et al., 2009). The importance of the region preceding the polyQ expansion in 
HD pathology is further confirmed by experiments with BACHD mice where 
mutating serines S13 and S16 to phospho-mimicking aspartate alleviates 
behavioural symptoms and abolishes aggregation while retaining wild type HTT 
function (Gu et al., 2009). Given the plethora of aggregate species in HD, it is not 
surprising that there is great difficulty in determining how each structure 
contributes to HD pathogenesis.     
 
1.1.4.2. Toxic or protective? Significance of aggregation for HD pathology 
While mHTT inclusions can be found in the brains of HD patients and several mouse 
models (Crook and Housman, 2011; Gutekunst et al., 1999), their contribution to 
HD pathology is hotly debated within the field. Large mHTT intranuclear inclusions 
have been shown to sequester vital cellular proteins, including transcription factors 
and protein quality control components, arguing for their toxic role in HD 
pathogenesis (Hay et al., 2004; Jiang et al., 2003; Morton and Edwardson, 2001; 
Steffan et al., 2000). Equally, in at least three studies where motor symptoms were 
ameliorated in R6/2 mice a concomitant reduction of aggregate load was also 
observed (Mielcarek et al., unpublished data)(Labbadia et al., 2011; Labbadia et al., 
2012).  
In contrast, some studies have suggested that inclusion formation is not sufficient 
to cause cortical or striatal pathology in mice (Gu et al., 2007; Gu et al., 2005). Work 
in cell culture models has shown that the formation of large nuclear inclusions 
correlates with survival and that cell death is best predicted by the presence of 
smaller oligomeric species (Arrasate et al., 2004; Miller et al., 2011). These results 
have led some to suggest that the detergent soluble oligomeric species could be 
more reactive and thus more toxic than large insoluble inclusions. In this scenario, 
cells could be promoting the assembly of small toxic oligomers into large inert 
inclusions thereby minimising their deleterious effects.  





Figure 1.5. N-terminal mHTT forms a spectrum of aggregates in HD patient brains 
and mouse models.  
(A-G) HTT aggregates in the neuropil (A-C, F-G) and nuclei (D-E) of the cortex (A-D, 
F-G) and striatum (E) of HD patients (A-F) and a pre-symptomatic carrier (G) as 
revealed under light microscope after staining with huntingtin N-terminal specific 
antibodies. (H-O) Electron microscopy of aggregated material pulled from R6/2 and 
HdhQ150 brains with Seprion beads. HTT spherical, amorphous, protofibrillar 
species can be observed (H-K), as well as immature (L-M) and mature (N-O) fibrils. 
Scale bar A-D (as shown in D) and E-G (as shown in F and G) = 10 µm, H-O = 100 nm. 
Reproduced from (Gutekunst et al., 1999) (A-D), (DiFiglia et al., 1997) (E-F) and 
(Sathasivam et al., 2010) (H-O), with permissions of Society for Neuroscience (A-D), 
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1.1.4.3. Mutant huntingtin and protein quality control 
The fact that mHTT aggregation only occurs when the polyQ length exceeds a 
certain threshold indicates that the polyQ expansion confers a conformational 
change on mHTT that causes it to misfold. Cells are equipped with a network of 
inducible and constitutively expressed chaperones, and two efficient protein 
degradation systems that guard against misfolded proteins and eliminate terminally 
damaged proteins (Muchowski and Wacker, 2005). In theory, misfolding of mHTT 
into an unfavourable conformation should be recognised by chaperones which then 
act to neutralize proteotoxicity by re-folding or directing mHTT to the proteasome 
for degradation. In practice, though there is sufficient evidence that at least the N-
terminal part of mHTT becomes misfolded, the widespread toxicity that results 
from the expression of N-terminal mHTT fragments indicates that the quality 
control system is not efficient enough in correcting the fault (Gidalevitz et al., 
2006).  
One possible reason why mHTT is not simply re-folded is that chaperones are not 
able to perform this task. Their folding capacity could be inefficient, their ability to 
recognise misfolded mHTT could be compromised or they could be trapped in 
aggregates. It could also be a question of stoichiometry, where a constant supply of 
misfolded mHTT, combined with a transcriptional dysregulation resulting in a 
decrease in chaperone levels, overwhelms the quality control system. Several 
studies suggest that all of these could be true (Gidalevitz et al., 2006; Hageman et 
al., 2011; Hay et al., 2004; Zourlidou et al., 2007). Nevertheless, if the load of 
misfolded mHTT were too great, unfolded protein response or heat shock response 
(HSR) ought to become activated, increasing the cells’ capacity to deal with stress. 
However, a recent study demonstrated that though fully functional at early disease 
stage, the HSR is not activated in R6/2 or HdhQ150 mice (Labbadia et al., 2011). 
Interestingly, the same study demonstrated that pharmacological stimulation of the 
HSR only transiently improves behavioural phenotypes due to an impairment of the 
HSR with disease progression (Labbadia et al., 2011). 
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If mHTT cannot be properly refolded it ought to be eliminated by the ubiquitin – 
proteasome system (UPS). Current knowledge does not exclude the possibility that 
some level of mHTT degradation is taking place. Interestingly, ubiquitin has been 
found tightly associated to a subset of mHTT aggregates, suggesting that the UPS 
attempts to target mHTT for degradation but fails to execute the final steps 
(Gutekunst et al., 1999). Whether impairment of the UPS is a part of HD pathology 
remains debatable – HD post mortem brain samples show decreased proteasome 
activity and patient fibroblast and other cell culture models confirm this hypothesis 
(Bence et al., 2001; Bennett et al., 2005; Seo et al., 2004). No overall dysfunction of 
the proteasome has been found in the brains of R6/2 or R6/1 mice (Bett et al., 
2006; Maynard et al., 2009), though one study demonstrated that the proteasome 
is specifically impaired at the synapse in R6/2 and HdhQ150 mice (Wang et al., 
2008b). Equally, it is not clear whether the proteasome is efficient in the 
degradation of mHTT. Some studies have reported an inability to process the polyQ 
tract and suggested that mHTT could in fact impair the UPS by physically blocking 
the proteasome (Holmberg et al., 2004; Venkatraman et al., 2004). Conversely, it 
has also been shown that the proteasome is capable of processing synthetic polyQ 
containing peptides (Bennett et al., 2005). More research is needed to determine 
whether proteasomal targeting of mHTT is possible, feasible and could serve as a 
therapeutic strategy for HD. 
The ubiquitination of HTT aggregates need not necessarily signify a failed attempt 
at targeting this protein or its fragments to the UPS. Instead, it has been 
hypothesized that cells could be directing aggregates for bulk degradation by 
autophagy (Johnston et al., 1998). Evidence for such endeavours comes from 
observations of increased numbers of autophagic structures in HD post mortem 
brains, mouse and cell culture models (Kegel et al., 2000; Petersen et al., 2001; 
Sapp et al., 1997). It has been shown that inhibition of autophagy can cause a 
neurodegenerative phenotype in mice, whereas chemically or genetically enhancing 
autophagy is protective in worm, fly and mouse HD models (Jia et al., 2007; 
Komatsu et al., 2006; Ravikumar et al., 2004). Additionally, it must be noted that a 
recent study that identified K444 as a site for acetylation on HTT has also 
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demonstrated that this signal serves for targeting HTT for autophagic degradation 
(Jeong et al., 2009).  
Though it is clear that cells are capable of degrading both soluble and aggregated 
HTT they appear to be unable to automatically employ these protective strategies. 
One explanation is that the UPS and autophagic systems are not adequately 
stimulated; alternatively there could be a malfunction or collapse in their 
functioning due to direct interference by mHTT, overloading, and/or age related 
phenomena occurring with disease progression (Ben-Zvi et al., 2009; Cuervo and 
Dice, 2000; Martinez-Vicente et al., 2010). Therefore, efforts to induce cells to 
degrade mHTT and eliminate aggregates more efficiently are a promising 
therapeutic avenue.  
 
1.1.4.4. Transcriptional dysregulation 
Evidence for transcriptional dysregulation in HD is overwhelming. Changes to global 
gene expression levels have been observed in HD patients, mouse and cell culture 
models (Hodges et al., 2006; Kuhn et al., 2007; Luthi-Carter et al., 2002; Luthi-Carter 
et al., 2000). Furthermore, the fact that these abnormalities are highly comparable 
between mouse models and HD patients, occur before symptom onset, and worsen 
with disease progression strongly indicates that transcriptional dysregulation is a 
major contributor to HD pathogenesis. 
The expression of many neuronal genes is regulated by the cAMP responsive 
element binding protein (CREB) (Lonze and Ginty, 2002). CREB binding protein 
(CBP), a transcriptional co-activator with histone acetyltransferase (HAT) activity 
that links CREB to the basal transcription machinery, is found dysregulated in HD 
(Nucifora et al., 2001). Mutant HTT interacts with CBP, both through its HAT domain 
and polyQ tract, which could explain why several (though not all) studies have 
found CBP in aggregates (Kazantsev et al., 1999; Nucifora et al., 2001). 
Other general transcription factors such as Sp1 (specificity protein 1), TBP (TATA-
box binding protein) and p53 have all been found to selectively interact with the 
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expanded polyQ of mHTT thereby making them dysfunctional and dysregulating the 
genes that they control (Dunah et al., 2002; Li et al., 2002; Schaffar et al., 2004; 
Steffan et al., 2000). Additionally, mHTT has been found to interact with and disrupt 
components of the basal transcription machinery such as TFIID, TFIIF and TAFII130, 
which might explain why most genes dysregulated in HD are down-regulated (Fig. 
1.6) (Dunah et al., 2002; Zhai et al., 2005). Evidence supporting the role of mHTT-
transcription factor interaction in HD pathogenesis comes from studies where co – 
expression of Sp1 and TAFII130 or over-expression of a component of TFIID in the 
context of HD inhibits cellular toxicity (Chen-Plotkin et al., 2006). 
There is also evidence of an interaction between mHTT and the nuclear receptor co-
repressor (NCoR), which is part of a large repressive complex containing mSin3A 
and histone deacetylases (HDACs). The localisation of this complex was found to be 
altered in HD post mortem cortical samples, suggesting that mHTT can also 
interfere with the regulation of nuclear hormone receptor transcription (Yohrling et 
al., 2003).   
Apart from the altered functioning of transcription factors, there is evidence 
supporting a significant contribution of abnormal distribution of histone 
modifications to dysregulated gene expression in HD. Global histone H3 and H4 
hypoacetylation as well as histone H3K9 hypermethylation have been observed in 
HD post mortem brains and mouse models (Ferrante et al., 2003; Gardian et al., 
2005; Ryu et al., 2006). Moreover, increased histone H2A ubiquitination, decreased 
H2B ubiquitination and H3 and H4 hypoacetylation have all been observed at 
promoters of genes downregulated in HD (Bett et al., 2009; Kim et al., 2008; 
Labbadia et al., 2011; Sadri-Vakili et al., 2007). Together with the finding that the 
majority of dysregulated genes in HD are down-regulated, this suggests that there 
could be a general shift towards a more repressive chromatin state in HD, arising 
possibly due to lowered HAT and increased HDAC activity (Fig. 1.6). Taken together 
these findings suggest a central role for transcriptional dysregulation in HD 
pathogenesis. 
 




Figure 1.6. Transcriptional dysregulation in HD. 
(A) Abnormal interaction of mHTT with Sp1, TFII130 and TFIIF leads to repression of 
Sp1-dependent promoter repression (e.g. the D2R gene). (B) mHTT also disrupts 
CREB, CBP and TBP regulated transcription of genes such as PGC1-α, which itself 
regulates transcription of many metabolic and mitochondrial genes. Reduced PGC1-
α levels lead to down-regulation of its target genes and may contribute to 
metabolic and mitochondrial dysfunction. (C) Transcription of genes (e.g. BDNF) 
regulated by REST/NRSF is impaired in HD when mHTT fails to sequester REST/NRSF 
in the cytoplasm. (D) SREBP-2 activation is impaired in the presence of mHTT 
leading to impairment in the expression of cholesterogenic enzymes. (E) Presence 
of mHTT leads to an imbalance in HAT and HDAC activities, resulting in abnormal 
chromatin acetylation, structure and leading to general gene downregulation. 










Excitotoxic cell death was one of the first mechanisms proposed to explain the 
selective vulnerability of medium sized spiny neurons (MSNs) in HD. The first 
evidence supporting this claim came from the development of similar biochemical 
and behavioural symptoms in animals injected with the N-methyl – D-aspartate 
receptor (NMDAR) agonist quinolinic acid (Beal et al., 1991). In contrast to the 
relatively spared interneurons, MSN’s express high levels of NMDARs activated by 
glutamate and their over-activation can cause an abnormal Ca2+ influx that results 
in apoptosis (Nicholls, 2009). Excitotoxic cell death could result from increased 
release of glutamate or metabolites such as 3-hydroxykynurenine or quinolinic acid 
which can activate NMDAR’s or cause oxidative stress (Guidetti et al., 2006; 
Schwarcz et al., 1983). At the same time, removal of glutamate from the synapse is 
reduced in HD through either reduced levels or abnormal posttratslational 
modifications of the glutamate transporter in the membranes of glial cells (Fig. 1.7) 
(Arzberger et al., 1997; Huang et al., 2010; Lievens et al., 2001). 
Studies have also demonstrated an enhanced sensitivity of NMDARs in HD models 
(Cepeda et al., 2001; Zeron et al., 2002). This could be due to an abnormal 
interaction of mHTT with the post-synaptic density protein 95 (PSD95) which is 
responsible for proper clustering of NMDARs in lipid rafts at the post-synaptic 
membrane or to a change in NMDAR subunit composition such that, the presence 
of  the more sensitive NR2B variant is favoured over NR2A (Fig. 1.7) (Milnerwood et 
al., 2010; Sun et al., 2001).  
In addition to glutamate, aberrant adenosine, dopamine and cannabinoid signalling 
could contribute to excitotoxicity (Dowie et al., 2009; Garrett and Soares-da-Silva, 
1992; Glass et al., 1993; Tarditi et al., 2006). Equally, excitotoxicity could be due to 
disturbances in the proper functioning of cortical neurons and in the downstream 
signalling cascades in striatal neurons. 
 




Figure 1.7. Synaptic dusfunction and excitotoxicity in HD. 
(1) Altered glutamate release can lead to over-stimulation of NMDA receptors 
(NMDAR) (2), enhanced by decreased glutamate removal by astrocytes (3) and 
hypersensitivity of NMDARs due to abnormal clustering by PSD-95 or altered sub-
unit composition (4). Hyperactive NMDARs cause increased Ca2+ levels (5). 
Mitochondria are already defective in Ca2+ handling and sensitised to depolarisation 
by presence of mHTT (6). Mitochondrial depolarisation (7) together with defective 
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1.1.4.6. Synaptic function 
Alongside excitotoxicity, neurons in HD are affected in many other ways. Firstly, 
mHTT can alter the availability of molecules involved in synaptic vesicle exocytosis 
(synaptobrevin-2, rabphilin 3A, complexin II) and recycling (PACSIN/syndapin) 
(Modregger et al., 2002; Morton and Edwardson, 2001; Morton et al., 2001). 
Secondly, levels of neurotransmitters such as dopamine, enkephalin, substance P, 
somatostatin, and corticotrophin releasing hormone, as well as γ-amino-butyric 
acid (GABA), metabotropic glutamate (mGluR1-3), cannabinoid (CB1), and 
dopamine receptors are disturbed in HD mice and patients (Augood et al., 1996; 
Bibb et al., 2000; Cha et al., 1999; Cha et al., 1998; Dowie et al., 2009; Sun et al., 
2005). Thirdly, microarray studies have shown abnormal expression levels of genes 
involved in membrane potential maintenance, intracellular signalling and neuronal 
differentiation (Luthi-Carter et al., 2000). Finally, studies have shown that 
microtubule based transport is impaired in HD due to abnormal interaction of 
mHTT with huntingtin associated protein 1 (HAP1) which prevents it from 
associating with p150glued – a component of dynein/dynactin motor complex 
(Gauthier et al., 2004; Gunawardena et al., 2003). Concomitantly, neuropil 
aggregates may physically impede intracellular trafficking along axons (Li et al., 
2001). All these observations imply that the proper functioning of the synapse is 
impaired on multiple levels which could explain why HD patients display a wide 
range of behavioural, cognitive and psychiatric disturbances. 
 
1.1.4.6.1. BDNF in Huntington’s Disease 
Of the four neurotrophins so far identified, Brain Derived Neurotrophic Factor 
(BDNF) is the best studied in the context of HD. BDNF is implicated in processes 
such as neurogenesis, neuronal differentiation, neuronal survival and synaptic 
plasticity (Zuccato and Cattaneo, 2007). Therefore, reductions in the levels of BDNF, 
which have been observed in both HD post mortem brains as well as mouse 
models, are very important to consider in terms of both mechanisms of disease 
pathology as well as therapeutic interventions (Zuccato et al., 2001; Zuccato et al., 
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2005; Zuccato et al., 2008). Reduced transcription of BDNF is attributed to a loss of 
wild type HTT function. To achieve BDNF transcription, HTT indirectly interacts with 
the REST/NRSF complex and prevents it from binding to the BDNF promoter and 
repressing transcription (Zuccato et al., 2003). Mutant HTT is not able to restrict the 
REST/NRSF complex to its perinuclear localisation and thus, transcription of BDNF is 
repressed (Zuccato et al., 2001).  
The major sites of BDNF synthesis are the hippocampus and cortex; the striatum, 
though containing similar levels of BDNF, has virtually no BDNF mRNA and depends 
mostly on the cortex for the delivery of this trophic factor (Altar et al., 1997). Apart 
from reduced BDNF synthesis, BDNF cortico-striatal anterograde transport has also 
been shown to be altered in HD (Gauthier et al., 2004). It is hypothesized that this is 
due to the modulation of HTT-HAP1 binding upon polyQ expansion in mHTT, which 
in turn reduces the efficiency of kinesin-1 dependent transport of BDNF containing-
vesicles (Gauthier et al., 2004). Another problem that has been suggested to affect 
the anterograde trafficking of BDNF is a reduced level of acetylated tubulin on the 
axonal microtubules (Dompierre et al., 2007). Kinesin-1 has been shown to move 
faster and pause less when tubulin acetylation is higher and one in vitro study has 
demonstrated that increasing tubulin acetylation levels rescued the BDNF transport 
defect (Dompierre et al., 2007). 
Whether the reduced availability of BDNF seen across HD patients and models is 
indeed responsible for the selective degeneration is still questionable and requires 
more study. At the same time, it does not explain all the deficits that are occurring 
in the degenerating brain or in the periphery, such as wide-spread transcriptional 
dysregulation, disrupted protein homeostasis or defects in metabolism. As such, it 
is likely that reduced BDNF levels are a contributing factor to, rather than a cause 
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1.1.4.7. Energy homeostasis 
Impairment in energy homeostasis has long been recognised as part of disease 
pathogenesis in HD. Mitochondria isolated from HD patients’ lymphoblasts and 
from YAC72 mouse brain cells have a lower mitochondrial membrane potential that 
has been attributed to the interaction of mHTT with the outer mitochondrial 
membrane (Choo et al., 2004; Panov et al., 2002). Data from these and other HD 
models support the notion that there is an impairment in Ca2+ handling by the 
mitochondria and a higher sensitivity to depolarisation, opening of the 
mitochondrial permeability transition pore, and collapse of the energy producing 
electron transport chain (Milakovic et al., 2006). This has also been proposed to 
result in release of cytochrome c and initiation of apoptosis (Fig. 1.7). At the same 
time, the transport of mitochondria seems to be impaired by the presence of mHTT 
aggregates, suggesting that energy dys-homeostasis is affected on many levels 
(Chang et al., 2006).  
Mutant HTT decreases the expression of peroxisome proliferator activated receptor 
γ coactivator 1 α (PGC1α) - a transcription factor that regulates many genes 
involved in oxidative phosphorylation, mitochondrial biogenesis, and glucose 
metabolism (Cui et al., 2006). Furthermore, a reduction in levels of succinate 
dehydrogenase subunits and lowered activity of the electron transport chain 
complexes II/III and IV may contribute to disease progression in HD patients 
(Benchoua et al., 2006; Brennan et al., 1985). Concomitantly, a collapse in oxidative 
phosphorylation has also been suggested to increase the production of reactive 
oxygen species (ROS) which in turn severely impairs the mitochondrial enzyme 
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1.1.4.7.1. Cholesterol metabolism 
The cholesterol synthesis pathway is another important metabolic process that 
appears to be disrupted in HD. Cholesterol is crucial to the proper functioning of 
neurons in several ways. Firstly, cholesterol determines the localisation and 
functioning of ion channels and membrane receptors by acting as a modulator of 
membrane fluidity and an organiser of lipid rafts (Allen et al., 2007). Secondly, 
cholesterol is essential for myelination, proper neurite outgrowth and 
synaptogenesis, and the synthesis of steroid hormones, isoprenoids and ubiquinone 
(Valenza and Cattaneo, 2011). It is thus conceivable that a disruption in cholesterol 
levels could contribute to HD pathogenesis.  
Several studies have already shown a decrease in expression of cholesterol 
synthesis enzymes in HD and it has been suggested that this is a result of mHTT 
perturbing the transcriptional activity of a master regulator of cholesterol synthesis 
- SREBP-2 (sterol response element binding protein 2) (Fig. 1.6) (Valenza et al., 
2005). Decreased activity of 4-hydroxy-4-methyl-glutaryl Coenzyme A (HMGCoA) 
reductase, that commits HMGCoA to cholesterol synthesis, and reduced brain 
cholesterol content have also been found in the R6/2, YAC, HdhQ111 and 
transgenic rat HD models (Valenza et al., 2007a; Valenza et al., 2010; Valenza et al., 
2007b).  However, other studies have shown increased cholesterol content in 
YAC72 striata and primary striatal neurons from YAC72 and other mouse models, as 
well as in the caudate from advanced stage disease post mortem patient samples 
(del Toro et al., 2010; Trushina et al., 2006). Further studies are required to resolve 
whether these discrepancies arise from the use of different methods to measure 
sterol content or from the differences between the different HD models in their 
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1.1.5. Therapeutic strategies 
Although an extensive amount of work has been put into elucidating pathogenic 
mechanisms, drug discovery and target validation, there is still no disease modifying 
treatment available for HD. Current therapies are based on treating the symptoms 
by administration of motor sedatives, cognitive enhancers or antidepressants. The 
first HD specific symptomatic drug to be approved by the Food and Drug 
Administration in the USA is tetrabenazine and though it alleviates chorea it can 
also have devastating side effects. Therefore, strategies targeting specific HD 
pathogenic mechanisms are currently underway to find a treatment for this 
debilitating disease. 
 
1.1.5.1. Targeting mutant HTT and protein homeostasis 
One obvious way to tackle HD is to specifically rid the organism of mutant HTT, its 
toxic cleavage products or the aggregates that it forms. Elimination of mHTT could 
be achieved by targeting it for proteasomal or autophagic degradation. The 
autophagy inducing drug rapamycin has already shown beneficial effects in 
D.melanogaster and mouse HD models, though there are concerns about its 
immunosuppressive effect (Ravikumar et al., 2004).  
The ambiguous role of aggregates in the pathology of HD caused the search for 
both targets that inhibit and promote aggregation. Aggregates arise from misfolded 
proteins, therefore many studies have focused on checking whether chaperones 
could be used to prevent their formation. Induction of the HSR provided promising 
results in the R6/2 mouse model, however, this approach may be more complicated 
than anticipated due to disease related impairment in the HSR (Labbadia et al., 
2011).  
Another way to tackle aggregation was discovered when it was found that cells 
sometimes act to concentrate the aggregates into a single peri-nuclear structure 
termed the aggresome which once formed is degraded by autophagy (Johnston et 
al., 1998). If such a coping mechanism existed in vivo, its upregulation should be of 
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therapeutic benefit. However, at present the benefits of this approach remain 
unknown. 
 
1.1.5.2. Improving neuronal function 
As excitotoxicity is considered one of the major causes of cell death in HD there are 
considerable efforts to suppress this pathway. Both memantine and riluzole are 
drugs directed against glutamate neurotransmission. Though riluzole has shown 
mild therapeutic effects in R6/2 mice, these findings could not be reproduced when 
the study was repeated (Hockly et al., 2006; Schiefer et al., 2002). Equally, a meta-
analysis of clinical trials performed in HD found no overall beneficial effect of 
riluzole treatment in HD patients (Mestre et al., 2009). Concomitantly, though 
memantine has shown some promise in HD mice, its effects in the clinic have only 
been tested on a small number of patients in an open label trial, and as such, the 
potential benefit of this drug should be considered with caution (Milnerwood et al., 
2010). One promising strategy aimed at reducing excitotoxicity is the inhibition of 
kynurenine monooxygenase which results in reduced levels of the NMDAR agonist 
quinolinic acid and increased levels of the NMDAR antagonist kynurenic acid. This 
intervention has already shown beneficial effects in yeast and mouse HD models 
(Giorgini et al., 2005; Zwilling et al., 2011). In addition, new approaches that target 
calcium signalling or specific NMDAR subunits are underway in preclinical studies.  
Increasing BDNF is another promising therapeutic strategy. Multiple studies in cell 
and transgenic animal HD models have shown the potential benefit of this 
approach. Over-expression of BDNF in the cortex and striatum of R6/1 and YAC128 
mice improved motor function, preserved brain weight, restored TrkB signalling in 
the striatum, and reduced aggregation (Gharami et al., 2008; Xie et al., 2010). 
Delayed motor impairment and extended survival were also observed in R6/2 mice 
after intrastriatal adenoviral delivery of BDNF with noggin, a molecule promoting 
neurogenesis (Cho et al., 2007). Additionally, it has been suggested that rescuing 
the BDNF transport deficit could be achieved through increasing levels of tubulin 
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acetylation (Dompierre et al., 2007). Thus far, strategies aimed at increasing striatal 
BDNF hold great promise for clinical therapies. 
 
1.1.5.3. Targeting transcriptional dysregulation 
In theory, alleviating transcriptional dysregulation could have profound effects on 
many other pathogenic mechanisms that stem from this defect, such as neuronal 
dysfunction, decreased BDNF levels, energy imbalance, cholesterol metabolism and 
protein homeostasis. Therapeutic intervention to target transcriptional 
dysregulation has mainly focused on inhibiting histone deacetylases in an attempt 
to reduce genome quiescence. While genetic or pharmacological inhibition of 
HDACs has shown great promise in worm, fly, cell and mouse HD models, broad 
range HDAC inhibitors have also shown toxicity, thereby warranting a search for 
specific HDAC targets that can be modulated to achieve therapeutic benefit without 
adverse effects (Bates et al., 2006; Hockly et al., 2003; Pallos et al., 2008; Steffan et 
al., 2001).   
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1.2. Protein deacetylation  
Acetylation of the ε-amino group of lysine on histone tails has long been considered 
to be instrumental in transcriptional control (Allfrey et al., 1964). The observation 
that euchromatin is heavily acetylated suggests that this post-translational 
modification (PTM) favours the more open, transcriptionally active DNA 
conformational state (Lee et al., 1993). Histones bound to promoters of many 
actively transcribed genes are often acetylated and multiple transcription activating 
complexes either contain HATs or recruit them to promoters (Nagy and Tora, 2007). 
At the same time, many transcription factors themselves become acetylated which 
can either enhance their DNA binding capacity (like for p53) or diminish it (like for 
HMGI(Y)) (Gu and Roeder, 1997; Munshi et al., 1998). However, the discovery that 
many proteins that are not involved in transcription are acetylated, suggests that 
this PTM could have a much broader regulatory role, perhaps similar to that of 
phosphorylation (Kouzarides, 2000).  
Functions outside of direct transcriptional control that have already been 
demonstrated for acetylation are regulation of protein stability, binding, and 
activity. Recently, a study has found that the gluconeogenic enzyme 
phosphoenolpyruvate carboxykinase 1 (PEPCK1) is more readily targeted for 
proteasomal degradation when acetylated, demonstrating that acetylation 
regulates protein stability (Jiang et al., 2011). Protein-protein interactions can also 
be dependent on acetylation as evidenced by the fact that acetylation of α-tubulin 
enhances the efficiency of kinesin-1 dependent transport or that deacetylation of 
HSP90 is required for its dissociation from the glucocorticoid receptor (Murphy et 
al., 2005; Reed et al., 2006). Enzymatic activity can equally be controlled by 
acetylation, as has been shown for PTEN where acetylation decreases its lipid 
phosphatase activity (Okumura et al., 2006).  
The cells’ acetylome is determined by the interplay between HATs and HDACs. Even 
though it is now well known that these enzymes also act on many non-histone 
substrates and despite efforts to correct the nomenclature, the groups are still 
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referred to as HATs and HDACs (Allis et al., 2007). For the purpose of clarity, this 
convention will be adhered to in this work. 
HDAC inhibition has recently emerged as an attractive therapeutic intervention for 
many complex diseases. Therefore, understanding the biology and effects of 
inhibition of individual HDACs in the context of mouse models of HD is extremely 
important in terms of using HDAC inhibitors in disease therapy. 
 
1.2.1. Histone deacetylases general classification 
There are altogether 18 mammalian HDACs, divided into four classes depending on 
their sequence homology to yeast enzymes. Class I includes HDAC1, HDAC2, HDAC3 
and HDAC8, which are homologous to the yeast enzyme Rpd3 (de Ruijter et al., 
2003). Class IIa encompasses HDAC4, HDAC5, HDAC7 and HDAC9, whereas class IIb 
contains HDAC6 and HDAC10 (Fig. 1.8) (de Ruijter et al., 2003). All members of class 
II share most homology with the yeast enzyme Hda1. Sirtuins form the class III 
deacetylases which contain 7 enzymes that are all similar to the yeast Sir2, thus 
named SIRT1 through SIRT7 (Fig. 1.9) (Finkel et al., 2009). Class IV’s only member is 
HDAC11, which due to insufficient sequence homology cannot be included in any 
other class (Gao et al., 2002). Though classes I, II and IV have different sequence 
homologies, one feature distinguishing them from the sirtuin class III is their 
mechanism of action. 
 




Figure 1.8. Class I, II and IV HDACs - the "conventional" HDAC family.  
Though the catalytic mechanism is conserved among HDACs 1-11, regions flanking 
the catalytic domain (orange) contain sequences for MEF2 (blue), 14-3-3 (green), 
and ubiquitin binding (purple), a leucine-rich domain (yellow), and phosphorylation 
sites (pink), and confer specific properties to individual HDACs. Class IIa HDAC N- 
and C- termini are highly similar (thick black line). MEF2 - myocyte enhancer factor 
2; Leu-rich - leucine rich region; SE14 - serine/glutamate tetradecapeptide; ZnF-Ub - 
zinc finger for ubiquitin binding. Modified from (Yang and Seto, 2008) with 
permission of Nature Publishing Group. 
 




Figure 1.9. Class III HDACs – the mammalian sirtuins.  
Catalytic domain (purple) and most prevalent intracellular localisation for SIRT1-7 
enzymes. Modified from (Li and Kazgan, 2011) with permission of Ivyspring 
International Publisher. 
  
1.2.1.1. Reaction mechanisms 
HDACs 1 through 11 are all zinc dependent enzymes and share the same reaction 
mechanism. They rely on a Zn2+ ion coordinated by histidine and aspartate residues 
in a highly conserved catalytic core. Deacetylation occurs by the activation of a 
water molecule by the zinc cation coupled to the histidine-aspartate charge relay 
system within the active site (Finnin et al., 1999). The sirtuin reaction mechanism is 
NAD+ (Nicotinamide Adenine Dinucleotide) dependent and proceeds through 
formation of an oxocarbenium-like transition species and release of nicotinamide 
(NAM). Upon completion, apart from the deacetylated substrate, 2’-O-acetyl ADP 
ribose is released (Liang et al., 2010). 
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1.2.1.2. Expression and functions of HDAC enzymes 
Class I HDACs are expressed in a variety of tissues suggesting that they have a 
general regulatory function in transcription control (Johnstone, 2002). HDAC1 and 
HDAC2 share 82% sequence homology and are thus far the best characterised 
HDACs (de Ruijter et al., 2003). They are found exclusively in the nucleus and 
generally form part of multi-protein transcription modulating complexes such as 
Sin3, NuRD (nuclear remodelling deacetylase) or Co-REST (co-repressor of REST) 
(Ahringer, 2000; Humphrey et al., 2001). HDAC3 is the only class I member that in 
addition to a nuclear localisation signal (NLS) also possesses a nuclear export signal 
(NES) (Yang et al., 2002). Consistent with this HDAC3 has been detected in both the 
nucleus and cytoplasm where it is believed to localise to the plasma membrane 
(Emiliani et al., 1998).  
 HDAC4, HDAC5, HDAC7 and HDAC9 have their catalytic domain at the C-terminus 
and an NLS at the N-teminus (Yang and Seto, 2008). However, their N-terminus also 
has conserved domains for binding the C-terminal binding protein (CtBP), myogenic 
enhancer factor (MEF2) and 14-3-3 proteins (Yang and Gregoire, 2005). MEF2 is 
essential for muscle differentiation and inhibited by binding to class IIa HDACs 
(Verdin et al., 2003). This association is disrupted by CaMK phosphorylation and 
export of HDACs to the cytoplasm via association with 14-3-3 proteins (McKinsey et 
al., 2000). HDAC4, HDAC5 and HDAC7 have also been shown to interact with HDAC3 
within the N-CoR/SMRT (nuclear co-repressor/silencing mediator for retinoic acid 
and thyroid hormone receptors) repressive complex (Fischle et al., 2002). In fact, 
recent data suggests that HDAC4, HDAC5 or HDAC7 might not possess histone 
deacetylase activity and therefore associate with HDAC3 to achieve transcriptional 
repression (Fischle et al., 2002).  
HDAC6 and HDAC10 are unique in that they have a duplication of the catalytic 
domain, though the duplicated domain appears to only be functional in HDAC6 
(Yang and Seto, 2008). HDAC10, as well as the class IV HDAC11 have only recently 
been identified and little is known of these two enzymes. HDAC10 has so far been 
implicated in DNA homologous recombination and 3’ pre-mRNA processing and 
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appears to be vertebrate specific, whereas HDAC 11 is conserved through 
invertebrates and plants but more investigation is needed to pinpoint its cellular 
functions (Gao et al., 2002; Kotian et al., 2011; Shimazu et al., 2007; Yang and Seto, 
2008). 
The sirtuins can be found in the nucleus (SIRT1, SIRT6 and SIRT7), the 
mitochondrion (SIRT3-5) and in the cytoplasm (SIRT2) (Fig. 1.8) (Finkel et al., 2009). 
So far, SIRT1 has been most extensively studied, due to its highest homology with 
the yeast sir2 enzyme and suggested role in mediating lifespan extension 
(Kaeberlein et al., 1999; Tissenbaum and Guarente, 2001). It has also been 
implicated in DNA damage response, oxidative stress and heat shock response, 
cellular differentiation and metabolism (Wang et al., 2008c; Westerheide et al., 
2009; Yuan et al., 2007).  
Mitochondrial sirtuins have been demonstrated to function as regulators of energy 
production through concerted action of deacetylation and ADP-ribosylation. SIRT3 
can deacetylate Acetyl-CoA synthetase 2, resulting in an increased production of 
Acetyl-CoA, an intermediate in the Krebs cycle, fatty acid metabolism, and 
cholesterol synthesis (Hallows et al., 2006).  SIRT4 does not seem to have 
deacetylase activity, but instead uses NAD+ to ADP-ribosylate glutamate 
dehydrogenase, inactivating it in the liver and pancreatic β-cells, and regulating 
gluconeogenesis and insulin secretion in response to glutamine (Haigis et al., 2006). 
Little is known about SIRT5, though it has recently been demonstrated to 
deacetylate carbamoyl phosphate synthetase 1, thereby activating it and causing 
increased urea production in the liver. As SIRT5 mRNA levels are upregulated during 
fasting, its action on the urea cycle could be protective by increasing the conversion 
of increased ammonia generated in the process (Ogura et al., 2010). 
SIRT6 is another sirtuin without deacetylase but with ADP-ribosylase activity. Its 
substrates are still unknown but studies from SIRT6 deficient mice indicate a role 
for this protein in base-excision repair (Mostoslavsky et al., 2006). SIRT7 is a 
nucleolar enzyme expressed mainly in proliferative tissues such as liver, spleen and 
testes and with little expression in heart, brain or muscle (Ford et al., 2006). SIRT7 
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can associate with Pol I and its over-expression increased transcription of rRNA, 
suggesting that SIRT7 could promote growth by driving ribosome biosynthesis in 
proliferating cells (Ford et al., 2006).  
Similarly to HDAC6, SIRT2 is the only predominantly cytosolic sirtuin. Both are α-
tubulin deacetylases and both have been suggested to play a role in Huntington’s 
disease pathogenesis.  
 
1.2.2.  HDAC inhibition as therapy for HD 
Transcriptional dysregulation in HD has been shown to mostly involve gene 
downregulation (Luthi-Carter et al., 2000). At the same time, global histone H3 and 
H4 hypoacetylation has been observed in patients and HD models (Ferrante et al., 
2003; Gardian et al., 2005; Ryu et al., 2006). It is therefore of no surprise that HDAC 
inhibition has emerged as an exciting avenue for therapeutic intervention.  
The first indication that HDAC inhibition could correct the transcriptional 
dysregulation observed in HD emerged in yeast cells where treatment with 
Trichostatin A (TSA), which inhibits Rpd3 and Hda1, corrected the decrease in 
transcription caused by expression of an expanded polyQ-GFP directed to the 
nucleus (Hughes et al., 2001). Subsequently, proof of principle experiments 
performed with inducible PC12 cells expressing mHTT exon 1 showed a restoration 
of histone acetylation upon treatment with TSA and other broad range HDAC 
inhibitors: sodium butyrate (NaB) and suberoylanilide hydroxamic acid (SAHA) 
(Steffan et al., 2001). The same study also demonstrated that treatment with SAHA 
or NaB can be neuroprotective in a D.melanogaster model of HD (Steffan et al., 
2001). These findings were then translated into a mammalian model when R6/2 
mice treated with SAHA or NaB showed improved body weight, rotarod 
performance, survival, and decreased transcriptional dysregulation (Ferrante et al., 
2003; Hockly et al., 2003). Sirtuin inhibitors have been less rigorously tested in the 
context of HD, though two groups found an amelioration of phenotype in 
Chapter 1  Introduction 
59 
 
D.melanogaster and mice after nicotinamide administration (Hathorn et al., 2011; 
Pallos et al., 2008). 
However, studies in mice have also identified significant toxicity associated with 
broad range HDAC inhibitor administration (Hockly et al., 2003). Therefore, efforts 
to identify the mechanisms mediating the protective HDAC inhibitor effects have 
been undertaken so that instead of targeting a whole family of HDACs 
simultaneously, more specific and thus, less toxic inhibitors could be developed.  
The search for HDAC targets relevant to HD pathgenesis triggered a cascade of 
studies in invertebrate HD models. RNAi experiments in C.elegans suggested that 
polyglutamine toxicity could be ameliorated by genetic reduction of hda-3 which is 
most homologous to human HDAC1 (Bates et al., 2006). Concomitantly, reduction 
of Rpd3, which is equally homologous to human HDAC1, HDAC2 and HDAC3, 
resulted in neuroprotection in a D.melanogaster HD model (Pallos et al., 2008). The 
same study has also demonstrated a neuroprotective effect of genetic reduction of 
Sir2 (homologous to SIRT1) and Sirt2 (homologous to SIRT2) in the same model 
(Pallos et al., 2008). At the same time, over-expression of HDAC6 has been shown 
to be protective in a D.melanogaster model of SBMA with implications that these 
findings could be translated to HD and other polyglutamine diseases (Pandey et al., 
2007b).  
However, though invertebrate studies provide important directions for future 
investigations, little is known about the validity of these targets in mammals.  
Therefore, this work encompasses the first attempt to validate previous findings 
from invertebrate and cell polyQ disease models to validate HDAC6 and SIRT2 as 
therapeutic targets for HD.  
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1.3. HDAC6 and SIRT2 as therapeutic targets in Huntington’s Disease 
HDAC6 and SIRT2 are deacetylases from two distinct families, and both are the only 
representative of each family to reside primarily in the cytoplasm (Bertos et al., 
2004; North et al., 2003). They have also both been described primarily as α-tubulin 
deacetylases and with the exception of H4K16 during cell cycle progression for 
SIRT2, their targets are non-histone proteins (Hubbert et al., 2002; Vaquero et al., 
2006). Thus, in terminally differentiated, non-dividing cell such as neurons, their 
role in HD pathogenesis would not be expected to be linked to transcriptional 
dysregulation, but rather depend on their regulation of non-histone targets. 
 
1.3.1. HDAC6 
HDAC6 is a class IIb HDAC with most sequence homology to the yeast Hda1 enzyme 
(Grozinger et al., 1999). It is located on the X-chromosome in both mice and 
humans and contains two deacetylase domains, though whether they can act 
independently is a subject of debate (Mahlknecht et al., 2001; Voelter-Mahlknecht 
and Mahlknecht, 2003; Zhang et al., 2006; Zou et al., 2006). HDAC6 is expressed in 
several tissues, including heart, brain and liver, with highest levels of expression in 
the testis (Zhang et al., 2008). A nuclear export signal and additionally in humans, 
an SE14 (serine-glutamate tetradecapeptide) cytoplasmic anchoring motif cause 
HDAC6 to be localised to the cytoplasm (Bertos et al., 2004). However, both mouse 
and human HDAC6 also contain an atypical nuclear localisation signal, which may 
explain why in some studies HDAC6 has also been detected in the nucleus (Bertos 
et al., 2004). The linker region between the two catalytic domains could be required 
for HDAC6 binding to other proteins, such as dynein and p150Glued (Fig.1.9) 
(Kawaguchi et al., 2003). Finally, the C-terminus of HDAC6 contains a Zn finger 
ubiquitin binding domain (ZnF-Ub) that is unique amongst HDACs and links HDAC6 
to the protein quality control machinery (Boyault et al., 2006; Kawaguchi et al., 
2003; Seigneurin-Berny et al., 2001). 
 




Figure 1.10. Domain organization of the HDAC6 protein.  
NES – nuclear export signal; DD – deacetylase domain; SE14 – serine/glutamate 
tetradecapeptide (only found in hHDAC6); ZnF-Ub – zinc finger for ubiquitin 
binding; hHDAC6 – human HDAC6. 
 
1.3.1.1. Functions of HDAC6 
HDAC6 is a versatile protein implicated in cell motility, signal transduction and 
protein quality control. Its client proteins include cortactin, HSP90, and β-catenin, 
but it can also bind mono- and polyubiquitin chains and ubiquitinated proteins with 
its ZnF-Ub domain (Kovacs et al., 2005; Li et al., 2008; Seigneurin-Berny et al., 2001; 
Zhang et al., 2007).  
Deacetylation of β-catenin in response to epithelial growth factor (EGF) signalling is 
required for EGF’s efficient translocation to the nucleus and induction of c-myc 
expression (Li et al., 2008). At the same time, inhibition of HDAC6 results in a hyper-
acetylated form of HSP90 that is defective in binding to the co-chaperone p23 
(Kovacs et al., 2005). This compromises maturation of the glucocorticoid receptor 
and its transcriptional activity upon ligand binding (Kovacs et al., 2005).  
Cortactin deacetylation promotes its binding to F-actin and is important for cell 
motility and angiogenesis (Kaluza et al., 2011). Additionally, deacetylated cortactin 
is crucial for the autophagosome to lysosome fusion during steady-state 
macroautophagy (Lee et al., 2010). Interaction with HSP90 also ties HDAC6 to 
protein homeostasis (Matthias et al., 2008). Though HDAC6 catalytic activity is 
dispensable for this process, ubiquitin binding induces HDAC6 to facilitate the 
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dissociation of the HSP90-HSF1 (heat shock transcription factor 1) repressive 
complex, allowing HSF1 to activate the HSR (Boyault et al., 2007). This shows that 
HDAC6 is involved in both steady state as well as inducible protein quality control. 
 
1.3.1.1.1. Significance of HDAC6 mediated tubulin deacetylation 
Although tubulin deacetylation is the most extensively studied HDAC6 activity, its 
basic biological significance is still unclear. It has been suggested that tubulin 
acetylation increases microtubule stability or dynamics (Matsuyama et al., 2002), 
though these findings are a subject of debate (Palazzo et al., 2003). Protein binding 
to microtubules, receptor internalization, podosome formation, starvation induced 
autophagy, dendritic arborisation, immune synapse formation and HIV-1 infection 
have all been shown to be modulated by HDAC6 mediated changes in tubulin 
acetylation (Deribe et al., 2009; Destaing et al., 2005; Geeraert et al., 2010; 
Giustiniani et al., 2009; Ohkawa et al., 2008; Serrador et al., 2004; Valenzuela-
Fernandez et al., 2005). 
Recently, a novel function for tubulin acetylation has been revealed in intracellular 
transport. Kinesin-1 dependent transport was enhanced when HDAC6 was inhibited 
and tubulin acetylation increased (Reed et al., 2006). At the same time, 
deacetylated tubulin mimicking mutants exhibited slower transport and less kinesin 
to microtubule binding (Reed et al., 2006). Together with the finding that acetylated 
microtubules have differential distribution in highly polarised cells such as neurons, 
one could speculate that the transport of cargoes could be directed to specific 
cellular locations by alterations of tubulin acetylation levels (Cambray-Deakin and 
Burgoyne, 1987). Alternatively, acetylation of microtubules could prioritize 
transporting one cargo over another, as not all kinesin motors respond to tubulin 
acetylation changes (Reed et al., 2006).  
Another interesting role for HDAC6 has been revealed in the formation of stress 
granules and aggresomes in response to stress (Kawaguchi et al., 2003; Kwon et al., 
2007). Stress granules accumulate protein translational machinery, including 
Chapter 1  Introduction 
63 
 
mRNAs, initiation factors, ribosomal subunit and proteins involved in RNA 
remodelling and degradation (Kwon et al., 2007). Aggresomes are perinuclear 
inclusion bodies of aggregated, ubiquitinated misfolded proteins found to associate 
with the microtubule organising centre (Johnston et al., 1998). Though a direct 
involvement of tubulin acetylation has not been demonstrated in the formation of 
these structures, both aggresomes and stress granules require intact microtubules 
and a catalytically active HDAC6, again highlighting the role of HDAC6 in protein 
homeostasis (Kawaguchi et al., 2003; Kwon et al., 2007).  
Interestingly, Tetrahymena thermophila cells with a deacetylation mimicking 
mutated tubulin have normal growth and morphology and mice depleted of HDAC6 
have highly elevated levels of acetylated tubulin but no obvious phenotypes 
(Gaertig et al., 1995; Zhang et al., 2008). This strongly suggests that HDAC6 may 
only become essential in response to stressful stimuli or in a pathogenic context.  
 
1.3.1.2. Therapeutic strategies involving HDAC6 
HDAC6 is of particular interest in HD. Firstly, it appears to play a role in protein 
homeostasis by sensing and responding to ubiquitinated protein accumulation 
(Matthias et al., 2008). Mutant HTT can become ubiquitinated and has been shown 
to accumulate in aggresomes in HD cell models (Iwata et al., 2005). HDAC6 
participated in aggresome formation by binding ubiquitinated proteins and the 
retrograde dynein motor (Iwata et al., 2005). Subsequent autophagic degradation 
of the aggresome was also HDAC6 dependent (Iwata et al., 2005). In addition, it has 
been demonstrated that in a D.melanogaster model of SBMA HDAC6 expression 
rescued neurodegeneration in an autophagy-dependent manner (Pandey et al., 
2007b). Similar results were observed when HDAC6 was overexpressed in 
D.melanogaster models of Alzheimer’s Disease and Parkinson’s Disease (Pandey et 
al., 2007a). Taken together with the observation that HDAC6 plays a role in 
autophagy and heat shock activation these observations indicate that HDAC6 could 
be protective in a disease where protein homeostasis is disrupted (Boyault et al., 
2007; Lee et al., 2010). 
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In contrast to its role in protein quality control, effects of HDAC6 on tubulin 
acetylation could be damaging in the context of HD. One study in an HD cell model 
has indicated that increasing tubulin acetylation by HDAC6 inhibition could rescue 
the BDNF transport deficit from the cortex to the striatum (Dompierre et al., 2007). 
This is supported by the fact that BDNF is a cargo of kinesin-1 and tubulin 
acetylation enhances kinesin-1 dependent transport (Dompierre et al., 2007; Reed 
et al., 2006). 
Taken together, these findings strongly suggest that HDAC6 inhibition should 
modify HD progression. Based on the previous studies in cell culture and 
invertebrate models of HD, loss of HDAC6 might be expected to increase aggregate 
load and exacerbate the phenotype in a mouse model of HD (Iwata et al., 2005; 
Pandey et al., 2007a; Pandey et al., 2007b). On the other hand, an increase in 
cortico-striatal BDNF transport might be expected to improve some HD-related 
phenotypes (Dompierre et al., 2007). In any instance, none of these suggested 
















SIRT2 is a member of class III HDACs also termed sirtuins (Fig. 1.9). SIRT2 contains a 
catalytic domain and N- and C-terminal extension regions (Fig. 1.11) (Frye, 1999). So 
far three SIRT2 isoforms, all catalytically active, have been described. Isoform 
SIRT2.1 is the largest protein produced from full length mRNA containing all 16 
exons (Frye, 1999; Maxwell et al., 2011). The two shorter transcripts are generated 
by skipping exon 2 or exons 2-4, resulting in SIRT2.2 and SIRT2.3 isoforms 
respectively, both with an altered N-terminus. Little is known of the regulation of 
SIRT2 through PTMs, except that its deacetylase activity can be inhibited by 
phosphorylation by various cyclin dependent kinases (CDKs) at its C-terminus (Fig. 
1.11) (Pandithage et al., 2008). SIRT2 has also been shown to bind HDAC6 and 
HOX10a, though the significance of these interactions is currently unknown (Bae et 
al., 2004; North et al., 2003).  
 
 
Figure 1.11. Domain organization of the SIRT2 protein.  
H4K16 - histone 4 lysine 16; H - histidine; S - serine. 
 
Early data on SIRT2 expression indicated that it is ubiquitously expressed both in 
adult and fetal tissue (Afshar and Murnane, 1999). Mouse Sirt2 however appears to 
be most highly expressed in the brain, heart, kidney and testis, with less expression 
in the liver, spleen and skeletal muscle (Yang et al., 2000). Data on Sirt2 expression 
in the CNS indicate a peak during postnatal development and a slow reduction in 
expression with age (Werner et al., 2007). In contrast, recent studies on SIRT2 
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protein expression levels stipulate that the expression of the SIRT2.3 isoform is 
increased in the aging mouse brain (Maxwell et al., 2011).  
 
1.3.2.1. Proposed functions of SIRT2 
SIRT2 has been implicated in cell cycle progression after the observation that its 
levels peak during mitosis (Vaquero et al., 2006). Subsequently it was discovered 
that SIRT2 can deacetylate H4K16-Ac and that global levels of H4K16-Ac decrease 
during G2/M transition; a period that coincides with SIRT2 localisation to chromatin 
(Vaquero et al., 2006). Conflicting data exist on the precise role of SIRT2 in cell cycle 
regulation. While some groups report that SIRT2 is required for efficient G2/M 
transition, others claim that SIRT2 activity can block mitosis entry upon treatment 
with compounds that interfere with microtubule assembly (Dryden et al., 2003; 
Inoue et al., 2007). Yet another study has found no involvement of SIRT2 in mitosis 
under non-stressful conditions (Pandithage et al., 2008). At the same time the 
significance of SIRT2 phosphorylation by cyclin dependent kinases 1, 2 and 5 and 
dephosphorylation by CDC14B is unclear. While one study reported that 
phosphorylation reduces SIRT2 deacetylase activity another group reported that 
dephosphorylation targets SIRT2 for proteasomal degradation (Dryden et al., 2003; 
Pandithage et al., 2008). It seems counterintuitive that both phosphorylation and 
dephosphorylation would result in reducing a protein’s activity. Nevertheless, as 
these studies have been performed with different cell lines, SIRT2 regulation and its 
role in cell cycle progression could depend on the tissue under examination and be 
vastly different between normal and cancerous cells. Evidence in support of a 
negative role for SIRT2 in cell cycle progression also comes from the fact that 
expression of SIRT2 is down-regulated in many gliomas (Hiratsuka et al., 2003). 
Nonetheless, further investigation is required to accurately dissect the function of 
SIRT2 in cell division.  
The growing repertoire of non-histone SIRT2 substrates suggests that this protein 
could have many functions, some of which could be tissue dependent. In the liver, 
upon starvation, SIRT2 was found to deacetylate the gluconeogenic enzyme PEPCK1 
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thus protecting it from proteasomal degradation (Jiang et al., 2011). In kidney and 
white adipose tissue, levels of SIRT2 are increased upon caloric restriction and in 
brown adipose tissue upon cold exposure (Wang et al., 2007; Wang and Tong, 
2009). Oxidative stress also increased expression of SIRT2 in cells (Wang et al., 
2007). Subsequently, it was shown that SIRT2 deacetylates FOXO1 and FOXO3A 
(Wang and Tong, 2009). Deacetylation increases FOXO1’s binding to and inhibition 
of PPARγ, which results in inhibition of adipocyte differentiation (Wang and Tong, 
2009). Deacetylation of FOXO3A increases its transcriptional activity which results 
in increased expression of MnSOD, p27kip and the pro-apoptotic protein Bim (Wang 
et al., 2007). Interestingly, these effects are only observed upon low glucose 
(FOXO1) or oxidative stress (FOXO3A) conditions indicating that SIRT2 might play an 
important function when challenged with stressful environmental conditions (Wang 
et al., 2007; Wang and Tong, 2009). 
In general, SIRT2 appears to be a pro-survival protein, though some data challenge 
this assumption. SIRT2 has been suggested to deacetylate p53 thereby down-
regulating its transcriptional activity and promoting survival, a theory supported by 
reports that genetic or pharmacological down-regulation of SIRT2 activity induced 
apoptosis in cells (Peck et al., 2010). On the other hand, SIRT2 was found to be 
down-regulated in many gliomas while its ectopic expression reduced glioma 
proliferation (Hiratsuka et al., 2003). These seemingly contrasting data on SIRT2’s 
role in survival could be a result of differences in SIRT2 function between the 
periphery and the nervous system.  
In the CNS, SIRT2 is expressed in oligodendrocytes and neurons, and possibly in 
astrocytes (Li et al., 2007; Werner et al., 2007). As SIRT2 levels peak during 
myelination it has been suggested to function in oligodendrocyte differentiation. 
Two studies have confirmed this hypothesis, though one showed that SIRT2 is 
necessary for oligodendrocyte differentiation while the other reported an inhibitory 
role (Ji et al., 2011; Li et al., 2007). SIRT2 was also suggested to have a function in 
the mature CNS when it was observed that over-expression of SIRT2 inhibited 
neurite outgrowth and growth cone collapse in primary hipoccampal neurons 
(Harting and Knoll, 2010). This indicates that the level of SIRT2 could be a factor 
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influencing both axonal plasticity and degeneration and that SIRT2 inhibition could 
prevent neurodegeneration.  
 
1.3.2.2. Therapeutic strategies involving SIRT2  
A role for SIRT2 in neurodegeneration is supported by the finding that SIRT2 over-
expression promotes axonal degeneration in the slow Wallerian degeneration 
model, while SIRT2 knock-down protects wild type cerebellar granule cells against 
axonal degeneration (Suzuki and Koike, 2007). Additionally, in cell models of 
Parkinson’s Disease inhibition of SIRT2 rescued cells from α-synuclein induced 
toxicity (Outeiro et al., 2007). The same study also found that pharmacological 
inhibition of SIRT2 protected tyrosine hydroxylase neurons from death in primary 
midbrain culture and D.melanogaster Parkinson’s Disease models (Outeiro et al., 
2007). 
Evidence for a protective role of SIRT2 inhibition in HD came from two important 
studies. Firstly, genetic knock-down of Sirt2 to 50% of normal levels prevented 
photoreceptor neuron degeneration but did not rescue lethality in a HTT exon 1 
D.melanogaster HD model (Pallos et al., 2008). In a second study, a specific SIRT2 
inhibitor was demonstrated to be protective in D.melanogaster, C.elegans and 
primary striatal cell fragment models of HD (Luthi-Carter et al., 2010). Though 
microarray profiling of HD striatal cells showed that SIRT2 inhibition did not correct 
HD transcriptional dysregulation, it revealed an unanticipated function for SIRT2 in 
cholesterol biosynthesis. Treatment of striatal cells with the SIRT2 inhibitor AK-1 
resulted in a down-regulation of key enzymes in the cholesterol synthesis pathway. 
Further examination revealed that SIRT2 facilitates the nuclear translocation of 
SREBP-2 and subsequent activation of the cholesterol synthesis pathway. Inhibition 
of SIRT2 decreased nuclear SREBP-2, cholesterogenic enzymes’ transcript levels and 
cholesterol levels. It was therefore suggested that the neuroprotective effect 
observed after treatment with SIRT2 inhibitors was due to reducing the high 
cholesterol levels observed in the HD striatal cells used (Luthi-Carter et al., 2010).  
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Taken together these findings strongly indicate that SIRT2 inhibition could be 
protective in HD. Sirt2 knock-out (Sirt2KO) mice develop normally and do not show 
any overt phenotypes, supporting a role for SIRT2 only under some, possibly stress 
related, circumstances. It is conceivable that a normally beneficial stress response 
of SIRT2 could be deleterious to the cell in a pathological context. Therefore, 
investigating the effect of Sirt2 knock-out in a mouse model of HD will be vital to 




1.4. Focus of this work 
The therapeutic potential of HDAC6 or SIRT2 inhibition for neurodegenerative 
disease has so far only been tested in cell or invertebrate models of HD. In this 
study, Hdac6 and Sirt2 knock-out mice have been crossed to the R6/2 mouse model 
of HD and disease progression assessed with physiological, behavioural and 
molecular readouts. Genetic ablation of either of the two proteins did not modify 
HD progression, though absence of HDAC6 caused tubulin hyperacetylation 
throughout the brain. This work provides the first indication that previous findings 
about the therapeutic potential of HDAC6 or SIRT2 modulation in HD might not 
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2.0. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Commercial kits 
Amersham ECLTM Plus Western Blotting detection kit (GE Healthcare) 
BDNF Emax immuno-assay kit (Promega) 
Bicinchocinic acid (BCA) Assay (Thermo Scientific) 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) 
DNase I set (Qiagen) 
Qiaquick Gel Extraction Kit (Qiagen) 
Qiaprep Spin Miniprep Kit (Qiagen) 
QIAzol Lysis reagent (Qiagen) 
RNeasy Mini kit (Qiagen) 
Seprion ELISA kit (Microsens Technology) 
SIRT2 Fluor-de-Lys activity assay (Enzo Life Sciences) 
TOPO TA cloning kit (Invitrogen) 
Type-it Mutation Detection kit (Qiagen) 
Vectastain ABC kit (Vector Labs) 
 
2.1.2. Equipment 
7650 accelerating rotarod (Ugo Basile) 
96-well transparent polypropylene PCR plates for sequencing (Abgene) 
96-well transparent polypropylene PCR plates (Bio-Rad) 
96-well white polypropylene PCR plates (Bio-Rad) 
96-well clear hard shell polystyrene ELISA plates (Nunc) 
ABI 3730xl sequencer (Applied Biosystems) 
AM1053 activity cages (Linton Instruments) 
Analytical balance (Fisher) 
Axiocam camera (Zeiss) 
Axioscope 2.0 light microscope (Zeiss) 
Bicycle inner tubing (for rotarod) (Evans Cycles) 
Biofuge pico centrifuge (Heraeus) 
Bio-Rad 680 96-well microplate reader (Bio-Rad) 
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CFX96 Real-time system thermocycler (Bio-Rad) 
Chromo-4 thermo cycler (Bio-Rad) 
Dyad thermocycler (Bio-Rad) 
Fast-Prep ribolyser (MP Biomedicals) 
GD40/50 vacuum gel drier (Life Technologies) 
Gel-Doc EQ UV-transilluminator (Bio-Rad) 
Grip strength meter (San Diego Instruments) 
GS-800 Calibrated Densitometer (Bio-Rad) 
Lysing matrix-D tubes (MP Biomedicals) 
Nanodrop spectrophotometer (Thermo Scientific) 
Omega plate reader (BMG Labtech) 
OTF cryostat and 5040 microtome (Bright Instruments) 
Polypropylene tubes (1.5 ml) (Eppendorf) 
Protean Minigel Western blotting system (Bio-Rad) 
PT 1200 homogenizer (Polytron) 
Semi-transparent shoebox mouse cage (Techniplast Limited) 
Seprion capture buffer (Microsens Technologies) 
Seprion coated 96-well plates (Microsens Technologies) 
TL-100 ultra-centrifuge (Beckman Coulter) 
Transparent activity box (367 × 207 × 140 cm) (Techniplast Limited) 
UBD2 heating block (Grant Instruments) 
Vibra-Cell sonicator (Sonics and Materials Incorporated) 
Xenon lamp envision fluorescent plate reader (Perkin Elmer) 
X-ray film developer (Xenograph) 
 
2.1.3. Reagents 
2’ – deoxynucelotide triphosphates (dNTPs) (Invitrogen) 
2-mercaptoethanol (Sigma) 
3,3’diaminobenzidine (DAB) (Sigma) 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonicacid sodium salt (HEPES) (Sigma) 
Bacto Agar (BD) 
Bacto Tryptone (BD) 
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Bacto Yeast extract (BD) 
Ampicillin (Sigma) 
Amplitaq DNA polymerase (Applied Biosystems) 
Ammonium  persulfate ((NH4)2S2O8) (Sigma) 
Bovine serum albumin (BSA) (Sigma) 
Bromophenol blue (Sigma) 
Brilliant blue – R250 (Pierce) 
Calcium chloride (CaCl2) (VWR) 
Chloroform (Sigma) 
CHDI-001945-0000-005 (Evotec) 
Complete protease inhibitor tablets (Roche) 
Dimethyl sulphoxide (DMSO) (Sigma) 
Dithiothreitol (DTT) (Sigma) 
DPX mounting medium (Fluka) 
Ethanol (VWR) 




Hidi formamide (Applied Biosystems) 
Histoclear (National Diagnostics) 
Hydrochloric acid (HCl) (Sigma) 
Hyperfilm ECL (Amersham) 
Igepal-CA630 (NP-40) (Sigma) 
Isopentane (Sigma)  
Kanamycin (Sigma) 
Lutrol F68 (BASF) 
Magnesium chloride (MgCl2) (Sigma) 
MegaBACE ET900 size standards (Amersham)  
Methanol (VWR) 
Moloney murine leukemia virus reverse transcriptase (MMLV-RT) (Invitrogen) 
MMLV-RT 1st strand buffer (5x) (Invitrogen) 
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Nicotinamide (NAM) (Sigma) 
Non-fat dry milk powder (Marvel) 
Polyethyleneglycol (PEG)-400 (BASF) 
Phenyl methane sulphonyl fluoride (PMSF) (Fluka) 
Phire Hot Start II Polymerase (New England Biolabs) 
PhiX-HindIII Ladder (New England Biolabs) 
PIPES (1,4-piperazinediethanesulphonic acid) (Sigma) 
Phosphate buffered saline (PBS) tablets (Sigma) 
Potassium chloride (VWR) 
Potassium di-hydrogen phosphate (Sigma) 
Precision mastermix (2x) (Primer Design) 
Proteinase K (Fermentas) 
Protogel (GeneFlow) 
Protogel resolving buffer (GeneFlow) 
Protogel stacking buffer (GeneFlow) 
Protran nitrocellulose membrane (0.2 µm pore) (Whatman) 
Rodent breeding chow (Special Diet Services) 
RNasin (Promega) 
Sodium dodecyl sulphate (SDS) (Sigma) 
SDS-PAGE running buffer (10x) (GeneFlow) 
Sodium bicarbonate (NaHCO3) 
Sodium carbonate (Na2CO3) 
Sodium chloride (NaCl) (VWR)  
Sodium deoxycholate (Sigma) 
Sodium dihydrogen phosphate (NaH2PO4) 
Sodium fluoride (NaF) (Sigma) 
Sodium hydroxide (NaOH) (VWR) 
Solutol HS15 (BASF) 
Spectra pre-stained protein marker (Fermentas) 
Sucrose (VWR) 
Tetra methyl ethylene diamine (TEMED) (Sigma) 
Thermostart master mix (Thermo Scientific) 
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TMB plus (Serotec) 
Trichostatin A (TSA) (Sigma) 
Triethanolamine hydrochloride (Sigma) 
Tris Base (Sigma) 
Ethylene di-amine tetra-acetic acid (EDTA) (Sigma) 
Taq DNA Polymerase from Thermus aquaticus (Sigma) 
Triton-X100 (Sigma) 
Tween-20 (Sigma) 
Ultra-pure agarose (Invitrogen) 










S830 N/A In House 1:3000 WB 
S830 N/A In House 1:2000 IHC 
S829 N/A In House 1:1000 WB 
MW8 N/A P.Patterson 1:2000 SEP 
MW8 N/A P.Patterson 10 ng in 6µl TR-FRET 
MW8 N/A P.Patterson 1ng in 6µl  TR-FRET 
2B7 N/A Novartis 10 ng in 6µl TR-FRET 
MW1 N/A P.Patterson 1ng in 6µl TR-FRET 
HDAC6 N/A T.Yao 1:250 WB 
SIRT2 sc-20966 Santa Cruz 1:1000 WB 
SIRT2 S8847 Sigma 1:1000 WB 
SIRT1 2028 Cell Signalling 1:1000 WB 
SIRT1 S5313 Sigma 1:1000 WB 
SIRT1 sc-15404 Santa Cruz 1:1000 WB 
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SIRT1 ab12193 Abcam 1:1000 WB 
SIRT1 04-1557 Millipore 1:1000 WB 
SREBP-2 ab30682 Abcam 1:1000 WB 
Ac-FOXO1/3a sc-49473 Santa Cruz 1:500 WB 
Ac-p53 2570 Cell Signalling 1:100 WB 
Ac-H4K16 07-329 Millipore 1:1000 WB 
Ac-tubulin T7451 Sigma 1:40 000 WB 
Histone H4 04-858 Millipore 1:5000 WB 
Histone H3 ab1791 Abcam 1:30 000 WB 
α-tubulin T9026 Sigma 1:30 000 WB 
Actin sc-47778 Sigma 1:40 000 WB 
anti-Goat HRP P044901 Dako 1:5000 WB 
anti-Mouse HRP P0260 Dako 1:5000 WB 
anti-Rabbit HRP 32460 Pierce 1:20 000 WB 
Anti-Goat 
biotinylated 
BA-9500 Dako 1:2000 IHC 
anti-BDNF 
(monoclonal) 
BDNF EMAX kit Promega 1:500 ELISA 
anti-BDNF 
(polyclonal) 
BDNF EMAX kit Promega 1:1000 ELISA 
Key: WB Western blotting, SEP Seprion ligand ELISA for aggregated huntingtin,  
TR-FRET time resolved Förster resonance energy transfer for soluble huntingtin, IHC 
immuno-histochemistry, HRP horse radish peroxidise conjugated. 
 
The antibodies MW1 (Ko et al., 2001), MW8 (Ko et al., 2001), 2B7 (Weiss et al., 
2009) and HDAC6 (Lee et al., 2010) are not commercially available and were kind 
gifts as noted in table 2.1. The antibodies S829 and S830 were developed in house 
by the Scottish Antibody Production Unit (Sathasivam et al., 2001).  
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2.1.5. Genotyping, sequencing and real time quantitative PCR primers and probes.  
Table 2.2 Summary of in house designed primer and probe sequences used in this 
thesis. 
Name Application 5’ – 3’ sequence 
HTT exon 1 forward RT-qPCR GCTGCACCGACCGAGT 
HTT exon 1 reverse RT-qPCR CGCAGGCTGCAGTTAC 
HTT exon 1 probe RT-qPCR CAGCTCCCTGTCCCGGCGG 
Hdac1 forward RT-qPCR TCTGAATACAGCAAGCAGATGCA 
Hdac1 reverse RT-qPCR ACAGAACTCAAACAAGCCATCAAAC 
Hdac1 probe RT-qPCR AGATTCAATGTTGGTGAGGACTGTCCGG 
Hdac2 forward RT-qPCR AGAAGATTGTCCGGTGTTTGATG 
Hdac2 reverse RT-qPCR CACAGCCCCAGCAACTGAA 
Hdac2 probe RT-qPCR TTGAGTTTTGTCAGCTCTCCACGGGTG 
Hdac3 forward RT-qPCR TCAGCCCCACCAATATGCA 
Hdac3 reverse RT-qPCR GAACTCGAAAAGTCCTGGAAACA 
Hdac3 probe RT-qPCR CCTTAATGCCTTCAACGTGGGT 
Hdac4 forward RT-qPCR CTGGCATCCCTGTGTCATTTG 
Hdac4 reverse RT-qPCR ACACAAGACCTGTGGTGAACCTT 
Hdac4 probe RT-qPCR CTGCCACCTTCCCCATGTCAGTCC 
Hdac5 forward RT-qPCR CCAGAGCCGGCATAACT 
Hdac5 reverse RT-qPCR GCAGGATTTCCAAGATGGTT 
Hdac5 probe RT-qPCR TCCCAACGAGTCGGATGGCATGT 
Hdac6 forward RT-qPCR GGAGACAACCCAGTACATGAATGAA 
Hdac6 reverse RT-qPCR CGGAGGACAGAGCCTGTAG 
Hdac6 probe RT-qPCR T ATCTGCATCC GAACTCATAT TCCTGTGCCT G  
Hdac7 forward RT-qPCR CCCACCTGTCAGACCCAAGT 
Hdac7 reverse RT-qPCR AGTCATAGACCAGCCCTGTAGCA 
Hdac7 probe RT-qPCR CTCAACAGCTCAGAGACA 
Hdac8 forward RT-qPCR GGCCCATCCATCCCTGTAG 
Hdac8 reverse RT-qPCR TTTAGATCGCCGGAGACAGTTT 
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Table 2.2. Continued. 
Name Application 5’ – 3’ sequence 
Hdac8 probe RT-qPCR TGGACGAGGGACCAGG 
Hdac9 forward RT-qPCR TGGCAGAATCCTCGGTCAGT 
Hdac9 reverse RT-qPCR CCCAGCAGGGCCATTGT 
Hdac9 probe RT-qPCR TCTCCAGGGTCAGGTCCCAGTTCACC 
Hdac10 forward RT-qPCR CCGCTATGAGCATGGAAGCT 
Hdac10 reverse RT-qPCR CAACTGCATCTGCATCAGACTCT 
Hdac10 probe RT-qPCR CTGGCCGTTTCTC 
Hdac11 forward RT-qPCR TGGGCATGAGCGAGACTTC 
Hdac11 reverse RT-qPCR GCGGTTGTAAACATCCATGATG 
Hdac11 probe RT-qPCR TGGGTGACAAGCGAG 
Sirt1 forward RT-qPCR TGTTGGTTGACTTCATCTTCCTT 
Sirt1 reverse RT-qPCR TCCAATGGCTTTTGAAAACTTTA 
Sirt1 probe RT-qPCR TTCATTTGTATGATACATTCGTATGTATG 
Sirt2 forward RT-qPCR TCCTGCAGAAAAGAATACACGAT 
Sirt2 reverse RT-qPCR CGATATCAGGCTTTACCACACTC 
Sirt2 probe RT-qPCR AGAGAAGATCTTCTCAGAAGCAACTCC 
Sirt3 forward RT-qPCR ACAAGAACTGCTGGATCTTATGC 
Sirt3 reverse RT-qPCR TCTTGCTGGACATAGGATGATCT 
Sirt3 probe RT-qPCR ACGTGGCAAGCTG GATGGACAGGA 
Sirt5 forward RT-qPCR CAGAGGCGCTGGAGGTTACTGGAG 
Sirt5 reverse RT-qPCR CCGGGCTTCACACTGGGCAATGGC 
Sirt5 probe RT-qPCR AGGCTCAGGACCTGGCAACCCCTCAG 
Sirt7 forward RT-qPCR GCCTCCCTCTTTCTACTCCTTATC 
Sirt7 reverse RT-qPCR TGCTCAGACTGGAGGCTTAGTTA 
Sirt7 probe RT-qPCR TACAAGTGTTCACTTTATAGAAGCCT 
Bdnf-b forward RT-qPCR CTGGATGCCGCAAACATGTC 
Bdnf-b reverse RT-qPCR GCAACCGAAGTATGAAATAACCATAG 
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Table 2.2. Continued. 
Name Application 5’ – 3’ sequence 
Bdnf-b probe RT-qPCR TTCCACCAGGTGAGAAGAGTGATGACCAT 
KEY: RT-qPCR - real time - quantitative PCR; Bdnf-b refers to protein coding exon i.e. 
Bdnf expressed from all promoters); HTT exon 1 (Human Huntington's disease 
transgene), Primer and probe mixes for ActB, Atp5b, Canx, Gapdh, Rpl13a and Ubc 
RT-qPCR assays were purchased from Primer Design. All RT-qPCR probes were 
labelled 5’ with FAM and 3’ with TAMRA. 
 
Table 2.3. Primer probe mixes obtained from Primer Design. Forward and reverse 
primer sequences shown as given by manufacturer. Probe sequences were not 
disclosed. 
Name Application 5’ – 3’ sequence 
Hmgcr forward RT-qPCR CCGAATTGTATGTGGCACTG 
Hmgcr reverse RT-qPCR TTATCTTTGATCTGTTGTGAACCAT 
Hmgcs1forward RT-qPCR CCTGGACCGCTGCTATTCT 
Hmgcs1 reverse RT-qPCR CAGTTTACAATATGGTGAGTGAAAGA 
Fdft1 forward RT-qPCR GGCGGAATTTTATACCCAAGATG 
Fdft1 reverse RT-qPCR GCTGCGACTGGTCTGATTG 
Fdps forward RT-qPCR TACAACCGCCTCAAGAGTCT 
Fdps reverse RT-qPCR GGGGTCACTTTCTCGTTTG 
Sqle forward RT-qPCR CAGAGCCCAATGTAAAGTTTATAGAA 
Sqle reverse RT-qPCR CCCAGTCTCCTTGTCCTTGT 
Idi1 forward RT-qPCR GTTGTTGAGTCCCTAACCCTAAA 
Idi1 reverse RT-qPCR CGCCATATACTTCCCTATGAAC 
Dhcr7 forward RT-qPCR CTGCCCTACCTCTACACACT 
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Table 2.3. Continued. 
Name Application 5’ – 3’ sequence 
Sirt4 forward RT-qPCR GGAAGAAGGACCAGGCAGAA 
Sirt4 reverse RT-qPCR GCTTCAGTCAGACACATCCATT 
Sirt6 forward RT-qPCR ACCCTGCGTGCTAGACAAA 
Sirt6 reverse RT-qPCR GGGCTTGGACTTATACGAAACA 
KEY: RT-qPCR - real time - quantitative PCR; Hmgcr – 3-hydroxy-3-methylglutaryl 
CoA reductase; Hmgcs1 - 3-hydroxy-3-methylglutaryl Coenzyme A synthase 1; Fdft1 
– farnesyl diphosphate farnesyltransferase 1, Fdps – farnesyl diphosphate synthase,  
Sqle – squalene epoxidase, Dhcr7 – 7-dehydrocholesterol reductase, Idi1 – 
isopentenyl diphosphate delta isomerase 1. 
 
Table 2.4. Primers used for genotyping and repeat sizing mice. 
Name Application 5’ – 3’ sequence 
HTT exon 1 forward Genotyping CGCAGGCTAGGGCTGTCAATCATGCT 
HTT exon1 reverse Genotyping GACTCACGGTCGGTGCAGCGGTTCC 
Hdac4 forward Genotyping CTTGTTGAGAACAAACTCCTGCAGCT 
Hdac4 reverse Genotyping AGCCCTACACTAGTGTGTGTTACACA 
Hdac6 forward Genotyping GTACAATGTGGCTCACAGAA 
Hdac6 reverse 1 Genotyping CAACTCTGCCTCTCCTGGAT 
Hdac6 reverse 2 Genotyping CAGGCACAGGAATATGAGTT 
Sirt2 forward Genotyping CAGGTGTGAGCAGTGTCAGAGTG 
Sirt2 reverse KO Genotyping GACGTCGAGGTGCCCGAAGGACC 
Sirt2 reverse WT Genotyping CCAGCCCAGAGTGGACACT 
HTT exon 1 forward Repeat sizing GAGTCCCTCAAGTCCTTCCAGCA 
HTT exon1 reverse Repeat sizing GCCCAAACTCACGGTCGGT 
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Table 2.5. Primers used for sequencing the Sirt2 mutation. 
Name Application 5’ – 3’ sequence 
Sirt2 forward Sequencing CAGGTGTGAGCAGTGTCAGAGTG 
Sirt2 reverse KO Sequencing GACGTCGAGGTGCCCGAAGGACC 
Sirt2 reverse WT Sequencing CCAGCCCAGAGTGGACACT 
Sirt2 forward Seq 2 Sequencing TCGTGCGCTCCTTTCGGTC 
Sirt2 forward Seq 3 Sequencing TGGCTTCGGTCGGAGCCAT 
Sirt2 forward Seq 4 Sequencing AGATCATCAATTTCGATCCGCTCCT 
Sirt2 forward Seq 5 Sequencing TGTTCAGCAGGGTCGGCGTGTT 
Sirt2 forward Seq 6 Sequencing TCAACTCGGCCATGCGCGGG 
Sirt2 forward Seq 7 Sequencing AGGCCTTCCATCTGTTGCTG 
Sirt2 reverse Seq 1 Sequencing ATGCAGGAGAAGAAGCGCGA 
Sirt2 reverse Seq 2 Sequencing CCAGCCCAGAGTGGACACT 
Chapter 2  Materials and Methods 
81 
 
2.1.6. Prepared solutions, buffers, and gels 
All solutions, buffers, and gels were prepared with distilled deionized water unless 
otherwise stated.  
 
Inhibitors added to buffers consisted of:  
1 mM PMSF 
5 µM TSA 
10 mM nicotinamide 
Complete protease inhibitor cocktail (1 tablet in 50 mL) 
 
Acid extraction buffer 
5% (v/v) Triton X-100 
3 mM DTT 
1 mM Orthovanadate  
5 mM NaF 
Inhibitors 
 
Agarose gel for resolution of PCR products (Prepared in 1x TE) 
1% (w/v) Ultra-pure agarose 
0.1 μg/ml Ethidium bromide 
 
AM buffer  
67 mM Tris-HCl pH 8.8 
16.6 mM (NH4)2SO4 
2 mM MgCl2 
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BDNF ELISA lysis buffer 
100 mM PIPES pH 7.0 
500 mM NaCl 
0.2% (v/v) Triton-X100 
0.1% (w/v) NaN3 
2 mM EDTA pH 8.0 
2% (w/v) BSA 
200 µM PMSF 
Complete protease inhibitor cocktail (1 tablet in 50 mL) 
 
Carbonate buffer 
25 mM NaHCO3 
25 mM Na2CO3 
Adjusted to pH 9.7 with 1 M HCl/1 M NaOH 
 
Coomassie staining solution 
0.25% (w/v) Brilliant blue R-250  
50% (v/v) methanol  
10% (v/v) acetic acid  
 
Coomassie de-staining solution 
16.5% (v/v) methanol  
0.5% (v/v) acetic acid 
 
HEPES Buffer 
50 mM HEPES pH 7.0 
150 mM NaCl 
10 mM EDTA 
1% NP-40 
0.5% sodium deoxycholate 
0.1% SDS 
Inhibitors 
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Immuno-peroxidase blocking solution (prepared in TBS) 
2% (w/v) BSA 
0.1% (v/v) Triton-X100 
 
Immuno-peroxidase staining solution (prepared in TBS) 
0.05% (w/v) DAB 
100 mM Tris–HCl pH 7.5  
0.03% (v/v) H2O2 solution 
 
KCl buffer 
50 mM Tris–HCl pH 8.0 
10% glycerol 
5 mM EDTA 
150 mM KCl 
10 mM DTT 
Inhibitors 
 
Laemmli loading buffer (2x) 
125 mM Tris–HCl pH 6.8 
20% glycerol 
4% SDS 
0.01% (w/v) bromophenol blue  
 
Luria-Berthani (LB) liquid medium 
1% (w/v) Bacto-tryptone 
0.5% (w/v) yeast extract 
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Luria-Berthani (LB) solid medium 
1% (w/v) Bacto-tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
1.5% (w/v) agar 
 
Phosphate buffered saline (PBS) 
137 mM NaCl 
2.7 mM KCl 
100 mM Na2HPO4 
2 mM KH2PO4 
Adjusted pH to 7.4 with HCl 
 
Resolving Gel 
20 – 60% (v/v) (for 6-18% arylamide gels) Protogel  
25% (v/v) Protogel resolving buffer  
1% (w/v) APS  
0.1% (v/v) TEMED 
 
RIPA Buffer 
150 mM NaCl 
1% (v/v) NP-40 
0.5% (w/v) Na deoxycholate 
0.1% (w/v) SDS 
50 mM Tris-HCl pH 8.0 
1 mM 2-mercaptoethanol 
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Seprion ELISA conjugate buffer  
150 mM NaCl 
4% (w/v) BSA 
1% (w/v) non-fat dried milk 
0.1% (v/v) Tween-20 
 
Sequencing precipitation solution 
120 mM C2H3O2Na (sodium acetate) 
Made up in 95% absolute ethanol 
 
Stacking Gel  
13% (v/v) Protogel  
25% (v/v) Protogel stacking buffer  
0.1% (w/v) APS  
0.2% (v/v) TEMED 
 
Sucrose buffer 
320 mM sucrose 
10 mM Tris-HCl pH 7.4 
50 mM KCl 




Sucrose Buffer 1 (for nuclear/cytoplasmic fractionation) 
575 mM sucrose 
25 mM KCL 
50 mM triethanolamine hydrochloride pH 7.5 
5 mM MgCl2 
1 mM DTT 
Inhibitors 
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Sucrose Buffer 2 (for nuclear/cytoplasmic fractionation) 
2.3 M sucrose 
2.5 mM KCL 
50 mM triethanolamine hydrochloride pH 7.5 
2.5 mM MgCl2 
1 mM DTT 
Inhibitors 
 
Tail lysis buffer (For DNA extraction) 
50 mM Tris-HCl pH 8.0 
100 mM EDTA 
0.5% (w/v) SDS  
0.5 mg/ml proteinase K 
 
Tris buffered saline (TBS) 
100 mM Tris-HCl pH 7.4 
150 mM NaCl 
Adjust pH to 7.4 using HCl 
 
Tris buffered saline-Tween 20 (TBST) 
20 mM Tris-HCl pH 7.6 
150 mM NaCl 
0.05% (v/v) Tween 20 
 
Tris-EDTA (TE) (1x) 
10 mM Tris-HCl pH 8 
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TR-FRET Antibody master mix buffer 
50 mM NaH2PO4 
400 mM NaF 
0.1% (w/v) BSA 
0.05% (v/v) Tween 20 
 
"Trottier" buffer 
100 mM Tris-HCl pH 9.0 
2% SDS 
6.7% glycerol 




50 mM Tris-HCl pH 7.5 
150 mM NaCl 
2 mM EDTA 
1% (v/v) Triton - X100 
Inhibitors 
 
Vehicle for CHDI-001945-0000-005 dosing 
30% PEG-400 
20% Solutol HS15 
0.5% Lutrol F68 
 
Western blotting transfer buffer 
25 mM Tris–HCl 
192 mM glycine 
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2.1.7. Computer programs and internet pages 
AM logger software (Linton Instruments) 
SPSS statistics software (IBM) 
Axiovision 4.1 (Zeiss) 
Quantity One (Biorad) 
Excel (Microsoft) 
Opticon 4 (Biorad) 
Omega (BMG Labtech) 
Gene Mapper v5.2 - 3730xl (Applied Biosystems) 
Vector NTI (Invitrogen) 
Sequencing Analysis 5.3.1 (Applied Biosystems) 
BLAST (NCBI) 
  




2.2.1. Mouse strains 
Hemizygous R6/2 mice were maintained by backcrossing R6/2 males to 
CBAxC57BL/6 F1 (CBF) females (B6CBAF1/OlaHsd, Harlan Olac, UK). Hdac6 knock-
out (Hdac6KO) mice were on C57BL/6 background and were backcrossed once to 
CBF. Sirt2 knock-out (Sirt2KO) mice were on C57BL/6/129Ola background and were 
backcrossed to CBF three times.  
2.2.2. Mouse husbandry 
At 4 weeks of age, mice were weaned into cages of 5 or 6 animals (Sirt2KOxR6/2 
phenotypic assessment study only). For both Hdac6KOxR6/2 and Sirt2KOxR6/2 
phenotypic assessment studies, each cage contained at least one representative of 
each genotype when available. Animals were housed under 12h light/12h dark 
cycle, with unlimited access to water and chow (Special Diet Services, Witham, UK). 
Cages were environmentally enriched with a cardboard tube. R6/2 mice and all 
mice in phenotypic assessment trials were always given mash food consisting of 
powdered chow mixed with water from 12 weeks of age until sacrificed. Mice in the 
Hdac6KOxR6/2 phenotypic assessment study were additionally given mash food at 
4-6 weeks of age. 
All procedures were approved by the King’s College London Ethical Review Process 
and were in accordance with the UK Home Office regulations. 
2.2.3. Mouse genotyping and repeat sizing 
All mice were genotyped by PCR of tail-tip DNA. Tails were collected at 10-14 days 
of age or post mortem and incubated at 50°C overnight in lysis buffer. Proteins 
were precipitated with 300 µL saturated salt solution and spun at 16,200 X g for 30 
min. The supernatant was decanted into tubes containing 650 µL 100% ethanol and 
shaken vigorously. The DNA was pelleted by centrifugation at 16,200  X g for 15 
min. The supernatant was discarded and pellets were washed with 70% ethanol, 
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spun for 5 min at 16,200 X g and the supernatant was removed. Pellets were air 
dried until all ethanol was evaporated and re-suspended in 250 µL 0.1x TE buffer. 
R6/2 mice were genotyped with HTT exon 1 forward and reverse primers at 5 µM 
final concentration. Hdac4 forward and reverse primers at 10 µM final 
concentration were included as internal control. All primers were used in a 10 µL 
reaction also containing 1 µL 100 ng/µL DNA, 5 µL Thermostart Mastermix (2x) and 
1 µL DMSO. Cycling conditions were as follows: 94°C for 15 min, (30 s at 94°C; 30 s 
at 60°C, 60 s at 72°C)x35 and 10 min at 72°C. 
For Hdac6 genotyping, 1 µL of all 3 primers was used at 10 µM in one multiplex 10 
µL reaction, also containing 1 µL of 100 ng/µL DNA, 0.8 µL 25 mM MgCl2, 1 µL 2 mM 
dNTP, 1 µL Sigma 10xPCR buffer and 0.1 µL Sigma Taq Polymerase. Cycling 
conditions were as follows: 94°C for 5 min, (94°C for 30s, 64°C for 30s and 72°C for 
1 min)x40, followed by 10 min at 72°C. 
Sirt2 mice were genotyped with all 3 primers at 5 µM final concentration in a 10 µL 
multiplex reaction also containing 1 µL 100 ng/µL DNA, 1.5 µL 2 mM dNTP, 3 µL 
Phire reaction buffer (5x) and 0.2 µL Phire Hot Start II Polymerase. Cycling 
conditions were as follows: 98°C for 30 s, (98°C for 20s, 63°C for 20s and 72°C for 30 
min)x35, followed by 1 min at 72°C. 
The CAG repeat size was determined using a FAM labelled forward primer and an 
unlabelled reverse primer, both at 100 mM in a 10 µL reaction also containing 100 
ng DNA,  1 µL dNTP's (2 mM), 1 µL DMSO, 1 µL AM buffer, 0.1 µL Amplitaq, with 
cycling conditions of 94°C for 90 s, (94°C for 30 s, 65°C for 30 s, 72°C for 90 s)x25, 
followed by 10 min at 72°C. Sequencing reactions containing 1 µL of the FAM 
labelled PCR product, 0.04 µL of MegaBACE ET900 size standard, and 9 µL of Hidi-
formamide were denatured at 94°C for 5 min and analysied with the ABI3730 
sequencer. Data was analysed using Gene Mapper software. 
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2.2.4. Dosing of mice with CHDI-001945-0000-005 
CHDI-001945-0000-005 (CHDI194500) SIRT1/SIRT2 inhibitor was obtained from 
Evotec through the CHDI Foundation. The desired amount of CHDI194500 was 
prepared freshly before dosing by weighing out the desired amount using an 
analytical balance and dissolving in “vehicle for CHDI194500 dosing solution”. 12 
week old wild type and R6/2 mice were weighed and given one acute dose of either 
vehicle, 1 mg/kg or 3 mg/kg solution of CHDI194500 by oral gavage in the morning 
and dissected either 4 or 8 hours later. Each treatment group contained age, sex 
and CAG repeat number matched mice. 
 
2.2.5. Mouse phenotypic assessment 
Mice from Hdac6KOxR6/2 and Sirt2KOxR6/2 crosses were phenotyped using the 
same procedures. All tests were performed blind to the genotype.  
 
2.2.5.1. Weight/brain weight 
Mice were weighed weekly to the nearest 0.01 g. Brains were harvested with optic 
bulbs and weighed to the nearest 0.001 g immediately after cervical dislocation. 
 
2.2.5.2. Grip strength 
Forelimb grip strength was assessed at 4 weeks of age and then weekly from 11 to 
14 weeks (Hdac6KOxR6/2) or bi-weekly from 7 weeks of age (Sirt2KOxR6/2), always 
prior to rotarod measurements. Mice were gently swung forward to firmly grasp 
onto the central metal frame and were pulled back until the grip on the metal 
frame was released, the force exerted measured by the attached force meter. Five 
measurements were performed for each mouse and the best three were used for 
statistical analysis. 




Motor coordination was assessed using an Ugo Basile 7650 rotarod, modified to 
accelerate from 4 to 44 rpm over 300 s. The ridges of the plastic drums were 
covered with bicycle inner tubing to provide a smooth slip-free surface. Mice were 
placed on the rotarod drum for 20 s for acclimatisation before the rotarod was 
allowed to accelerate. If a mouse fell 3 times before acceleration was switched on, 
the latency to fall was recorded as 20 s.  Mice were measured three times a day for 
4 days at 4 weeks of age and three times a day for 3 days at 8, 10, 12 and 14 weeks 
of age. Data from the first two days (at 4 weeks of age) or first day (all other time 
points) were not used for statistical analysis. 
 
2.2.5.4. Activity 
Spontaneous exploratory motor activity was measured at 5, 7, 9, 11 and 13 weeks 
of age by placing mice individually in the 1053 activity cages for 30 min during the 
light phase. Each cage measured 367 x 207 x 140 cm, had a thin layer of wood 
chippings, 4 food pellets and a water bottle distributed so as not to interfere with 
the array of infrared beams that measured the mouse activity and mobility. Mice 
were tested at the same time of day, with male mice always tested before female 
mice and cages cleaned thoroughly in between the two sexes. Data collection was 
started immediately after the mouse was placed in the activity cage, by the AM 
Logger software recording the number of beam breaks occurring in 1 min intervals. 
Data was then exported to Microsoft Excel and analysed for activity (total number 
of beam brakes in the lower level), mobility (at least two consecutive beam breaks 
in the lower level), rearing (beam break in upper level) and centre rearing (beam 
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2.2.6. Sirt2 KO mutation sequencing 
 
2.2.6.1. PCR and cloning of the product 
DNA was isolated from Sirt2KO and wild type littermate mice as described above 
(2.2.3). PCR was performed with Qiagen Type-it Mutation Detection kit using 200 ng 
DNA in 50 µL reaction containing also 25 µL 2x Master mix, 5 µL forward primer,  5 
µL reverse primer and 10 µL Q solution, with cycling conditions of: 95°C for 10 min, 
(95°C for 30 s, 65°C for 90 s, 72°C for 60 s)x30 and 68°C for 10 min. The product was 
run on a 1.5% agarose gel and excised under long range UV light (360 nm). The 
Qiaquick Gel Extraction kit was used according to manufacturer's instructions. 
Briefly, the gel slice was solubilised at 50°C in 3 volumes of buffer QG (provided 
with the kit). Before loading onto an anion exchange chromatography column, 1 
volume of isopropanol was added. DNA was washed with buffer QG and PE 
(provided with the kit), eluted with ultra-pure water and quantified using nanodrop. 
The purified PCR product was cloned into TOP10 bacteria using the TOPO TA 
cloning kit according to manufacturer's instructions. Briefly, 1 µL TOPO vector 
(provided with the kit) was incubated with 1 µL PCR product (50-100 ng DNA) in 
ligation reaction containing also 1 µL salt solution (provided with the kit) and 1 µL 
water for 30 min at room temperature. The ligation reaction was then added to 
TOP10 heat competent bacteria and left for 30 min on ice. Bacteria were heat 
shocked for 45 s at 42°C, transferred to ice for 5 min, incubated with pre-warmed 
SOC medium (provided with the kit) for 30 min at 37°C shaking at 200 rpm and 
streaked onto agar plates with 100 µg/mL of appropriate antibiotic.  
 
2.2.6.2. DNA isolation and sequencing 
Bacterial colonies were picked and grown overnight in 3 mL LB medium with 100 
µg/mL of appropriate antibiotic at 37°C and shaking at 200 rpm. Plasmid DNA was 
isolated with Qiaprep Spin Miniprep Kit according to manufacturer's instructions 
and eluted in ultra-pure water. 
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Sequencing reactions were carried out in 6.25 µL volume containing 200-500 ng 
DNA, 0.25 µL BigDye v3.1, 1.25 sequencing buffer (provided with the BigDye kit), 
0.25 µL primer (80 ng/µL) under cycling conditions of: 96°C for 2 min, (96°C for 30 s, 
50°C for 20 s, 60°C for 1 min)x30. Sequencing PCR products were precipitated with 
26 µL sequencing precipitation solution, incubated for 10 min at room temperature 
and centrifuged at 3,000 X g for 20 min. The supernatant was removed with a brief 
spin (<200 X g and less than 5 s) of the plate inverted onto tissue paper. The pellet 
was washed with 100 µL 70% ethanol, centrifuged at 3,000 X g for 20 min, cleared 
of supernatant as described above and re-suspended in 10 µL Hidi-formamide. The 
sample was then denatured at 96°C for 2 min and analysed with an ABI3730 
sequencer. Sequence traces were analysed with the ABI Sequencing Analysis and 
Vector NTI programmes.  
 
2.2.7. Tissue preparation 
Dissected brain regions or peripheral tissues were snap frozen in liquid nitrogen and 
stored at -80°C until use. Dissected whole brains were snap frozen in isopentane at 
-55°C, transferred to 5 mL Bijou tubes and stored at -80°C until used.  
 
2.2.7.1. Nuclear/cytoplasmic fractionation 
Whole brains were homogenised in 2 volumes of ice cold sucrose buffer 1 with 10 
gentle pestle strokes in a Dounce homogeniser. The homogenates were centrifuged 
at 500 X g for 15 min at 4°C. The supernatant (cytoplasmic fraction) was removed 
and stored at -80°C. The pellet was re-suspended in 1 mL of ice cold buffer 1 with 
an additional 10 gentle pestle strokes in the Dounce homogeniser. Two volumes of 
ice cold sucrose buffer 2 were added to the homogenate and the solution was 
mixed until uniform. Ultracentrifuge tubes were layered with a 0.5 mL cushion of 
sucrose buffer 2 and the homogenate was gently layered on top. The tubes were 
appropriately balanced and spun in pre-cooled SW41 rotor tubes at 124,000 X g for 
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1h at 4°C. Subsequently, the supernatant was removed and the pellet re-suspended 
in 0.5 mL buffer 1, transferred to fresh 1.5 mL tubes and spun at 800 X g for 15 min 
at 4°C. The supernatant was removed and the pellet was re-suspended in 0.5mL 
buffer 1, spun at 800 X g for 15 min at 4°C twice more before being re-suspended in 
50 µL of buffer 1. The nuclear fraction was sonicated on ice for 10s at 80Hz. The 
protein concentration of both fractions was determined with the BCA assay for 
each sample. 
 
2.2.7.2. Acid extraction of histone proteins 
Tissues were homogenised in 1 volume of acid extraction buffer using a polytron 
homogenising probe and centrifuged at 800 X g for 8 min at 4°C. The supernatant 
was removed and the pellet washed twice by re-suspending in acid extraction 
buffer, and centrifuging at 800 X g for 8 min at 4°C. The pellet was then re-
suspended in 80 µL of 0.2 M HCl and incubated for 3 h at 4°C with constant shaking 
at 800 rpm. Samples were then centrifuged at 800 X g for 8 min at 4°C, the 
supernatant collected, neutralised with 16 µL of 1 M NaOH, and the protein 
concentration determined for each sample with the BCA kit. 
 
2.2.7.3. Tissue preparation for SDS PAGE and Western blotting 
Unless nuclear/cytoplasmic fractionation, acid extraction or Seprion ELISA were 
performed, tissue was homogenised in 1 volume of ice cold Hepes, KCl, RIPA, 
Sucrose, “Trottier” or TX buffer (all buffers – SIRT1 antibody testing; TX – tubulin 
acetylation, RIPA – all other experiments) with a polytron homogenising probe. 
Homogenates were sonicated on ice for 10 s at 80 Hz. Lysates were cleared by 
centrifugation at 16,200 X g for 15 min at 4°C. Protein concentration was measured 
by BCA assay for each sample. 
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2.2.8. SDS PAGE and Western blotting 
Samples were diluted with 2x Laemmli buffer and denatured for 5 min at 95°C.  
Equal amounts of protein were loaded onto SDS polyacrylamide gel with a size 
reference. Proteins were transferred onto nitrocellulose membrane at 120 V for 90 
min by submerged transfer apparatus in transfer buffer. Membranes were blocked 
in 5% non-fat dried milk in PBS for at least 1 h. Primary antibodies were applied in 
0.02% PBS-Tween 20 (PBST) for 20 min (acetylated α-tubulin; α-tubulin; actin; H3 
and H4), 1 hour (S830; SIRT2 (S8847) at room temperature or overnight (HDAC6; 
SIRT2 (sc-20966); SIRT1 (all), SREBP-2, Acetylated H4K16; Acetylated p53; 
Acetylated FOXO1) at 4°C. Blots were washed three times for 5 min in 0.2% PBST 
and incubated with appropriate HRP coupled secondary antibody. For signal 
detection enhanced chemi-luminescence (ECL) detection system, hyperfilms and 
Xenograph developer were used according to the manufacturers’ instructions. 
Signals were quantified using GS-800 densitometer.  
Antibodies and dilutions at which they were used are presented in Table 2.1. 
 
2.2.8.1. Coomassie staining of polyacrylamide gels 
Polyacrylamide gels were stained with Coomassie solution for 30 min with gentle 
agitation. Gels were then washed several times in ddH2O and three times for 10 
min in de-staining solution. Gels were dried in a vacuum gel drier. 
 
2.2.9. Seprion ELISA 
2.5% (w/v) (brain) or 10% (quadriceps muscle) lysates were prepared by 
homogenising tissue in ice cold RIPA buffer in Lysing Matrix D tubes in a ribolyser. 
15 µL of homogenate was mixed in sequential order with 3 µL of 10% SDS, 62 µL of 
ultra-pure water and 20 µL 5x Seprion capture buffer. Samples was loaded onto 
Seprion plates and incubated for 1 h at room temperature with gentle shaking. 
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Samples were removed and the plate was washed 5x with sterile filtered 0.1% PBS-
Tween 20 (PBST). Plates were incubated with MW8 antibody diluted in freshly 
prepared conjugate buffer for 1 h at room temperature with gentle shaking. 
Primary antibody was removed, plates washed as above, incubated with secondary 
antibody for 45 min at room temperature with gentle shaking, washed again and 
incubated for 5-10 min with TMB Plus (in the dark). Signal development was 
stopped with 0.5 M HCl and absorbance was immediately measured with a 
microplate reader at 450 nm.  
 
2.2.10. BDNF ELISA 
Flat bottom 96-well ELISA plates were coated with BDNF monoclonal antibody 
diluted in carbonate buffer and incubated overnight at 4°C. Contents were removed 
and plates were washed 5x with TBST and blocked with Block&Sample buffer 
(provided with the kit) for 1 h at room temperature without shaking. 2.2% (w/v) 
lysates were prepared in BDNF ELISA lysis buffer, sonicated briefly on ice (10 pulses 
at 80 Hz), and cleared by centrifugation at 16,200 X g for 15 min at 4°C. After the 
Block&Sample buffer was removed from the plate, it was washed as above and 
lysates as well as a series of dilutions of BDNF standard (provided with the kit) were 
applied to the plate and incubated for 2 h at room temperature with a shaking 
speed of 400 rpm. Contents were removed, plates washed as above and incubated 
with anti-human BDNF polyclonal antibody in Block&Sample buffer for 2 h as 
before. Next, plates were washed, incubated with secondary antibody in 
Block&Sample buffer for 1 h, washed again, and incubated with 100 µL TMB One 
for 10 min (in the dark). The reaction was stopped with 1 M HCl and optical density 








Mouse brain and liver tissues were sonicated on ice in 10 volumes of 0.4% PBS-
Triton-X100 supplemented with protease inhibitors. Quadriceps muscle was 
homogenised in 10 volumes of the above buffer by ribolysing in Lysing Matrix D 
tubes. 1.5 ng/well europium-cryptate and 30 ng/well D2-conjugated antibodies 
were incubated with 10 µL homogenate in a 384-well microplate overnight at 4°C. 
Signal was measured after excitation at 320 nm (time delay 100 µs, window 400 µs, 
100 flashes/well) with a xenon lamp Envision plate reader. Signal was measured at 
680 nm (europium-cryptate background excitation) and at 665 nm (specific 
excitation of D2 by europium-cryptate). Relative fluorescence of 665/680 nm 
represented artefact corrected amount of simultaneous binding of both antibodies 
to huntingtin trans-protein. 
 
2.2.12. RNA extraction 
RNA extraction was performed using Qiazol, an RNeasy kit, and Rnase-free DNaseI 
supplied by Qiagen, according to manufacturer’s instructions. All steps were 
performed at room temperature. Mouse tissue was homogenised in two volumes 
of Qiazol and snap frozen on dry ice. After thawing, the homogenates were left for 
5 min at room temperature. Subsequently, 200 µL of chloroform was added and 
homogenates were shaken vigorously for 15 s and spun at 16,200 X g for 15 min. 
The aqueous phase was transferred to a fresh tube to which one volume of 70% 
ethanol was added. The tubes were shaken and the contents were transferred to 
Qiagen RNeasy kit extraction columns. Binding of the RNA and all subsequent 
washing steps were achieved by centrifugation for 15 s at 16,200 X g. The columns 
were washed with 350 µL buffer RW1 (provided with kit) and 80 µL of Qiagen 
RNase-free DNaseI (10 µL DNaseI stock in 70 µL RDD buffer) was applied to the 
column centre and incubated at room temperature for 30 min. The DNaseI was 
washed away with 350 µL buffer RW1. Next, the columns were washed twice with 
500 µL buffer RPE (provided with kit). Columns were then placed into fresh 
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collection tubes and spun again to remove any residual buffer. RNA was eluted into 
new 1.5 mL collection tubes by applying 50-40 µL RNase free water directly to the 
middle of the column and incubating for 1 min before centrifugation. 
 
2.2.13. cDNA synthesis 
RNA concentration and quality were assessed by measuring absorbance at 230 nm 
and 260 nm by nanodrop spectrophotometer for each sample. 1 µg total RNA was 
incubated with 9 µL ultra-pure water, 2 µL DTT (0.1 M) and 1 µL random hexamer 
primers (100 ng/µL) for 2 min at 94°C and cooled on ice for 2 min. To this, 8 µL 
master mix containing 2 µL dNTPs (10 mM), 4 µL 1st strand buffer (5x), 0.25 µL 
RNasin, 1 µL MMLV-Reverse transcriptase, and 0.75 µL ultra-pure water was added 
and the samples were incubated for 10 min at 23°C, 40 min at 37°C and 5 min at 
94°C, cooled down to 4°C and subsequently diluted 1:10 with ultra-pure water. 
 
2.2.14. Real Time qPCR 
Taqman real time qPCR reactions were performed in triplicate or duplicate 
(technical replicates) on thermocyclers Chromo4 or CFX96 respectively. For genes 
where primer/probe mix was available, 3 µL of cDNA was incubated with 0.6 µL 
primer/probe mix, 6 µL Precision Master Mix (2x) and 2.4 µL water. For other 
genes, 3 µL of cDNA was combined with 0.45 µL of each primer (100 µM), 0.3 µL of 
the probe (100 µM), 7.5 µL of Precision Master Mix and 3.3 µL water. The reaction 
for housekeeping genes was incubated for 10 min at 95°C, followed by 40 cycles of 
95°C for 15 s, 50°C for 30 s and then signal reading. The reaction for genes of 
interest was incubated for 10 min at 95°C, followed by 40 cycles of 95°C for 15 s, 
60°C for 30 s and then signal reading. The data was analysed relative to 
housekeeping genes with the ΔCt method. Samples that did not have two reads less 
than 0.5 Ct from each other were excluded from analysis.  
 




Whole brains were cut into 15 µm saggital sections with a Bright instruments 
cryostat. Sections were incubated briefly in TBS for rehydration, fixed for 15 min in 
4% paraformaldehyde in TBS, washed twice in TBS for 15 min and permeabilised in 
0.1% TBS-Triton-X100 (v/v) for 15 min. Next, sections were washed twice for 15 min 
in TBS, incubated for 10 min in 4% hydrogen peroxide, washed in water and blocked 
in immune-peroxidase blocking solution. S830 primary antibody was diluted in 
immune-peroxidase solution and incubated with the sections overnight at 4°C. 
Subsequently, sections were washed twice for 15 min in TBS and incubated for 1 h 
at room temperature with biotinylated secondary antibody diluted in immune-
peroxidase blocking solution. After washing twice with TBS for 15 min, sections 
were incubated with the ABC-HRP complex from Elite ABC kit according to 
manufacturer’s instructions. Staining solution was then applied, colour allowed to 
develop for 5 min and sections were washed extensively. Sections were then 
stained with 20% (v/v) Methyl green, washed and allowed to dry overnight. Further 
dehydration was achieved by washing with 100% ethanol and histoclear. Slides 
were mounted with coverslips with DPX mounting media. Images were taken from 
the Axioscope 2 light microscope with Axiocam camera and Axiovision software.  
 
2.2.16. Statistical Analysis 
Statistical analysis was performed with SPSS (two-way ANOVA, repeated measures 
ANOVA General Linear Model with Greenhouse-Geisser correction for non-
sphericity) or Microsoft Excel (Student’s t-test) software.   
For mouse phenotypic assessment, weight, rotarod and grip strength were analysed 
with repeated measures ANOVA to determine overall effects of genotype and time 
and at each time point with two-way ANOVA (Hdac6KOxR6/2) or three-way ANOVA 
(Sirt2KOxR6/2) to determine when the effects were occurring. Brain weight was 
analysed by two-way ANOVA (Hdac6KOxR6/2 cross) or three-way ANOVA 
(Sirt2KOxR6/2 cross). Activity was analysed with repeated measures ANOVA at each 
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time point separately to determine whether there were differences in activity 
patterns between the genotypes.  
For western blotting, ELISA, TR-FRET and qPCR, group means were compared by 
Student’s t-test. When more than two groups were investigated, they were 
compared by one- or two-way ANOVA. Post-hoc pairwise comparison with 
Bonferroni correction was used for the analysis of cholesterol genes expression in 
Sirt2KOxR6/2 at 15 weeks of age.  
 
2.2.17. Fluor de Lys SIRT2 activity assay 
Tissues were homogenised in Assay Buffer (provided with the kit) supplemented 
with protease inhibitor cocktail (1 tablet/10 mL), sonicated at 80 Hz for 10 s, and 
centrifuged at 16,200 X g for 15 min at 4°C before protein concentration was 
determined for each sample with the BCA kit. Lysates were diluted to 0.2 µg/µL, 
incubated for 10, 20, 40 or 60 min at 37°C, supplemented with DTT to a final 
concentration of 10 mM, and again incubated for 10 min at 37°C. Samples were 
loaded onto 96-well plates (provided with the kit) and Fluor-de-Lys acetylated 
substrate was added to a final concentration of 100 µM with or without 3 mM 
NAD+. Reactions were incubated at 37°C for 1 h and stopped by adding 1 volume of 
Developer (provided with the kit). The plate was incubated for 30 min at room 
temperature and signal was read (excitation at 355 nm, emission at 460 nm) using 
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Abstract
Huntington’s disease (HD) is a progressive neurodegenerative disorder for which there is no effective disease modifying
treatment. Following-on from studies in HD animal models, histone deacetylase (HDAC) inhibition has emerged as an
attractive therapeutic option. In parallel, several reports have demonstrated a role for histone deacetylase 6 (HDAC6) in the
modulation of the toxicity caused by the accumulation of misfolded proteins, including that of expanded polyglutamine in
an N-terminal huntingtin fragment. An important role for HDAC6 in kinesin-1 dependent transport of brain-derived
neurotrophic factor (BDNF) from the cortex to the striatum has also been demonstrated. To elucidate the role that HDAC6
plays in HD progression, we evaluated the effects of the genetic depletion of HDAC6 in the R6/2 mouse model of HD. Loss
of HDAC6 resulted in a marked increase in tubulin acetylation throughout the brain. Despite this, there was no effect on the
onset and progression of a wide range of behavioural, physiological, molecular and pathological HD-related phenotypes.
We observed no change in the aggregate load or in the levels of soluble mutant exon 1 transprotein. HDAC6 genetic
depletion did not affect the efficiency of BDNF transport from the cortex to the striatum. Therefore, we conclude that
HDAC6 inhibition does not modify disease progression in R6/2 mice and HDAC6 should not be prioritized as a therapeutic
target for HD.
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Introduction
Huntington’s disease (HD) is an autosomal dominant progres-
sive neurodegenerative disorder with a mean age of onset of 40
years [1]. The most characteristic features of symptomatic HD
patients are motor disorders, cognitive decline, psychiatric
disturbances and weight loss. The disease progresses on average
for 15–20 years and although the first symptomatic drug has
recently been approved by the Federal Drug Administration, there
is still no disease modifying treatment available [2]. The cause of
HD is the expansion of a CAG trinucleotide repeat in the HTT
gene, resulting in an expanded polyglutamine (polyQ) tract in the
N-terminus of the huntingtin protein [3]. HD pathology is mostly
observed in the brain with the striatum displaying pronounced
atrophy, although other brain regions are also affected [4,5]. A
prominent feature of HD is the presence of mutant huntingtin
containing cytoplasmic aggregates and nuclear inclusions that are
ubiquitin positive [6]. At the molecular level, many changes have
been observed that may contribute to HD pathology including
abnormal levels of neurotransmitters and their receptors, mito-
chondrial dysfunction, metabolic disturbances, transcriptional
dysregulation and disruption of microtubule based transport,
among others [7].
Histone deacetylases (HDACs) have been proposed as possible
therapeutic targets for HD [8]. There are altogether 18
mammalian HDAC’s, divided into four classes depending on
their homology to yeast enzymes. Class I and II enzymes have
Zn2+ dependent catalytic domains and are homologous to yeast
Rpd3 and Hda1, respectively. HDAC11 is also Zn2+ dependent
but has been placed in a separate category (class IV) due to a lack
of sufficient sequence similarity to any other group [9]. Sirtuins
(class III) are homologous to yeast Sir2 and use a different
mechanism requiring NAD+ as a co-factor [10]. Studies on HDAC
inhibition have shown promising results in fly, worm and mouse
models of HD [11,12,13,14].
HDAC6 is a target of some of the broad range HDAC inhibitors
including suberoyl anilide hydroxamic acid (SAHA) and trichostatin
A (TSA) [15]. It is a particularly interesting protein, in that it is the
only known HDAC with two catalytically active deacetylase
domains and a ubiquitin interacting domain [16,17]. Moreover,
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its main activity appears to be in the cytoplasm, where it has been
shown to deacetylate a-tubulin, HSP90 and cortactin, among others
[18,19,20,21]. HDAC6 is also of particular interest in HD. In cell
models, HDAC6 has been shown to act against protein misfolding
toxicity by taking part in the formation of a juxtanuclear structure
termed the aggresome, a microtubule dependent inclusion body to
which dispersed aggregates are targeted and transported by the
dynein motor [22]. HDAC6 is required for the targeting of
ubiquitinated aggregates to the aggresome, thought to serve as an
adaptor protein by binding both poly-ubiquitin chains and the
dynein motor. Interestingly, deacetylase activity and intact
microtubules are essential to this process implying that aggresome
formation depends on tubulin acetylation status [23]. Similarly, it
has been shown that HDAC6 is critical for the formation of stress
granules [24]. In addition, it has recently been shown that in the
case of proteasome overload, aggresome formation might provide
the means by which the cell removes accumulated misfolded
proteins by autophagy and that HDAC6 is essential for this pathway
[25]. In a Drosophila melanogastermodel of spinal and bulbar muscular
atrophy (SBMA) HDAC6 expression rescued neurodegeneration in
an autophagy-dependent manner [26]. In fact, HDAC6 has also
recently been shown to be involved in ubiquitin selective quality
control autophagy by regulating the lysosome to autophagosome
fusion [27]. On the other hand, a study in an HD cell model has
indicated that increasing tubulin acetylation by HDAC6 inhibition
could rescue the brain-derived neurotrophic factor (BDNF)
transport deficit from the cortex to the striatum [28]. Taken
together, these findings strongly suggest that HDAC6 inhibition
should modify HD progression.
Based on the previous studies in cell culture models of HD, we
might expect that loss of HDAC6 would increase aggregate load and
exacerbate the phenotype in a mouse model of HD. On the other
hand, an increase in cortico-striatal BDNF transport might be
expected to improve some HD-related phenotypes. To determine
whether HDAC6 regulates aggregate formation and turnover and/or
plays a role in BDNF transport in a mouse model of HD, we crossed
the R6/2 transgene onto an Hdac6 knock-out background. As Hdac6
is located on the X-chromosome, hemizygous male mice are
nullizygous for Hdac6 [29]. The R6/2 mouse has an early onset
and rapid phenotype progression [30] and at late stage disease
expresses HD-related phenotypes that are extremely similar to those
that develop in the HdhQ150 knock-in model of HD
[31,32,33,34,35]. We showed that in the absence of HDAC6, levels
of tubulin acetylation were increased throughout the brain. However,
this had no effect on R6/2 readouts in a battery of physiological and
behavioural assessments. We also found no difference in levels of
soluble or aggregated huntingtin trans-protein upon ablation of
HDAC6. Our data thus suggest that HDAC6 is not important for
aggregate clearance in a mouse model of HD. Finally, we established
that increased tubulin acetylation did not affect levels of BDNF in the
striatum. We conclude that inhibition of HDAC6 should not be
pursued as a high priority therapeutic target for HD.
Results
Hdac6 knock-out mice (Hdac6KO) are viable and fertile, and do not
show any overt phenotypes [36]. Before analysing the effect of the
genetic depletion of HDAC6 on phenotype progression in the R6/2
mice, we wanted to verify that these mice do not express HDAC6 at
the mRNA or protein level. cDNA was prepared from cortex,
striatum, cerebellum, muscle and liver from 4 week old wild type
(WT) andHdac6KOmice and analysed by real-time quantitative RT-
PCR (qPCR).Hdac6 was not expressed in tissue fromHdac6KOmice
(Fig. 1A). HDAC6 protein could not be detected in brain or testes by
western blot analysis (Fig. 1B). Consistent with previous reports,
HDAC6 levels were higher in testes than in brain [36]. R6/2 mice in
our colony reach end-stage disease at 15 weeks of age. In order to
determine whetherHdac6 is stably expressed during this disease time-
frame, we compared the levels of Hdac6 mRNA in WT mice at 4, 9
and 15 weeks of age. We established that Hdac6 is expressed at
relatively stable levels in WT mice from 4 to 15 weeks of age, with
only a 15% reduction being detected in the cortex at 9 weeks as
compared to 4 weeks of age (Fig. 1C). Transcriptional dysregulation is
a hallmark of the molecular pathogenesis of HD and is recapitulated
by the R6/2 mouse model [37]. Thus, to ensure that Hdac6 is not
dysregulated in R6/2 mice, we measured Hdac6 expression levels in
R6/2 mice at 4, 9 and 15 weeks of age in cortex, striatum and
cerebellum and compared them to those observed in WT mice.
Hdac6 levels were unchanged between WT and R6/2 mice (Fig. 1D)
indicating that there was no effect of disease progression on the
expression of Hdac6.
Tubulin is hyperacetylated upon genetic depletion of
HDAC6 but is not altered by the presence of the R6/2
transgene
As HDAC6 is an a-tubulin deacetylase, depletion of HDAC6
should result in tubulin hyper-acetylation. It has been previously
reported that the Hdac6KO line of mice used in this study, has
elevated levels of acetylated tubulin in peripheral tissue but not in
brain [36]. However, increased tubulin acetylation has been
shown to occur in brain as a consequence of HDAC6 depletion in
an alternative Hdac6 knock-out mouse [38]. To resolve this
discrepancy, we analysed tubulin acetylation in our Hdac6KO
mice by western blotting, normalising levels of acetylated tubulin
to those of total a–tubulin. We found that tubulin is hyperace-
tylated in the cortex, striatum and cerebellum of Hdac6KO mice at
4, 9 and 15 weeks of age as compared to WT littermates (Fig. 2A
and C). The extent of hyperacetylation in Hdac6KO mice became
less pronounced with age in the cortex and cerebellum, perhaps
explaining the earlier results.
Acetylation of lysine 40 on a-tubulin has been demonstrated to
increase the binding of certain molecular motor proteins to
microtubules, thus modulating intracellular transport dynamics
[39]. Impairment of intracellular transport has been suggested to
contribute to the molecular pathology of HD [40]. Therefore, we
investigated whether tubulin acetylation is altered by the presence
of the R6/2 transgene. Our results indicate that there is no
difference in tubulin acetylation between R6/2 and WT mice in
cortex, striatum and cerebellum at 4, 9 or 15 weeks of age (Fig. 2B
and D). This is consistent with the fact that there is no difference in
the expression of Hdac6 between WT and R6/2 mice in the same
tissues throughout disease progression (Fig. 1D).
Genetic Depletion of HDAC6 does not modify HD
physiological and behavioural phenotypes in R6/2 mice
Previous studies have indicated that both over-expression and
depletion of HDAC6 could ameliorate HD phenotypes in cell
culture [25,28]. Here, we investigate whether HD-related
phenotypes are modulated by the genetic depletion of HDAC6
in an HD mouse model. R6/2 males were bred to Hdac6KO
heterozygous females and a longitudinal phenotyping study was
performed to compare Hdac6KOxR6/2 double mutant (Dble)
mice to WT, Hdac6KO and R6/2 littermates. As Hdac6 is an X-
linked gene [29], males carrying the mutant allele are effectively
nullizygous for Hdac6 (Fig. 1A–B). We obtained at least 16 males
for each genotype and the R6/2 and Dble groups were well
matched for their CAG repeat size (p = 0.338) (Fig. 3A).
No Effect of Hdac6 Knock-Out in an HD Mouse Model
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Mice were weighed weekly to the nearest 0.1 g from 4 weeks of
age onwards (Fig. 3B). R6/2 mice weighed significantly less than
WT mice overall (F(1,64) = 14.28, p,0.001) and gained weight at a
significantly slower rate (F(2,640) = 55.99, p,0.001). HDAC6
depletion by itself had no impact on the weight (F(1,64) = 0.567,
p = 0.454) and weight gain (F(2,640) = 0.247, p= 0.741) when
compared to WT mice. Absence of HDAC6 did not affect the
loss of weight in R6/2 (F(1,64) = 0.007, p = 0.931) or the decreased
rate in weight gain (F(2,640) = 0.512, p = 0.567). These data indicate
that depletion of HDAC6 does not affect weight loss in the R6/2
mice (Fig. 3B).
RotaRod measures motor coordination and balance, both of
which become significantly impaired in R6/2 mice. Here the
animals were subjected to RotaRod analysis at 4, 8, 10, 12 and 14
weeks of age (Fig. 3C). As expected, R6/2 mice performed worse
than WT mice (F(1,71) = 39.74, p,0.001) and that performance
deteriorated over the course of the study (F(3,1420) = 18.23,
p,0.001). The performance of Hdac6KO mice was similar to
WT (F(1,71) = 0.32, p= 0.573) but the variability in their perfor-
mance over time was significantly different to that of WT mice
(F(3,1420) = 3.53, p= 0.020). Nevertheless, the Hdac6 knock-out
genotype did not modify the performance of R6/2 mice overall
(F(1,71) = 0.40, p= 0.529) or with age (F(3,1420) = 1.09, p = 0.352).
Forelimb grip strength was measured at 4 weeks of age and
weekly from 11 to 14 weeks of age (Fig. 3D). As expected, the
overall grip strength of R6/2 mice was worse than that of WT
(F(1,67) = 142.41, p,0.001) and deteriorated over time
(F(3,536) = 50.69, p,0.001). The grip strength of Hdac6KO mice
was no different from WT mice either overall (F(1,67) = 0.621,
p = 0.434) or with time (F(3,536) = 1.97, p = 0.121). Nullizygosity for
Hdac6 did not have an effect on the overall grip strength of R6/2
mice (F(1,67) = 3.17, p = 0.081) nor did it influence the deterioration
in grip strength over the course of the experiment (F(3,536) = 0.856,
p = 0.463). Therefore, genetic depletion of HDAC6 does not
modify loss of forelimb muscle strength in R6/2 mice.
Spontaneous motor activity was recorded for each mouse for
30 min in an infrared activity monitoring cage bi-weekly from 5
weeks of age onwards (Fig. 3E and Fig. S1). Data were analysed by
repeated measures general linear model ANOVA and p-values are
presented in Table S1. At 5 weeks of age, levels of activity between
mice of all genotypes were comparable (Fig. 3E and Table S1: R6/
2 Genotype and Hdac6KO Genotype), but a significant difference
in the pattern of activity over time was already evident for activity
(p = 0.011) and rearing (p = 0.016) for mice carrying the R6/2
transgene. At 7 weeks of age the R6/2 genotype significantly
affected the activity and mobility (p,0.001) of the mice. A clear
Figure 1. HDAC6 expression in Hdac6KO, WT and R6/2 mice. (A) Taqman qPCR assay showing absence of Hdac6mRNA expression in Hdac6KO
mice as compared to WT; n = 3/genotype. Data normalised to Atp5b and expressed as fold change of WT for each tissue. (B) Western blot showing
absence of HDAC6 protein expression in Hdac6KO mice as compared to WT. (C) Taqman qPCR assay showing that Hdac6 mRNA expression does not
change with age in WT mice in cortex, striatum and cerebellum; n= 8/genotype, data normalised to Atp5b and Rpl13a (cortex), Gapdh (striatum) and
18S RNA (cerebellum) and expressed as fold change of 4 weeks. (D) Taqman qPCR assay showing no difference in Hdac6 mRNA expression between
WT and R6/2 mice in cortex, striatum and cerebellum at 4, 9 and 15 weeks; n$6/genotype, data normalised to WT for each time point and brain
region. Error bars represent SEM. * p,0.05 as compared to 4 weeks. KO – Hdac6 knock out, WT – wild type, Cor - cortex, Str - striatum, Cer -
cerebellum, Mus - muscle, Liv - liver.
doi:10.1371/journal.pone.0020696.g001
No Effect of Hdac6 Knock-Out in an HD Mouse Model
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hypoactivity was evident in both the R6/2 and Dble mice at 9, 11
and 13 weeks of age (Fig. 3E and Table S1, R6/2 Genotype).
Hdac6KO mice were comparable to WT and the Dble mutant
mice to R6/2 at almost all time points indicating that depletion of
HDAC6 had no influence on the R6/2 hypoactivity phenotype.
Mice were sacrificed at 15 weeks of age and brains weighed to
the nearest 0.001 g (Fig. 3F). As expected, R6/2 mice had a
significantly lower brain weight than WT mice (p,0.001). The
weight of Hdac6KO brains was similar to WT (p,0.057) and that
of the Dble mutant mice was similar to R6/2 (p = 0.784). Thus,
absence of HDAC6 does not modify the loss in brain weight
exhibited by the R6/2 mice at end-stage disease.
Genetic Depletion of HDAC6 does not modify huntingtin
aggregation
Aggregation of mutant huntingtin is a prominent feature of HD
neuropathology and occurs in all of the HD rodent models that have
thus far been developed. Aggregates in the R6/2 mouse appear prior
to the onset of behavioural symptoms and continue to accumulate
throughout the course of the disease. At the same time, a steady
decrease in the levels of soluble transprotein can be observed. In cells,
HDAC6 acts as a linker between ubiquitinated protein and/or
aggregates and the dynein/dynactin motor complex enabling their
transport to the aggresome for autophagic degradation [23]. If this
phenomenon is relevant to the mammalian brain, an absence of
HDAC6 should result in an increase in aggregate load [25].
We measured the amount of SDS insoluble aggregates by the
Seprion ligand ELISA [34] and found no difference in aggregate
load between R6/2 and Dble mice at 4, 9 and 15 weeks of age in
cortex, hippocampus and brain stem (Fig. 4A and Fig. S2A), or at
9 and 15 weeks in quadriceps muscle (Fig. S2E). The
corresponding levels of soluble transprotein were measured in
these tissues by means of TR-FRET (Fig. 4B and Fig. S2D–E),
similarly, no difference between R6/2 and Dble mice was
detected. These results were confirmed by a TR-FRET aggrega-
tion assay (Fig. S2D) and by western blotting of SDS-PAGE
resolved lysates with an antibody that detects soluble and
aggregated huntingtin (S830) (Fig. 4C and Fig. S2B).
Our data show that HDAC6 ablation does not influence
aggregate load or levels of soluble mutant huntingtin in the cortex,
hippocampus or brain stem at 4, 9 or 15 weeks of age (Fig. 4, Fig.
S2A–C) or in quadriceps muscle at 9 and 15 weeks of age (Fig.
S2E). In support of this, we did not detect any obvious differences
in the level or distribution of aggregates between R6/2 and Dble
Figure 2. Tubulin acetylation in the brains of Hdac6KO and R6/2 mice compared to WT. (A–B) Representative western blots showing
acetylated tubulin (Ac-tub) between Hdac6KO and WT mice (A) and R6/2 and WT mice (B) at 4, 9 and 15 weeks in cortex, striatum and cerebellum
with tubulin (Tub) as a loading control. (C–D) Densitometric quantification of western blots represented in (A–B). Acetylated tubulin was normalised
to a-tubulin and the relative signal for Hdac6KO (C) or R6/2 (D) expressed as fold change compared to WT. Error bars represent SEM. * p,0.05,
** p,0.01, *** p,0.001; n$4/genotype. KO – Hdac6 knock out, WT – wild type.
doi:10.1371/journal.pone.0020696.g002
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striata at 9 weeks of age by immunohistochemistry (Fig. 4D).
Although a significant decrease in soluble cortical transprotein
levels was detected by TR-FRET in the Dble as compared to the
R6/2 mice at 9 weeks of age, further analysis by western blot has
shown that this difference, if real, is not large (Fig. 4B–C). At the
same age, there was no difference in the cortical aggregate load
measured by either Seprion ELISA or TR-FRET (Fig. 4A and Fig.
S2D).
Genetic Depletion of HDAC6 results in tubulin
hyperacetylation in the brains of R6/2 mice
We have found that the absence of HDAC6 has no effect on
R6/2 behavioural phenotypes or on the accumulation of
aggregated transprotein in these animals. It is possible that the
presence of the R6/2 transgene prevented the hyperacetylation of
tubulin from occurring in response to HDAC6 depletion.
Therefore, we compared the levels of acetylated tubulin between
R6/2 and Dble mice at 4, 9 and 15 weeks of age in the cortex,
striatum and cerebellum. We found that HDAC6 depletion
resulted in a pronounced increase in tubulin acetylation in R6/2
mice in all brain regions and at all time-points studied (Fig. 5).
The increase in tubulin acetylation was comparable between
Hdac6KO and Dble mutant mice (Fig. S3). We conclude that the
substantial increase in tubulin acetylation levels throughout the
brain has no consequence on HD-related phenotypes in the R6/2
mouse.
Figure 3. Behavioural and physiological phenotypes in the absence of HDAC6. (A) The number of male mice analysed per genotype with
the mean CAG repeat size for the groups carrying the R6/2 transgene (SD-standard deviation). (B) Body weight (C) Time spent on RotaRod (D)
Forelimb grip strength (E) Spontaneous motor activity recorded at the beginning (week 5) and end (week 13) of the study. Graphs were created by
plotting 5 min moving averages (F) Brain weight measured at week 15. Error bars represent SEM.
doi:10.1371/journal.pone.0020696.g003
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Genetic Depletion of HDAC6 does not modify BDNF
content in the striatum
Cell culture studies have shown that an increase in tubulin
acetylation increases the transport of BDNF from the cortex to
the striatum in the context of both WT and HD [28]. In
accordance with previous data [41], we found that Bdnf mRNA
expression is lower in the cortex of R6/2 mice at 9 weeks of
age and that this phenotype is not altered by HDAC6
depletion (Fig. 6A). However, at the same age, levels of BDNF
protein in the cortex as measured by ELISA were comparable
between mice of all four genotypes (Fig. 6B). Equally, BDNF
protein levels in the striatum of Hdac6KO, R6/2 and Dble
mice were not different from those of WT mice (Fig. 6C).
Therefore, the decrease in Bdnf mRNA did not translate to a
reduction in BDNF protein. As Bdnf is expressed in the
striatum at a very low level (Fig. S4A) and it has been
published that most striatal BDNF protein originates in the
cortex [42], we conclude that there is no effect of HDAC6
ablation on the transport efficiency of BDNF from the cortex
to the striatum in either WT or R6/2 mice.
Discussion
Previous studies in cell culture models of HD have shown that
modulation of HDAC6 levels alters HD-related phenotypes
[25,28]. To extend this analysis to a mouse model, we investigated
the effects of HDAC6 genetic depletion in the R6/2 mouse. We
showed that Hdac6 knock-out mice (Hdac6KO) do not express
HDAC6 at the mRNA or protein levels and have hyperacetylated
tubulin in the cortex, striatum and cerebellum from 4 to 15 weeks
of age. We show that in the presence of the polyQ expanded R6/2
transprotein, levels of acetylated tubulin do not differ from that in
wild type animals and similarly, the HD mutation does not
interfere with the effect that HDAC6 ablation has on tubulin
hyperacetylation. We found that depletion of HDAC6 had no
effect on the aggregate load or BDNF levels in the R6/2 brain and
did not modify physiological or behavioural HD-related pheno-
types in R6/2 mice.
In this study, we have used mice in which the endogenous Hdac6
gene has been disrupted [36]. One possible concern with using
mice that do not express HDAC6 throughout development is that
Figure 4. No effect of Hdac6 knock-out on aggregate load or soluble transprotein levels. (A) Aggregate load was measured by Seprion
ligand ELISA (MW8 antibody) and (B) soluble transprotein levels were measured by TR-FRET (2B7-MW1 antibodies) in the cortex, hippocampus and
brain stem of R6/2 and Dble mice at 9 and 15 weeks. The average of the WT and Hdac6KO background signal was subtracted from both R6/2 and
Dble signals. The Dble signal is expressed as fold change of the R6/2 signal. * p,0.05; n$8/genotype. (C) Representative western blots with S830
anti-huntingtin antibody showing aggregated and soluble transprotein (Htt) in the cortex at 9 (upper panel) and 15 (lower panel) weeks. a-tubulin
(Tub) was used as a loading control. Specificity of S830 staining is confirmed by lack of signal in WT and Hdac6KO cortices. (D) Representative sagittal
sections from 9 week old mice showing the striatum immunostained with S830 antibody. Nuclei are counterstained with methyl green. Scale
bar = 10 mm. Arrow=nuclear inclusion, arrowhead= cytoplasmic aggregate. Error bars represent SEM.
doi:10.1371/journal.pone.0020696.g004
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the expression of other genes will adjust to compensate for the
deficit. The HDAC6 mechanisms of action under investigation
here are based on HDAC6-tubulin interactions. Our demonstra-
tion that tubulin acetylation is increased in the brain from 4 to 15
weeks of age indicates that compensation has not occurred for the
HDAC6 target in which we are primarily interested and that the
constitutive Hdac6 knock-out mice used here are a suitable model.
There are numerous mouse models of HD, which include mice
transgenic for an N-terminal fragment of HTT, YAC and BAC
mice that are transgenic for full-length HTT gene and knock-in
mice in which an expanded CAG repeat has been introduced into
the mouse Hdh gene [43]. The HD cell culture model used by
Iwata and colleagues [25] to show that HDAC6 is required for
aggresome formation expressed an exon 1 huntingtin transprotein.
The R6/2 mice express an exon 1 N-terminal fragment of mutant
huntingtin [30] and therefore, they represent an appropriate
model with which to first follow-up on their findings. Also, recent
analysis has shown that the R6/2 mice develop HD-related
phenotypes that are highly comparable to a genetically accurate
knock-in mouse model of HD [31,33,34,35] and that, in these
knock-in mice, mutant huntingtin is processed to generate N-
terminal fragments [32]. Despite this, analysing the effects of the
Figure 5. Tubulin acetylation in the brains of Dble as compared to R6/2 mice. (A) Representative western blots showing acetylated tubulin
in Dble and R6/2 mice at 4, 9 and 15 weeks in cortex, striatum and cerebellum with a-tubulin as a loading control. (B) Densitometric quantification of
western blots presented in (A). Acetylated tubulin was normalised to a-tubulin and the relative signal for Dble mice expressed as fold change to R6/2.
Error bars represent SEM. * p,0.05, ** p,0.01, ***p,0.001; n$4/genotype.
doi:10.1371/journal.pone.0020696.g005
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modulation of Hdac6 levels on HD phenotypes in these more
genetically precise models might be considered important.
However, before embarking on such a project, it would be wise
to determine whether a reduction in HDAC6 levels has an effect in
cell culture models expressing a mutant version of full-length
huntingtin.
HDAC6 has been extensively characterised as being required
for the formation and subsequent autophagic degradation of the
aggresome [23,25,27]. In an HD cell culture model, HDAC6 was
required for aggresome formation and an increase in aggregate
load was observed upon HDAC6 knock-down [25]. Proteasome
inhibition resulted in an increase in ubiquitin positive aggregates in
Hdac6KO mouse embryonic fibroblasts as compared to wild type
cells indicating that HDAC6 is important for autophagy [44].
HDAC6 knock-down in a Drosophila melanogaster model of SBMA
exacerbated retinal degeneration and overexpression of HDAC6
decreased aggregate load and ameliorated retinal degeneration,
effects that required HDAC6 catalytic activity [26]. In keeping
with a role for HDAC6 in protein homeostasis, ubiquitin positive
aggregates have been reported to accumulate in the brains of
another strain of Hdac6KO mice by 6 months of age [27]. Given
that an increase in aggregation was not detected in R6/2 mice that
lack HDAC6, we conclude that either quality-control autophagy is
not important for the clearance of polyQ aggregates or that
HDAC6 is not essential for this process in the R6/2 mouse brain.
It is possible that the mechanism of aggregate handling could differ
between lower organisms/cell culture models and HD mice.
In cultured cells, an increase in tubulin acetylation has been
shown to enhance kinesin-1 binding and microtubule-based
transport [39]. BDNF is a kinesin-1 cargoe [28], which is actively
transported from the cortex to the striatum [42]. A recent study in
cells has shown that by increasing tubulin acetylation one can
increase BDNF cortico-striatal transport and that this is an HDAC6
dependent process [28]. In HD there is a well documented decrease
in cortical BDNF mRNA expression [41] and we have confirmed
that R6/2 mice at 9 weeks of age recapitulate this phenotype,
regardless of presence or absence of HDAC6. However, this did not
translate into a reduction in BDNF in either the cortex or the
striatum in accordance with some, but not all previously published
data [45,46,47], suggesting that R6/2 mice at 9 weeks do not
display a deficit in BDNF transport. If HDAC6 depletion increases
BDNF transport independent of the presence of the huntingtin
mutation, as has been reported [28], we would expect to see an
increase in striatal BDNF protein levels in both Hdac6KO and
double mutant mice. We did not observe any change in BDNF
levels. Strategies that increase BDNF levels have been shown to be
beneficial in R6/2 mice and other N-terminal fragment models
[45,48,49,50]. If small changes had occurred, that were beyond the
sensitivity of our detection method, they were not sufficient to
improve the phenotype of R6/2 mice.
There has been an increased focus on HDAC6 in neurodegen-
erative disease. In addition to the polyglutamine diseases, over-
expression of HDAC6 was protective in Drosophila melanogaster
models of Parkinson’s disease [51] and Alzheimer’s disease [52].
HDAC6 has also been found to localise to Lewy bodies in
Parkinson’s disease patient brains [23] and there is also evidence
supporting a role for HDAC6 in Alzheimer’s disease via its
association with tau [53]. Our finding that the knock-out of
HDAC6 does not affect the phenotype, aggregate load or BDNF
transport in R6/2 mice was very surprising. This study underlines
the importance of validating pathogenic mechanisms and
therapeutic targets in mammalian models. At the same time, our
findings indicate that the protective effect of broad range HDAC
inhibitors that has been observed in invertebrate and mouse HD
models [8] is not predominantly mediated via inhibition of
HDAC6. The current study is part of a wider project to investigate
the effects of the genetic depletion (knock-out or knock-down) of
specific HDACs on HD-related phenotypes in the R6/2 mouse.
Genetic reduction of Hdacs3, 5, 7 and 9 have not resulted in a
phenotypic improvement ([54] and unpublished data) whereas
knock-down of Hdac4 has shown beneficial effects (unpublished
data). Based on our data, we can conclude that HDAC6 inhibition
would not be a valid therapeutic strategy for HD.
Materials and Methods
Ethics statement
All experimental procedures performed on mice were approved
by the King’s College London Ethical Review Process Committee
and carried out under the UK Home Office License 70/6545.
Figure 6. Influence of Hdac6 knock-out on Bdnf mRNA and
protein levels. (A) Taqman qPCR assay showing a significant down-
regulation of Bdnf coding region mRNA expression in cortex of mice
carrying the R6/2 transgene. Data normalised to WT. ** p,0.01 (to
Hdac6KO), ***p,0.001 (to WT); n$4/genotype. (B–C) BDNF protein
content in the cortex (B) and striatum (C) measured by ELISA. Data
normalised to WT. n$3/genotype in (B) and n$4/genotype in (C). Error
bars represent SEM.
doi:10.1371/journal.pone.0020696.g006
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Mouse strains and husbandry
Hemizygous R6/2 mice were maintained by backcrossing R6/2
males to CBAxC57BL/6 F1 (CBF) females (B6CBAF1/OlaHsd,
Harlan Olac, UK) [30]. Hdac6 knock-out (Hdac6KO) mice [36] on
C57BL/6 background were backcrossed once to CBF. For the
R6/2xHdac6KO genetic cross, R6/2 males were bred to Hdac6
heterozygous females. At 4 weeks of age, mice were weaned into
cages of 5, each containing at least one representative of each
genotype. Animals were housed under 12 h light/12 h dark cycle,
with unlimited access to water and chow (Special Diet Services,
Witham, UK). Cages were environmentally enriched as described
[55]. Mice from the R6/2xHdac6KO cross were given mash food
consisting of powdered chow mixed with water during 4–6 and
12–15 weeks of age and sacrificed at 15 weeks.
Genotyping
Mice were genotyped by PCR of tail-tip DNA. R6/2 mice were
genotyped and their repeat sizes determined as described [34]. For
the Hdac6 genotyping, the primers were forward: 59-GTA-
CAATGTGGCTCACAGAA, reverse wt: 59-CAGGCACAG-
GAATATGAGTT and reverse KO: 59-CAACTCTGCCT-
CTCCTGG each used 1 mL at 10 mM in one multiplex 10 mL
reaction, containing also 1 mL of 100 ng/mL DNA, 0.8 mL 25 mM
MgCl2, 1 mL 2 mM dNTP, 1 mL Sigma 106PCR buffer and
0.1 mL Sigma Taq Polymerase (D4545, Sigma). Cycling condi-
tions were as follows: 94uC for 5 min, (94uC for 30 s, 64uC for 30 s
and 72uC for 1 min)640 followed by 10 min at 72uC.
Phenotypic assessment
The phenotypes of the mice from the R6/2xHdac6KO cross were
assessed blind to genotype. Mice were weighed weekly to the nearest
0.1 g. RotaRod performance was measured at 4 weeks of age for 4
consecutive days, 3 runs a day and after that at 8, 10, 12 and 14
weeks of age for 3 consecutive days, 3 runs a day, using an
accelerating (4–44 rpm in 5 min) Ugo Basile 7650 Rotarod, (Linton
Instrumentation, UK) modified as described [55]. Exploratory,
spontaneous motor activity was recorded at 5, 7, 9, 11 and 13 weeks
of age by placing mice in AM1053 activity cages for 30 min during
the day, as described previously [56]. Activity was the total number
of lower level beam breaks. Mobility was the number of at least two
consecutive beam breaks occurring in the lower level. Rearing was
the number of rearing beam breaks and centre rearing was the
number of rearing beam breaks occurring away from the cage walls.
Forelimb grip strength was assessed at 4 weeks of age and then
weekly from 11 to 14 weeks, always prior to RotaRod measure-
ments, with San Diego Instruments Grip Strength Meter (San
Diego, CA, USA) as described previously [55]. Mice were sacrificed
at 15 weeks of age and brains were weighed to the nearest 0.001 g.
Antibodies
The HDAC6 antibody was a kind gift from Dr. Tso-Pang Yao
[38]. Acetylated a-tubulin (6-11B-1, T7451) and a-tubulin (DM1A,
T9026) antibodies were purchased from Sigma. S830 is a sheep
polyclonal antibody raised against a GST tagged huntingtin exon 1
with 53 glutamines, characterized elsewhere [57] and was generated
at Scottish Antibody Production Unit. MW8, MW1 [58] and 2B7
[59] were obtained from Novartis, Basel. Secondary peroxidase
coupled antibodies were purchased from Dako (anti-goat, anti-
mouse), Pierce (anti-rabbit) or KPL (anti-mouse for Seprion).
Sample preparation
For tubulin acetylation analysis, tissues were homogenised using
1% Triton X-100 buffer with 50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 2 mM EDTA, 5 mM TSA (Trichostatin A, Sigma) and
10 mM nicotinamide (Sigma), supplemented with protease inhib-
itor cocktail (Roche). For HDAC6 immuno-detection, tissues were
homogenised in RIPA buffer (1%NP-40, 0.5%Deoxycholate, 0.1%
SDS, 50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM b-mercapto-
ethanol, 100 mM PMSF, 1 mM DTT) supplemented with protease
inhibitor cocktail (Roche). Samples were sonicated on ice for 10 s at
80 Hz (Vibracell Sonicator). Lysates were cleared by centrifugation
at 16 200 rcf for 15 min at 4uC. Protein concentration was
measured with Pierce BCA assay kit (Thermo Scientific). Samples
were diluted with 26 protein Laemmli buffer (1 M Tris-HCl
pH 6.8, 2.3% SDS, 4.5% glycerol, 10% b-mercaptoethanol,
0.001 g/mL bromophenol blue) and denatured for 5 min at 95uC.
Western blotting
Equal amounts of protein were loaded onto SDS polyacrylamide
gel with a size reference (Broad Range Protein Marker, Cell
Signalling or Spectra Broad Range Protein Ladder, Fermentas).
Proteins were transferred onto Protran nitrocellulose membrane
(Whatman) at 120 V for 90 min by submerged transfer apparatus
(Bio-Rad) in transfer buffer (20% v/v methanol, 25 mM Tris,
192 mM glycine).Membranes were blocked in 5% non-fat dried milk
in PBS for at least 1 hour. Primary antibodies were applied in 0.02%
PBS-Tween 20 (PBST) for 20 min (1:40000 acetylated a-tubulin;
1:30000 a-tubulin) or 1 hour (1:5000 S830) at room temperature or
overnight (1:250 HDAC6) at 4uC. Blots were washed thrice for 5 min
in 0.2% PBST and incubated with appropriate HRP coupled
secondary antibody (all 1:5000 except anti-rabbit 1:20000). For signal
detection, GE Healthcare Enhanced Chemiluminescence detection
system and Amersham Hyperfilms (both GE Healthcare) were used
according to the manufacturer’s instructions. Signals were quantified
using a GS-800 densitometer (Bio-Rad).
Aggregate detection with Seprion ligand ELISA
For aggregate detection 2.5% lysates (w/v) were prepared by
homogenising tissue in RIPA. Aggregate capture and detection
were performed in Seprion ligand coated plates (Microsens) as
described [34].
TR-FRET
Time resolved - Fo¨rster resonance energy transfer experiments
(TR-FRET) were performed as described [60].
BDNF ELISA
BDNF protein content was measured by the commercially
available ELISA kit (Promega) according to manufacturer’s
instructions modified as described [61]. Lysates were prepared at
2.2% dilution (w/v) and were not acid treated.
Taqman real time quantitative PCR
RNA extraction, cDNA synthesis, Taqman RT-qPCR and DCt
analysis were performed as described previously [62]. Housekeep-
ing genes (primer and probe mix purchased from Primer Design)
were chosen appropriate to the brain region analysed. For time-
course or across tissue analysis, several housekeeping genes were
tested and the most stable ones chosen. Primers for Hdac6
expression analysis were forward: 59 - GGAGACAACCCAGTA-
CATGAATGAA; reverse: 59 - CGGAGGACAGAGCCTGTAG
and the probe was 59-FAM-TATCTGCATCCGAACTCATA-
TTCCTGTGCCTG-TAMRA. Primers for Bdnf coding region
were forward: 59 - GGGTCACAGCGGCAGATAAA; reverse: 59
- GCCTTTGGATACCGGGACTT; and the probe was: 59 -
FAM - TCTGGCGGGACGGTCACAGTCC - TAMRA.
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Immunohistochemistry
Whole brains were snap frozen in isopentane at 250uC.
Immunohistochemistry was performed as described [31].
Statistical Analysis
Data from the R6/2xHdac6KO cross were analysed with SPSS
using one way ANOVA or General Linear Model ANOVA with
Greenhouse-Geisser correction for non-sphericity. Data from
qPCR and tubulin acetylation assay were analysed with Microsoft
Excel using Student’s t-test (two tailed).
Supporting Information
Figure S1 Hdac6 knock-out has no effect on spontane-
ous motor activity in WT or R6/2 mice. Five minute moving
averages for Activity, Mobility, Rearing and Centre rearing at 5, 7,
9, 11 and 13 weeks of age for WT, Hdac6KO, R6/2 and Dble mice.
n$16/genotype (as shown in Fig. 3A).
(TIF)
Figure S2 Hdac6 knock-out does not change aggregate load
in the brain or muscle. (A) Aggregate load was measured by
Seprion ligand ELISA with the MW8 antibody in the cortex,
hippocampus and brain stem of R6/2 and Dble mice at 4 weeks.
n$5/genotype. (B) Representative western blot with S830 anti-
huntingtin antibody showing aggregated and soluble transprotein (Htt)
in the cortex at 4 weeks. a-tubulin (Tub) was used as a loading control.
Specificity of S830 staining is confirmed by lack of signal in WT and
Hdac6KO cortices. (C) Densitometric quantification of soluble Htt
fromwestern blots shown in (A) and Fig. 4C. Htt signal was normalised
to a-tubulin and the relative signal for Dble mice expressed as fold
change to R6/2 for each time point. (D) Soluble (2B7-MW1
antibodies, upper panel) and aggregated (MW8-MW8 antibodies,
lower panel) transprotein levels were measured by TR-FRET in the
cortex at 9 and 15 weeks. Data normalised to R6/2 at 9 weeks.
* p,0.05; n$8/genotype. (E) Aggregate load was measured by
Seprion ligand ELISA with the MW8 antibody and soluble
transprotein levels were measured by TR-FRET (2B7-MW1 antibod-
ies) in the quadriceps muscle at 9 and 15 weeks. Data normalised to
R6/2 at each time point. n$7/genotype. Error bars represent SEM.
(TIF)
Figure S3 The increase in tubulin acetylation in brain is
comparable between Hdac6KO and Dble mice. (A)
Representative western blots showing acetylated tubulin (Ac-tub)
in Dble and Hdac6KO mice at 4, 9 and 15 weeks in cortex,
striatum and cerebellum with a-tubulin (Tub) as a loading control.
There was insufficient tissue to perform the analysis on striatum at
9 and 15 weeks. (B) Densitometric quantification of western blots
presented in (A). Acetylated tubulin was normalised to a-tubulin
and the relative signal for Dble mice expressed as fold change to
Hdac6KO. Error bars represent SEM. KO - Hdac6KO, Dble -
Hdac6KOxR6/2; n$3/genotype.
(TIF)
Figure S4 Similar levels of BDNF protein in striatum,
cortex and hippocampus despite very low Bdnf mRNA
striatal expression. (A) Bdnf mRNA coding region expression in
WT mice at 9 weeks between cortex, striatum and hippocampus.
Data normalised to Ubc and expressed as fold change of cortex.
n$3/genotype. ** p,0.01 (to cortex) *** p,0.001 (to cortex and to
hippocampus) (B) BDNF protein content measured by ELISA in
cortex, striatum, hippocampus and liver in WT mice at 9 weeks of
age. Data normalised to cortex. * p,0.05; n= 3/genotype. Error
bars represent SEM.
(TIF)
Table S1 Statistical analysis of the influence of time (30 min
duration) and genotype(s) on the spontaneous motor activity
parameters: activity, mobility, rearing and centre rearing present-
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Experimental Paper - Supporting Information 
Table S1.  
Statistical analysis of the influence of time (30 min duration) and genotype(s) on the 
spontaneous motor activity parameters: activity, mobility, rearing and centre 
rearing presented as p - values calculated via ANOVA General Linear Model with 
Greenhouse-Geisser correction 
 
  Week Activity Mobility Rearing 
Centre 
Rearing 
P = < 0.001 
Time 
5 <0.001 <0.001 <0.001 <0.001 P = < 0.01 
7 <0.001 <0.001 0.001 0.008 P = < 0.05 
9 <0.001 <0.001 <0.001 0.010 
 
11 <0.001 <0.001 0.019 0.038 
 
13 <0.001 <0.001 0.045 0.054 
 
R6/2 Genotype 
5 0.254 0.064 0.241 0.428 
 
7 <0.001 <0.001 0.527 0.338 
9 <0.001 <0.001 <0.001 <0.001 
11 <0.001 <0.001 <0.001 <0.001 
13 <0.001 <0.001 <0.001 <0.001 
Time*R6/2 Genotype 
5 0.011 0.078 0.016 0.091 
7 <0.001 <0.001 <0.001 0.002 
9 <0.001 <0.001 0.001 0.071 
11 <0.001 <0.001 0.001 0.138 
13 0.009 <0.001 0.063 0.171 
Hdac6KO Genotype 
5 0.771 0.946 0.421 0.380 
7 0.204 0.411 0.297 0.452 
9 0.511 0.906 0.447 0.563 
11 0.272 0.378 0.876 0.781 
13 0.557 0.908 0.795 0.765 
Time*Hdac6KO Genotype 
5 0.053 0.070 0.815 0.515 
7 0.330 0.083 0.449 0.262 
9 0.401 0.371 0.225 0.229 
11 0.808 0.747 0.133 0.192 
13 0.704 0.705 0.726 0.339 
R6/2 Genotype*Hdac6KO 
Genotype 
5 0.201 0.357 0.950 0.635 
7 0.718 0.701 0.490 0.891 
9 0.907 0.746 0.032 0.091 
11 0.542 0.488 0.638 0.922 
13 0.587 0.610 0.443 0.499 
Time*R6/2*Hdac6KO 
5 0.160 0.481 0.184 0.315 
7 0.019 0.022 0.167 0.325 
9 0.263 0.206 0.270 0.559 
11 0.304 0.495 0.822 0.739 
13 0.189 0.490 0.556 0.493 
 
  




Figure S1. Hdac6 knock-out has no effect on spontaneous motor activity in WT or 
R6/2 mice. 
Five minute moving averages for Activity, Mobility, Rearing and Centre rearing at 5, 
7, 9, 11 and 13 weeks of age for WT, Hdac6KO, R6/2 and Dble mice. n ≥ 
16/genotype (as shown in Fig. 3A). 
  





Figure S2. Hdac6 knock-out does not change aggregate load in the brain or 
muscle.  
(A) Aggregate load was measured by Seprion ligand ELISA with the MW8 antibody 
in the cortex, hippocampus and brain stem of R6/2 and Dble mice at 4 weeks. n ≥ 
5/genotype. (B) Representative western blot with S830 anti-huntingtin antibody 
showing aggregated and soluble transprotein (Htt) in the cortex at 4 weeks.  α-
tubulin (Tub) was used as a loading control. Specificity of S830 staining is confirmed 
by lack of signal in WT and Hdac6KO cortices. (C) Densitometric quantification of 
soluble Htt from western blots shown in (A) and Fig. 4C. Htt signal was normalised 
to α-tubulin and the relative signal for Dble mice expressed as fold change to R6/2 
for each time point.  (D) Soluble (2B7-MW1 antibodies, upper panel) and 
aggregated (MW8-MW8 antibodies, lower panel) transprotein levels were 
measured by TR-FRET in the cortex at 9 and 15 weeks. Data normalised to R6/2 at 9 
weeks. * p<0.05; n ≥ 8/genotype. (E)  Aggregate load was measured by Seprion 
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ligand ELISA with the MW8 antibody and soluble transprotein levels were measured 
by TR-FRET (2B7-MW1 antibodies) in the quadriceps muscle at 9 and 15 weeks. 







Figure S3. The increase in tubulin acetylation in brain is comparable between 
Hdac6KO and Dble mice.   
(A) Representative western blots showing acetylated tubulin (Ac-tub) in Dble and 
Hdac6KO mice at 4, 9 and 15 weeks in cortex, striatum and cerebellum with α-
tubulin (Tub) as a loading control. There was insufficient tissue to perform the 
analysis on striatum at 9 and 15 weeks. (B) Densitometric quantification of western 
blots presented in (A). Acetylated tubulin was normalised to α-tubulin and the 
relative signal for Dble mice expressed as fold change to Hdac6KO. Error bars 
represent SEM. KO - Hdac6KO, Dble - Hdac6KOxR6/2; n ≥ 3/genotype. 





Figure S4. Similar levels of BDNF protein in striatum, cortex and hippocampus 
despite very low Bdnf mRNA striatal expression. 
(A) Bdnf mRNA coding region expression in WT mice at 9 weeks between cortex, 
striatum and hippocampus. Data normalised to Ubc and expressed as fold change of 
cortex. n ≥ 3/genotype. ** p<0.01 (to cortex) *** p<0.001 (to cortex and to 
hippocampus) (B) BDNF protein content measured by ELISA in cortex, striatum, 
hippocampus and liver in WT mice at 9 weeks of age. Data normalised to cortex. * 
p<0.05; n = 3/genotype. Error bars represent SEM. 
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4.0. RESULTS CHAPTER 4 - GENETIC REDUCTION OF SIRT2 IN R6/2 MICE 
4.1. Reducing levels of SIRT2 does not modify disease progression in R6/2 mice 
Studies in worms, flies and cells have demonstrated that SIRT2 inhibition could be 
beneficial in HD by acting to correct cholesterol dys-homeostasis (Luthi-Carter et al., 
2010). However, whether this effect translates to an in vivo mammalian system 
remains unknown. To address this question, Sirt2 was genetically depleted in the 
R6/2 mouse model of HD and the effects on behaviour, mutant huntingtin (mHTT) 
aggregation and expression of cholesterogenic enzymes were assessed. 
 
4.2. Sirt2 knock-out mice express Sirt2 mRNA, but not SIRT2 protein 
Sirt2 knock-out (Sirt2KO) mice (a kind gift from Prof. Leonard Guarente) were 
generated by targeted insertion of a puromycin resistance gene into exon 11 of the 
Sirt2 locus. However, the specific position, length and sequence of the insertion 
were unknown. 
4.2.1. Sequencing the Sirt2 knock-out mutation 
To sequence the insertion that disrupts the Sirt2 gene in Sirt2KO mice (Fig. 4.1 A), 
genotyping primers (primers  1 and A in Fig. 4.1 A) were used to obtain a DNA 
fragment that contained a part of the Sirt2 gene and a part of the insertion. 
Sequencing this product facilitated the design of additional primers that were then 
used to amplify a second DNA fragment covering the remaining part of the insertion 
(primers 2-5 in Fig. 4.1 A). As the sequencing reaction was not efficient enough to 
cover the whole length of the second DNA fragment (with primers 2-5 and B-C in 
Fig. 4.1 A), more primers were designed to amplify the remainder of the insertion 
based on the sequence obtained (primers 6 and 7 in Fig. 4.1 A). BLAST analysis of 
the sequence obtained confirmed that the insertion contains a puromycin 
resistance gene countersense to the Sirt2 gene and revealed sequences of at least 3 
different vector backbones (Fig. 4.2 A). Further analysis showed that although the 
insertion does not result in a frameshift in the downstream part of the Sirt2 gene, 
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the mutation introduces a stop codon that should result in nonsense-mediated 
decay of the Sirt2 mRNA (full sequence of the insertion and its position within the 
Sirt2 gene can be found in the Appendix 1). 
 
4.2.2. Sirt2 knock-out mice express Sirt2 mRNA at 60% of wild type levels, but lack 
SIRT2 protein 
To investigate how the insertion in the Sirt2 gene affects Sirt2 expression, RNA was 
extracted and cDNA prepared from cortices of Sirt2KO, Sirt2HET (Sirt2 
heterozygous) and wild type (WT) mice at 4 weeks of age. Levels of total Sirt2 
mRNA were measured by real-time qPCR with primers binding upstream of the 
insertion. Sirt2HET and Sirt2KO mice were found to express 80% and 60% of Sirt2 
mRNA as compared to WT levels respectively (Fig. 4.1 B). To investigate whether 
the mRNA produced in the presence of the insertion is translated, western blotting 
was performed on brain lysates from 4 week old Sirt2KO, Sirt2HET and WT mice. 
Antibodies directed against the N-terminus (Santa Cruz H-95) or the C-terminus 
(Sigma S8447) of SIRT2 revealed two bands, the lower of which is a doublet. The 3 
bands detected correspond to the predicted molecular weight of the three SIRT2 
isoforms (43, 37 and 34 kDa) (Fig. 4.1 C) (Maxwell et al., 2011). This signal was 
absent in Sirt2KO samples indicating that no SIRT2 protein is produced in these 
mice. At the same time, Sirt2HET mice were shown to express 55% of SIRT2 levels 
of WT mice (Fig 4.1 C). Equally, no shorter N-terminal fragment were observed 
specifically in HET or KO samples with the Santa Cruz H-95 antibody. Though both 
antibodies detected non-specific bands on western blot, the signal obtained with 
the S8447 antibody had a lower background and was therefore used for all 
subsequent experiments.  




Figure 4.1. The Sirt2 knock-out mutation results in reduced Sirt2 mRNA 
production and an absence of SIRT2 protein.  
(A) Exon-intron structure of the Sirt2 gene in mouse and the location of the 
insertion (light blue) in exon 11 (after the 18883rd nucleotide) in Sirt2KO mice.  
Positions of genotyping and sequencing forward (green arrows) and reverse (dark 
blue arrows) primers are shown. 1-Sirt2For, 2-Sirt2ForSeq2, 3-Sirt2ForSeq3, 4-
Sirt2ForSeq4, 5-Sirt2ForSeq5, 6-Sirt2ForSeq6, 7-Sirt2ForSeq7, A-Sirt2RevKO, B-
Sirt2RevSeq2, C-Sirt2RevSeq3, D-Sirt2RevWT. (B) Sirt2 mRNA levels in 4 week old 
cortex from Sirt2KO (KO), Sirt2HET (HET) and wild type (WT) mice. Expression levels 
were normalised to the housekeeping genes Atp5b and Canx and expressed as fold 
change of WT levels ±SEM. n=8/genotype. (C) Western blotting of Sirt2KO (KO), 
Sirt2HET (HET) and wild type (WT) brain lysates with SantaCruz H-95 (upper panel) 
and Sigma S8447 (lower panel) antibodies. The S8447 probed blot was used to 
quantify SIRT2 levels (both bands) between HET and WT (right panel). Values were 
normalised to α-tubulin (Tub) and expressed as fold change of WT ±SEM. (D) 
Western blotting of KO, HET and WT brain lysates with SantaCruz H-95 antibody 
(long exposure) showing no short N-terminal fragments are produced as a result of 
the Sirt2 disrupting mutation. * denotes a non-specific bands. 
 
Chapter 4 Genetic reduction of SIRT2 in R6/2 mice 
121 
 
4.3. Characterisation of SIRT2 expression, sub-cellular localisation and effects of 
SIRT2 reduction on acetylation of tubulin and H4K16 
 
4.3.1. SIRT2 expression between 4 and 15 weeks in mouse brain 
At 4 weeks of age R6/2 mice are generally indistinguishable from their wild type 
littermates by rotarod, grip strength or spontaneous exploratory activity tests 
(Benn et al., 2009; Hockly et al., 2002). However, disease progression in R6/2 is 
rapid and mice from the King's College London colony generally do not survive 
longer than 15 weeks. To investigate the levels of SIRT2 expression in the brain over 
this time frame, proteins were extracted from cortex, striatum, hippocampus, 
cerebellum, brain stem and “rest of brain” (what remained after dissecting the 5 
regions) from 4 and 15 week old wild type mice. Western blotting revealed that the 
highest levels of SIRT2 expression are observed in the brain stem (Fig 4.2 A - B). 
SIRT2 expression was comparable in cortex, striatum, hippocampus and cerebellum 
with levels between 0.5 and 1.5 times less than that in brain stem. Although levels 
of SIRT2 were slightly decreased in 15 week brain tissues, the regional distribution 
of SIRT2 expression remained unchanged (Fig. 4.2 A - B).  
4.3.2. Genetic reduction of SIRT2 has no effect on its sub-cellular localisation 
The sub-cellular localisation of SIRT2 has previously been reported to be 
cytoplasmic, with the exception of during cell division, when SIRT2 is reported to 
translocate to the nucleus (North et al., 2003; North and Verdin, 2007). To ascertain 
whether this is the case in the mouse brain and whether knock-down of Sirt2 
affects its sub-cellular localisation, nuclear and cytoplasmic fractions were prepared 
from whole brains of 4 week old Sirt2HET and WT mice. Western blotting against 
actin (cytoplasmic marker) and histone H3 (nuclear marker) revealed minimal cross-
contamination of the fractions (Fig. 4.2 C), thereby confirming their purity. 
Consistent with previous reports, the SIRT2 signal was found predominantly in the 
cytoplasm. Additionally, the cytoplasmic localisation of SIRT2 was found to be 
unaltered in the Sirt2HET mice, which confirms that SIRT2 reduction does not affect 
its sub-cellular localisation. 





Figure 4.2. SIRT2 is expressed most highly in the brain stem, localised 
cytoplasmatically and its depletion does not affect tubulin or H4K16 acetylation 
levels. 
(A) Representative western blot showing SIRT2 expression in different brain regions 
at 4 and 15 weeks of age. (B)The signal for SIRT2 was normalised to total protein 
loaded (Coomasie stain) and expressed as fold change of rest of brain 
(Rb)(containing all regions except cortex (Cx), striatum (S), hippocampus (H), 
cerebellum (Cb) and brain stem (BS)) ± SEM. n=4/brain region/time point. (C) SIRT2 
is localised to the cytoplasm. Purity of fractions was determined by measuring the 
expression of actin (C-cytoplasm) and H3 (N-nucleus). (D) Representative western 
blots of acetylated tubulin (Ac-Tub) at 4 weeks of age in the cortex, striatum and 
cerebellum of WT, HET and KO mice and their quantification (E). Signal was 
normalised to the level of total tubulin (Tub) and expressed as fold change of WT ± 
SEM. n=4/genotype. (F) Representative western blots of acetylated H4K16 (H4K16-
Ac) and total H4 (H4) at 4 weeks of age in the cortex and liver of WT, HET and KO 
mice. n=3/genotype (cortex) and n=6/genotype (liver). WT – wild type, HET – 
Sirt2HET, KO – Sirt2KO 
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4.3.3. No changes in acetylation of tubulin or H4K16 can be detected upon SIRT2 
genetic reduction 
The first two proposed SIRT2 deacetylation substrates were lysine (K) 40 of α-
tubulin and K16 of histone 4 (H4) (North et al., 2003; Vaquero et al., 2006). It has 
already been shown that knock-out of another tubulin deacetylase, HDAC6, causes 
tubulin hyperacetylation across the brain (Results Chapter 3 – Experimental Paper, 
Fig. 2 A). To verify whether a similar effect would be observed after SIRT2 genetic 
depletion, western blotting was performed on cortical, striatal and cerebellar 
samples obtained from 4 week old WT, Sirt2HET and Sirt2KO mice. Interestingly, no 
differences were observed between WT, HET and KO mice in the levels of 
acetylated tubulin, indicating that HDAC6, not SIRT2, is the major tubulin 
deacetylase in the brain (Fig. 4.2 D - E). To check the effect of Sirt2 knock-out and 
knock-down on the levels of H4K16 acetylation, histones were enriched by acid 
extraction from cortices and livers of 4 week old mice. No genotype specific 
differences could be detected in the levels of acetylated H4K16 in the tissues 
examined (Fig. 4.2 F). 
 
4.4. Reduction or elimination of SIRT2 has no effect on the expression levels of 
cholesterol biosynthesis enzymes 
Previous studies using mRNA microarray analysis suggested that inhibition of SIRT2 
results in a decrease in the expression of enzymes that take part in cholesterol 
synthesis (Luthi-Carter et al., 2010). To verify whether genetic depletion of SIRT2 
causes a reduction in the expression of cholesterogenic enzymes, 7 genes were 
chosen for analysis on the basis of previously published microarray data (Luthi-
Carter et al., 2010). RNA was extracted and cDNA prepared from cortices of 4 week 
old WT, Sirt2HET and Sirt2KO mice, an age when SIRT2 levels are highest in the 
brain. Surprisingly, the expression of cholesterogenic enzymes was not modified by 
SIRT2 reduction or ablation (Fig. 4.3 A). To ascertain that this effect was not masked 
by focusing on a specific time point, gene expression was also measured in cortices 
from 9 week old mice. However, no difference between WT, Sirt2HET and Sirt2KO 
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mice could be detected (Fig. 4.3 B). As the expression of SIRT2 is lowest in the 
cortex but highest in the brain stem at 4 weeks of age (Fig. 4.2 A), there was a 
possibility that the reduction in SIRT2 levels could only have a detectable effect on 
cholesterogenic enzymes in brain regions where the reduction of SIRT2 is more 
dramatic (Fig.4.3 A). Therefore, the effect of SIRT2 depletion on the expression of 
cholesterol synthesis enzymes was analysed in the brain stem. Nevertheless, the 
expression levels of cholesterogenic enzymes were unchanged in Sirt2HET and 
Sirt2KO mice as compared to WT mice in the brain stem at 4 weeks of age (Fig. 4.3 
C). In a final attempt to determine whether Sirt2 knock-down or knock-out on has 
an effect on cholesterol synthesis, levels of cholesterogenic enzymes were 
measured in the liver of 4 week old mice.  However, consistent with observations in 
brain tissue, reduction or ablation of SIRT2 did not produce a detectable change in 
the levels of cholesterogenic enzymes’ mRNA (Fig. 4.3 D). Taken together these 
results suggest that the expression of enzymes responsible for cholesterol synthesis 
are not affected in Sirt2HET or Sirt2KO mice. This may be due to an absence of a 
role for SIRT2 in the regulation of cholesterol synthesis, or a compensation that 
occurs when the mammals are faced with a chronic reduction in SIRT2 levels, as is 
the case in Sirt2KO mice. 
The mechanism by which SIRT2 was proposed to modulate the expression of 
cholesterogenic enzymes was that SIRT2 controls the sub-cellular localisation of the 
transcription factor SREBP-2, a master regulator of cholesterol enzymes’ expression 
(Luthi-Carter et al., 2010). SREBP-2 is synthesised as an inactive, 120 kDa precursor 
and resides in the cytoplasm, bound to the ER membrane (Eberle et al., 2004). 
When cholesterol levels are low, SREBP-2 is cleaved into an active, 60 kDa form and 
translocates to the nucleus to activate transcription of cholesterogenic enzymes 
(Eberle et al., 2004). To investigate whether compensation in Sirt2HET/KO mice 
occurred downstream of SREBP-2 nuclear translocation, cytoplasmic and nuclear 
fractions previously used to investigate SIRT2 sub-cellular localisation (Fig. 4.2 B) 
were used to determine the sub-cellular localisation of SREBP-2. Only a faint 60 kDa 
signal could be seen in the nuclear fractions and there was no genotype dependent 
change in the intensity of bands detected, suggesting that if compensation for the 
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absence of SIRT2 occurs, it is prior to SREBP-2 activation and nuclear translocation 
(Fig. 4.3 E). 
 
Figure 4.3. Expression of cholesterogenic enzymes is not affected in Sirt2HET or 
Sirt2KO mice. 
(A - D) The mRNA expression levels of 7 cholesterogenic enzymes were determined 
by Taqman qPCR in the cortex at (A) 4 and (B) 9 weeks of age and in the (C) brain 
stem and (D) liver at 4 weeks of age between wild type (WT), Sirt2HET (HET) and 
Sirt2KO (KO) mice. n ≥ 6/genotype. Expression was normalised to the housekeeping 
genes Atp5b (4 and 9 wk cortex and brain stem), Canx (4 and 9 week cortex and 
liver), Gapdh (brain stem and liver), and ActB (liver) and expressed as fold change of 
WT ± SEM. (E) Representative immunoblot for SREBP-2 in whole brains of 4 week 
old wild type (WT), Sirt2HET (HET) and Sirt2KO (KO) mice. The active form of SREBP-
2 was expected to migrate at 60 kDa in the nuclear (N) fractions, the precursor of 
SREBP-2 was expected to migrate at 120 kDa in the cytoplasmic (C) fractions. 
n=4/genotype.  
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4.5. Expression of histone deacetylases is not altered in Sirt2KO mice and the 
expression of Sirt2 is not affected by disease progression in R6/2 mice 
As Sirt2HET/KO mice do not show any overt phenotypes or changes in the levels of 
acetylated tubulin, acetylated H4K16 or cholesterogenic enzyme expression, there 
was a possibility that other deacetylases are up-regulated to compensate for SIRT2 
loss. To investigate this possibility, the mRNA expression level of all 18 HDACs was 
assessed in cortices from 4 week old WT, Sirt2HET and Sirt2KO mice. Interestingly, 
the expression levels of none of the HDACs other than Sirt2 were changed upon 
Sirt2 knock-down or knock-out (Fig. 4.4 A-B). 
SIRT1 is the closest SIRT2 homologue in mammals and shares at least 3 common 
substrates with SIRT2 (p53, FOXO1 and FOXO3a) (Peck et al., 2010; Wang et al., 
2011; Wang and Tong, 2009; Yang et al., 2005). At the same time, it has recently 
been reported that SIRT1 deacetylates SREBP-1, a homologue of SREBP-2 and a 
master regulator of fatty acid synthesis, making SIRT1 the most likely candidate to 
compensate for SIRT2 loss (Ponugoti et al., 2010). To find the best antibody with 
which to assess SIRT1 levels in Sirt2KO mice, 5 commercially available SIRT1 
antibodies were tested in 6 different buffers. Western blotting of brain lysates from 
4 week old WT mice revealed that 4 out of 5 antibodies could detect the same 3 
bands roughly corresponding to the predicted SIRT1 size of 110 kDa, whereas the 
antibody from Millipore did not produce any signal of the expected size (Fig. 4.4 C). 
Of the 5 antibodies tested, the Cell Signalling antibody proved to be the cleanest, 
only detecting 3 bands at the expected SIRT1 size. SIRT1 has at least 2 isoforms, 
therefore there is a strong possibility that at least 2 out of the 3 bands observed 
with all four antibodies are SIRT1 specific. In any case, when lysates prepared from 
cortices from 4 week old Sirt2KO and WT mice were probed with the Cell Signalling 
SIRT1 antibody, none of the 3 bands detected displayed a change in intensity which 
suggests that SIRT1 is not up-regulated upon genetic depletion of SIRT2. However, 
the addition of reliable positive and negative controls is required to be certain of 
this result. 
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Surprising as it was to find that neither knock-down nor knock-out of SIRT2 elicited 
any changes in tubulin or H4K16 acetylation, or cholesterol enzyme expression, and 
that there was no compensatory up-regulation in the expression of any other 
HDACs, it is possible that SIRT2 is only required when cells are faced with stressful 
or toxic conditions.  
In HD, cells are confronted with an overload of toxic misfolded mutant huntingtin 
(mHTT) that causes widespread dysregulation to a number of pathways including 
cholesterol synthesis (Valenza et al., 2005). It is thus possible that an effect of SIRT2 
genetic reduction would only be evident once the knock-out or knock-down of 
SIRT2 is placed in the context of the disease. Before embarking on a full scale 
phenotyping study, it was first necessary to verify that levels of Sirt2 are not 
affected by the widespread transcriptional dysregulation that occurs in HD. 
Interestingly, no differences were found in the cortex, striatum and cerebellum 
from 4 and 15 weeks old mice in Sirt2 mRNA levels between WT and R6/2 mice, 











Figure 4.4. Expression of Hdacs 1-11, Sirt1, SIRT1 and Sirt3-7 is not affected by 
genetic reduction of SIRT2 and Sirt2 expression is not affected by HD progression 
in R6/2 mice. 
(A-B) Taqman qPCR assays measuring the mRNA expression of all known 
deacetylases in the cortex of 4 week old wild type (WT), Sirt2HET (HET) and Sirt2KO 
(KO) mice. Expression was normalised to the housekeeping genes Atp5b and Canx 
and expressed as fold change of WT ± SEM. n≥6/genotype. (C) Western blots 
probed with 5 SIRT1 antibodies tested on brain lysates from 4 week old wild type 
mice extracted with 6 different buffers: TX, sucrose buffer (Su), RIPA (RI), Hepes 
(He), KCl (KC) and “Trottier” (Tr – high pH buffer). (D) Representative western blot 
probed with SIRT1 Cell Signalling antibody showing SIRT1 expression between wild 
type (WT) and Sirt2KO (KO) brain lysates extracted from cortices of 9 week old mice 
in RIPA buffer. * denotes a non-specific band. Tubulin (Tub) was used as loading 
control. n≥3/genotype. (E) Taqman qPCR assay measuring levels of Sirt2 mRNA 
between wild type (WT) and R6/2 mice at 4 and 15 weeks of age in cortex, striatum 
and cerebellum. Expression was normalised to the housekeeping genes Atp5b and 
Canx, and expressed as fold change of WT ± SEM. n≥6/genotype. 
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4.6. SIRT2 genetic ablation does not improve phenotypes in the R6/2 mouse 
model of HD 
The potential therapeutic nature of SIRT2 inhibition has not yet been tested in a 
complex mammalian system. To address this, the Sirt2 gene disrupting insertion 
was crossed into the R6/2 mouse model of HD, by breeding Sirt2HET females to 
R6/2 males and subsequently, breeding Sirt2HETxR6/2 males to another cohort of 
Sirt2HET females. The progeny, consisting of wild type (WT), Sirt2HET (WT HET), 
Sirt2KO (WT KO), R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2 (R6/2 KO) mice 
(Table 4.1), were monitored in a phenotyping study from 4 to 14 weeks of age and 
sacrificed at 15 weeks of age. 
 
4.6.1. Repeat size was well matched between groups 
As the CAG repeat size is intimately linked to age of onset and mHTT toxicity 
(Andrew et al., 1993), it was ascertained that mice of different genotypes were well 
matched for the CAG repeat number. Table 4.1 shows the number of mice used in 
the phenotyping study and their mean CAG repeat length. 
 
Table 4.1 Numbers and CAG repeat sizes of mice used in the Sirt2KOxR6/2 
phenotyping study.  




R6/2 R6/2 HET R6/2 KO 
Males 9 11 11 9 10 6 
Females 9 10 5 9 9 9 
Total 18 21 16 18 19 15 
Mean CAG repeat size ± 
SD 






KEY: WT – wild type, WT HET – Sirt2HET, WT KO – Sirt2KO, R6/2 HET – 
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4.6.2. SIRT2 reduction increases body weight independently of HD progression 
Mice were weighed weekly from 4 until 14 weeks of age.  As the gender 
significantly affected the weight (F(1,96)=110.329, p<0.0005) and weight gain 
(F(3,282)=32.704, p<0.0005), male and female weights were depicted separately (Fig. 
4.5 A-B). R6/2 mice weighed significantly less than WT mice overall (F(1,96)=10.655, 
p=0.002) and gained weight at a significantly slower rate (F(3,282)=61.278, p<0.0005). 
Weight loss in R6/2 mice started at 9 weeks of age (F(1,96)=4.458, p=0.037) and 
increased with disease progression. Interestingly, Sirt2HET and Sirt2KO mice had 
significantly increased weight (F(2,96)=4.668, p=0.012) (Fig. 4.5 A-B), starting at 7 
weeks of age (F(2,96)=3.152,p=0.047). This phenomenon showed a trend to become 
significant with time (F(6,282)=2.131, p=0.051). However, the Sirt2 mutation had no 
overall effect on R6/2 weight loss (F(2,96)=0.087, p=0.917) or on the decrease in 
weight in R6/2 over time (F(6,282)=1.902, p=0.082), suggesting that if the Sirt2 
mutation modifies weight, it does so independently of HD progression. 
The effect of the Sirt2 genotype did not differ between males and females, 
(F(1,96)=0.739, p=392 for R6/2, and F(2,96)=0.13, p=878 for Sirt2) but the rate of 
weight loss was significantly different between male and female R6/2 mice 
(F(3,282)=18.833, p<0.0005), with weight loss being quicker and more pronounced in 
males (Fig. 4.5 A-B). 
 
4.6.3. Grip strength is not modified by a loss of SIRT2 in mice  
Grip strength was measured in mice at 4 weeks of age and bi-weekly from 7 to 13 
weeks of age. As there was a significant gender difference in overall grip strength 
performance (F(1,96)=108.4, p<0.0005), the average grip strength of male and female 
mice is presented separately (Fig. 4.5 C-D).  
R6/2 mice had reduced grip strength compared to WT mice (F(1,96)=66.79, 
p<0.0005). This deficit appeared by 11 weeks of age (F(1,96)=54.462, p<0.0005) and 
deteriorated over time (F(3,308)=78.857, p<0.0005) (Fig.  4.5 C-D). Weaker grip 
strength was more evident (F(1,96)=6.887, p=0.01) and the time dependent 
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deterioration was more pronounced (F(3,308)=16.308, p<0.0005) in male mice 
expressing the R6/2 transgene, which is in line with an earlier and more 
pronounced weight loss in males (Fig. 4.5 C-D). 
Grip strength was not altered in mice where SIRT2 was either reduced (Sirt2HET) or 
absent (Sirt2KO) overall (F(2,96)=0.654, p=0.522) or with time (F(6,308)=0.355, p=0.916) 
and there was no significant effect of modulation of SIRT2 levels on the worse grip 
strength performance observed in R6/2 mice either overall (F(2,96)=0.116, p=0.891), 
or with time (F(6,308)=0.9, p=0.5) (Fig. 4.5 C-D). These findings strongly suggest that 
reducing or ablating SIRT2 does not affect the grip strength in R6/2 mice. 
 




Figure 4.5. Behavioural and physiological phenotypes elicited by Sirt2 knock-down 
and knock-out in R6/2 mice. 
(A-B) Mean body weight measurements in (A) female and (B) male mice. (C-D) Grip 
strength in (C) female and (D) male mice. (E) Rotarod performance. (F) Brain weight 
measured at 9 and 15 weeks of age. Error bars represent SEM. WT – wild type, HET 
– Sirt2HET, KO – Sirt2KO, R6/2 HET – Sirt2HETxR6/2, R6/2 KO – Sirt2KOxR6/2. 
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4.6.4. Neither SIRT2 reduction nor depletion affect rotarod performance in mice 
Rotarod performance is a robust measure of motor coordination and was assessed 
at 4 weeks of age and bi-weekly from 8 to 14 weeks of age (Fig. 4.5 E). No gender 
effects were observed (F(1,95)=0.765, p=0.384) and thus rotarod performance of 
males and females was not analysed separately. In line with previous observations, 
R6/2 mice were indistinguishable from their WT littermates at 4 weeks of age 
(F(1,95)=2.128, p=0.148) (Hockly et al., 2002), but their performance deteriorated 
over time (F(3,237)=23.792, p<0.0005) starting at 8 weeks of age (F(1,95)=22.537, 
p<0.0005) (Fig. 4.5 E). Sirt2HET and Sirt2KO mice did not perform differently from 
WT mice overall (F(2,95)=0.23, p=0.795) or with time (F(5,237)=1.118, p=0.351) and 
down-regulation or ablation of SIRT2 had no effect on the rotarod performance of 
R6/2 mice (F(2,95)=0.634, p=532) or its deterioration over time (F(5,237)=0.376, 
p=0.865) (Fig. 4.5 E). Therefore, it was concluded that neither SIRT2 reduction nor 
depletion affect rotarod performance in WT or R6/2 mice.   
 
4.6.5. Reduced brain weight in R6/2 mice is not altered by genetic depletion of 
SIRT2 
Brains were harvested at 9 and 15 weeks of age and weighed to the nearest 0.001 
g. As expected, R6/2 brains weighed significantly less than those of WT mice 
(F(1,41)=17.197, p<0.0005 for 9 weeks and F(1,96)=268.291, p<0.0005 for 15 weeks) 
(Fig 4.5 F). Genetic modulation of Sirt2 on its own had no effect on brain weight 
(F(2,41)=0.734, p=0.486 at 9 weeks and F(2,96)=1.107, p=0.335 at 15 weeks). 
Interestingly, statistical analysis revealed a significant effect of the Sirt2 genotype 
on the R6/2 genotype at 9 weeks of age (F(2,41)=7.169, p=0.002). However, this is 
most likely due to the fact that WT Sirt2HET and Sirt2KO mice had a slightly higher 
brain weight than WT mice, whereas R6/2 Sirt2HET and Sirt2KO mice had a slightly 
lower brain weight than R6/2 mice (Fig. 4.5 F). 
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4.6.6. SIRT2 genetic reduction does not influence hypo-activity of R6/2 mice 
Spontaneous motor activity was measured bi-weekly from 5 to 13 weeks of age. 
Data were analysed with General Linear Model repeated measures ANOVA and p-
values are presented in Table 4.2. Figures 4.6 and 4.7 depict 5 min moving averages 
plotted separately for males and females for activity, mobility (Fig. 4.6), rearing and 
centre rearing (Fig. 4.7). 
The activity, mobility, rearing and centre rearing pattern of activity changed for all 
mice over the 30 min measurement window at all ages recorded (Table 4.2, Time), 
with highest levels of activity generally occurring in the first 15 min. Gender had no 
overall effect on any of the parameters at any time point (Table 4.2 Sex), though 
males and females had a different pattern of exploration over time at 5 (rearing and 
centre rearing) and 7 (Activity and mobility) weeks of age.  
Deficits in mobility were already apparent in R6/2 mice at 5 weeks of age. Although 
no hypoactivity was observed in the Hdac6KOxR6/2 phenotyping study at 5 weeks 
of age (Results Chapter 3 - Experimental Paper, Fig. S1 and Table S1), reduced 
hypoactivity of R6/2 mice can occur as early as 4 weeks of age (Hockly et al., 2006). 
These discrepancies are most likely due to phenotype onset and disease 
progression being modestly variable between the different generations and cohorts 
of mice studied. Hypoactivity became evident at 7 weeks of age, decreased centre 
rearing and rearing was detected at 11 and 13 weeks of age respectively (Table 4.2 
R6/2 Genotype). There was a pronounced gender difference in the effect of R6/2 
genotype only between 9 and 11 weeks of age and that was detected in all 
parameters (Table 4.2 Sex*R6/2). This was most likely due to the quicker 
deterioration of the R6/2 males as compared to R6/2 females, which had also been 
observed for weight and grip strength (Fig. 4.5 A-D) and is visualised in the moving 
averages (Fig. 4.6 and 4.7). 
Reduction or ablation of SIRT2 had no effect on any of the parameters at any age 
tested, did not modify the pattern of exploration over time and did not affect the 
hypoactivity of R6/2 mice (Table 4.2 Sirt2KO Genotype, Time*Sirt2KO, 
R6/2*Sirt2KO). Nevertheless, there was a Sirt2 Genotype dependent change in the 
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pattern of activity, mobility and rearing over time at 7 weeks of age that was 
different between WT and R6/2 mice. However, this effect is most likely caused by 
the WT female group that was slightly hyperactive in the first 10 min of the test 
(Fig. 4.6) and the fact that, the R6/2 KO mice were the most active in rearing group 
amongst females, whereas the R6/2 mice were more active in rearing amongst 
males (Fig 4.7). These data imply that Sirt2 knock-out or knock-down does not 
modify spontaneous motor activity in mice between 5 and 13 weeks of age and has 
no effect on the hypoactivity of R6/2 mice. 
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Table 4.2. Summary of p-values obtained from the statistical analysis of 
exploratory motor activity. 
 
Week Activity Mobility Rearing Centre Rearing 
Time 
5 <0.001 <0.001 <0.001 <0.001 
7 <0.001 <0.001 <0.001 <0.001 
9 <0.001 <0.001 <0.001 <0.001 
11 <0.001 <0.001 0.008 0.006 
13 <0.001 <0.001 0.013 0.004 
R6/2 Genotype 
5 0.212 0.044 0.708 0.655 
7 0.055 0.005 0.061 0.557 
9 <0.001 <0.001 0.487 0.910 
11 <0.001 <0.001 0.147 0.004 
13 <0.001 <0.001 <0.001 <0.001 
Time*R6/2 
5 0.041 0.043 0.134 0.025 
7 0.012 0.058 0.167 0.243 
9 0.697 0.561 0.036 0.158 
11 0.078 0.039 0.352 0.464 
13 0.248 0.300 0.060 0.375 
Sirt2KO Genotype 
5 0.651 0.685 0.160 0.314 
7 0.663 0.766 0.669 0.874 
9 0.133 0.243 0.158 0.216 
11 0.660 0.565 0.954 0.136 
13 0.938 0.933 0.195 0.168 
Time*Sirt2KO 
5 0.143 0.293 0.054 0.063 
7 0.607 0.545 0.366 0.094 
9 0.735 0.756 0.763 0.794 
11 0.469 0.240 0.222 0.271 
13 0.204 0.350 0.191 0.395 
Sex 
5 0.536 0.556 0.129 0.166 
7 0.598 0.381 0.059 0.117 
9 0.185 0.161 0.081 0.496 
11 0.090 0.406 0.309 0.165 
13 0.346 0.423 0.535 0.726 
Time*Sex 
5 0.110 0.166 0.004 0.025 
7 <0.001 <0.001 0.276 0.138 
9 0.654 0.469 0.648 0.579 
11 0.088 0.123 0.836 0.765 
13 0.559 0.494 0.199 0.240 
Sex*R6/2 
5 0.846 0.952 0.865 0.670 
7 0.277 0.569 0.518 0.783 
9 0.298 0.755 0.043 0.009 
11 0.012 0.032 0.007 0.001 
13 0.194 0.319 0.071 0.165 








Table 4.2 - Continued 
 
Week Activity Mobility Rearing Centre Rearing 
Sex*Sirt2KO  
5 0.071 0.147 0.004 0.056 
7 0.395 0.440 0.477 0.803 
9 0.496 0.575 0.645 0.286 
11 0.209 0.209 0.055 0.040 
13 0.909 0.836 0.094 0.206 
Sex*R6/2*Sirt2KO 
5 0.908 0.904 0.335 0.804 
7 0.706 0.704 0.772 0.575 
9 0.600 0.506 0.449 0.428 
11 0.079 0.078 0.259 0.524 
13 0.423 0.665 0.505 0.683 
R6/2*Sirt2KO 
5 0.431 0.391 0.279 0.872 
7 0.836 0.894 0.151 0.201 
9 0.546 0.662 0.640 0.688 
11 0.800 0.648 0.652 0.729 
13 0.934 0.840 0.483 0.855 
Time*R6/2*Sirt2KO 
5 0.436 0.640 0.549 0.617 
7 0.008 0.026 0.043 0.064 
9 0.598 0.579 0.282 0.148 
11 0.789 0.890 0.690 0.821 
13 0.812 0.893 0.293 0.632 
Time*Sex*R6/2* 
Sirt2KO 
5 0.660 0.587 0.562 0.186 
7 0.232 0.222 0.225 0.040 
9 0.683 0.554 0.672 0.780 
11 0.516 0.423 0.382 0.849 
13 0.457 0.603 0.422 0.818 
Key: Blue – p<0.05, Orange – p<0.01, Pink – p<0.001 
 




Figure 4.6. Activity and mobility. 
Activity and mobility were recorded for wild type (WT), Sirt2HET (HET), Sirt2KO 
(KO), R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2 (R6/2 KO) mice over the 
course of 30 min at 5, 7, 9, 11, and 13 weeks of age. Activity parameters 
measurements were visualised by plotting 5 min moving averages.   




Figure 4.7. Rearing and centre rearing. 
Rearing and centre rearing were recorded for wild type (WT), Sirt2HET (HET), 
Sirt2KO (KO), R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2 (R6/2 KO) mice 
over the course of 30 min at 5, 7, 9, 11, and 13 weeks of age. Activity parameters 
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4.7. SIRT2 knock-down and knock-out do not affect aggregate load or levels of 
soluble mHTT in R6/2 mice 
Although genetic ablation of SIRT2 had no discernible disease modifying effect on 
the HD related behavioural and physiological phenotypes in R6/2 mice, it remained 
possible that SIRT2 depletion elicited more subtle molecular changes. Mutant HTT 
aggregates are formed in HD patients and all known mouse models and correlate 
with disease progression (Crook and Housman, 2011; DiFiglia et al., 1997). To 
investigate whether SIRT2 genetic depletion modified levels of soluble or 
aggregated mHTT, Seprion ELISA, time resolved – Förster energy transfer (TR-FRET) 
and Mezoscale Discovery (MSD) were performed on the cortex, hippocampus, brain 
stem and cerebellum from 4, 9 and 15 week old R6/2, R6/2 HET and R6/2 KO mice. 
As has been observed previously, the aggregate load in R6/2 mice was highest in 
the cortex and hippocampus and much lower in the brain stem (Fig. 4.8-10 C) 
(Sathasivam et al., 2010). WT, Sirt2HET and Sirt2KO mouse tissues did not give any 
signal above background for aggregated or soluble HTT in any brain region or at any 
age tested (Fig. 4.8-10 B).  
Interestingly, Seprion ELISA did not detect any changes in aggregation in the cortex, 
hippocampus or brain stem at 4, 9 or 15 weeks of age between R6/2, R6/2 HET or 
R6/2 KO mice. To confirm this finding, samples were separated by SDS-PAGE and 
immunoblotted with an anti-HTT antibody (S829) (Fig. 4.8-10 A-B). Large SDS-
insoluble aggregates are unable to move into the resolving gel and can be only 
detected in the stacking gel. In contrast, the soluble mHTT transprotein is readily 
detected at a size of about 90 kDa (SDS-PAGE mobility of the monomeric 
transprotein is distorted due to its high glutamine content). No aggregated or 
soluble mHTT could be detected by western blot in any of the WT, Sirt2HET or 
Sirt2KO tissues at 4, 9 or 15 weeks of age (Fig. 4.8-10 B). At 9 and 15 weeks of age, 
aggregates could readily be detected in all brain regions examined, though no 
genotype specific difference could be observed. Interestingly, at 4 weeks of age 
aggregates could only be detected in the cortex, which is surprising, given that the 
Seprion ELISA assay revealed that levels of aggregated mHTT in the cortex were 
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comparable with those of hippocampus. However, cortical and hipoccampal lysates 
were run on separate gels and thus, signals obtained after immunodetection are 
not directly comparable as they depend on factors such as efficiency in protein 




Figure 4.8. Aggregate load in cortex, hippocampus and brain stem at 15 weeks of 
age. 
(A-B) Representative western blots from cortex, hippocampus and brain stem of 15 
week old wild type (WT), Sirt2HET (HET), Sirt2KO (KO), R6/2, Sirt2HETxR6/2 (R6/2 
HET) and Sirt2KOxR6/2 (R6/2 KO) mice probed with an anti-HTT antibody (S829) 
and tubulin (Tub) as loading control. Both soluble mHTT transprotein and 
aggregates stuck in the stacking gel can only be detected in mice expressing the 
R6/2 transgene (A-B). All samples were run on the same gel. White lines indicate 
where lanes are not contiguous. (C) Aggregate load as measured by Seprion ELISA 
with the MW8 antibody. The average signal for WT, HET and KO values was 
subtracted from each reading and expressed as  fold change of R6/2 cortex ± SEM. 
n=6/genotype(R6/2, R6/2 HET and R6/2 KO) or n=3/genotype (WT, HET, KO). 




Figure 4.9. Aggregate load in cortex, hippocampus and brain stem at 9 weeks of 
age. 
(A-B) Representative western blots from cortex, hippocampus and brain stem of 9 
week old wild type (WT), Sirt2HET (HET), Sirt2KO (KO), R6/2, Sirt2HETxR6/2 (R6/2 
HET) and Sirt2KOxR6/2 (R6/2 KO) mice probed with an anti-HTT antibody (S829) 
and tubulin (Tub) as loading control. Both soluble mHTT transprotein and 
aggregates stuck in the stacking gel can only be detected in mice expressing the 
R6/2 transgene (A-B). All samples were run on the same gel. White lines indicate 
where lanes are not contiguous. (C) Aggregate load as measured by Seprion ELISA 
with the MW8 antibody. The average signal for WT, HET and KO values was 
subtracted from each reading and expressed as  fold change of R6/2 cortex ± SEM. 








Figure 4.10. Aggregate load in cortex, hippocampus and brain stem at 4 weeks of 
age. 
(A-B) Representative western blots from cortex, hippocampus and brain stem of 4 
week old wild type (WT), Sirt2HET (HET), Sirt2KO (KO), R6/2, Sirt2HETxR6/2 (R6/2 
HET) and Sirt2KOxR6/2 (R6/2 KO) mice probed with an anti-HTT antibody (S829) 
and tubulin (Tub) as loading control. Soluble mHTT transprotein can only be 
detected in mice expressing the R6/2 transgene (A-B). Aggregates were only 
detectable in the cortex. (C) Aggregate load as measured by Seprion ELISA with the 
MW8 antibody. The average signal for WT, HET and KO values was subtracted from 
each reading and expressed as  fold change of R6/2 cortex ± SEM. 
n=6/genotype(R6/2 and R6/2 HET) or n=3/genotype (WT, HET, KO, R6/2 KO). 
 
TR-FRET analysis revealed no differences in the levels of soluble mHTT between 
R6/2, R6/2 HET and R6/2 KO brains at any of the ages tested in any tissue examined 
(Fig 4.11). These results were also confirmed by western blotting. As expected, 
levels of soluble mHTT are significantly decreased between 4 and 15 weeks of age 
in all brain regions tested. However, the rate at which levels of soluble mHTT 
decrease with disease progression varies greatly between different brain regions 
(Fig. 4.11 A – D). In the cortex, mHTT levels steadily decrease from 4 to 15 weeks of 
age. In contrast, levels of soluble mHTT in the hippocampus and brain stem exhibit 
dramatic decreases from 9 to 15, and 4 to 9, weeks of age respectively (Fig. 4.11 B -
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C). Furthermore, in the cerebellum, the reduction of soluble mHTT, occurs gradually 
and, is not as pronounced as in the other brain regions (Fig. 4.11 D). 
 
 
Figure 4.11. Soluble mHTT in the cortex, hippocampus, brain stem and cerebellum 
at 4, 9 and 15 weeks of age. 
Levels of soluble mHTT as measured by TR-FRET with 2B7-MW1 antibodies in the 
(A) cortex, (B) hippocampus (C) brain stem and (D) cerebellum at 4, 9 and 15 weeks 
of age in R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2 (R6/2 KO) mice. The 
signal for each tissue was expressed as fold change of R6/2 at 4 weeks. No signal 
above background was observed for mice without the R6/2 transgene. 
n≥4/genotype/tissue/time point (except for R6/2 KO at 4 weeks where n=3). Error 
bars represent SEM. 
 
These findings were confirmed by MSD assay (Fig. 4.12). Importantly, the profiles 
obtained for the decrease in soluble mHTT for each brain region were very similar 
to those seen by TR-FRET. Interestingly, the aggregate load is progressively 
increased between 4 and 15 weeks of age in every brain region examined (Fig. 
4.12). At first glance this appears contradictory to the soluble mHTT profiles 
obtained for hippocampus and brain stem. However, this could be explained by the 
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existence of a population of oligomeric mHTT that is undetected by either of the 
two antibody combinations in the assays amployed.  
Although a significant decrease in the aggregate load in R6/2 HET and R6/2 KO mice 
was detected in the cortex at 15 weeks of age, these differences were not observed 
by Seprion ELISA or western blot (Fig. 4.8 A, C and Fig. 4.12 A). At the same time, 
the Sirt2 genotype appears to significantly increase levels of soluble mHTT in the 
hippocampus at 4 weeks and in the brain stem at 15 weeks of age (Fig. 4.12 B – C), 
findings that were also not reproduced by TR-FRET or western blotting (Fig. 4.8 A, C; 
Fig. 4.10 A, C and Fig. 4.11 B – C). However, both TR-FRET and MSD assays have 
been performed on the same lysates and therefore, it is highly likely that any 
changes that reach statistical significance are a result of the large number of 
comparisons performed rather than a real biological effect. Taken together, these 
data demonstrate that genetic ablation of SIRT2 does not alter the dynamics of 
mHTT aggregation between 4 and 15 weeks of age in brain tissues from R6/2 mice. 
Furthermore, these results imply that the mechanisms or kinetics of aggregation 
vary between different brain regions in R6/2 mice and are therefore likely to be 
dependent on expression levels of mHTT and/or other factors specific to these 
brain regions. 
 




Figure 4.12. Soluble and aggregated mHTT in the cortex, hippocampus, brain stem 
and cerebellum at 4, 9 and 15 weeks of age as measured by Mezoscale Discovery.  
Levels of soluble (upper panels) and aggregated (lower panels) mHTT as measured 
by Mezoscale Discovery (MSD) in (A) cortex, (B) hippocampus, (C) brain stem, and 
(D) cerebellum at 4, 9 and 15 weeks of age in R6/2, Sirt2HETxR6/2 (R6/2 HET) and 
Sirt2KOxR6/2 (R6/2 KO) mice. Soluble mHTT was measured with 2B7-MW1 and 
aggregated mHTT with MW8-MW8 antibodies combination. The signal for each 
tissue was expressed as fold change of R6/2 at 4 weeks. No signal above 
background was observed for mice without the R6/2 transgene. 
n≥4/genotype/tissue/time point (except for R6/2 KO at 4 weeks where n=3). Error 
bars represent SEM. *p≤0.05, **p≤0.01 (to the R6/2 at the respective time point). 
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4.8. Cholesterogenic enzyme dys-homeostasis is not corrected by the genetic 
depletion of SIRT2 
Levels of cholesterol biosynthesis enzymes have been reported to be decreased in 
R6/2 mice (Valenza et al., 2007). SIRT2 genetic ablation had no effect on the 
expression of cholesterogenic enzymes in WT mice, however, it was possible that 
SIRT2 deletion effects would only be apparent in the context of HD pathogenesis. 
To verify if that is the case, RNA was extracted and cDNA prepared from the 
cortices of 15 week old WT, HET, KO, R6/2, R6/2 HET and R6/2 KO mice.  
 
 
Figure 4.13. Expression of cholesterogenic enzymes at 15 week of age. 
Taqman qPCR assay was used to measure cholesterogenic enzymes’ mRNA 
expression in the cortex of 15 week old wild type (WT), Sirt2HET (HET), Sirt2KO 
(KO), R6/2, Sirt2HETxR6/2 (R6/2 HET) and Sirt2KOxR6/2 (R6/2 KO) mice. Values 
were normalised to the housekeeping genes Atp5b and Canx and expressed as fold 
change of WT ± SEM. n≥7/genotype. 
 
The expression of cholesterogenic enzymes was measured by Taqman qPCR assays 
and data were analysed by two-way ANOVA. The R6/2 genotype had a statistically 
significant effect on the expression of all cholesterogenic enzymes examined (Fig. 
4.13). However, post-hoc pairwise comparison with Bonferroni correction revealed 
that there is no difference between WT and R6/2 groups in the expression of 
Hmgcs1 (p=1), Fdps (p=1), Dhcr7 (p=1), Idi1 (p=0.278) and Sqle (p=1) and the 
statistical significance obtained from ANOVA is derived from inclusion of Sirt2HET 
and Sirt2KO groups with higher than WT values, as well as R6/2 HET and R6/2 KO 
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groups with lower than R6/2 values. Taken together these data suggest that the 
expression of Hmgcs1, Fdps, Dhcr7, Idi1 and Sqle, is affected by R6/2 transgene only 
in the presence of SIRT2 genetic reduction or depletion. 
The Sirt2 genotype alone had no significant effect on the expression of any of the 
cholesterogenic enzymes. Surprisingly, however, Sirt2 genotype significantly 
modified the effect of the R6/2 genotype on the expression of Hmgcr (F(2,33)=6.03, 
p=0.006) , Dhcr7 (F(2,36)=5.14, p=0.011) and Sqle (F(2,36)=3.38, p=0.045). These 
changes could signify that Sirt2KO has a late stage disease-specific effect on the 
expression of some cholesterol biosynthesis genes. On the other hand, it is possible 
that statistical significance results from the fact that HET and KO values tend to be 
higher than WT, whereas R6/2 HET and R6/2 KO values appear to be lower than 
those of R6/2. If these results are depicting a real effect of SIRT2 deletion, it would 
appear that SIRT2 is positively regulating cholesterol gene expression in R6/2 mice, 
but inhibiting the expression of the same genes in WT mice, which is extremely 
unlikely. In any case, the mechanism proposed for SIRT2 regulation of cholesterol 
synthesis assumed SIRT2 increasing SREBP-2 nuclear translocation (Luthi-Carter et 
al., 2010). All of the tested cholesterogenic enzymes are targets of SREBP-2, 
therefore, if SIRT2 ablation was causing a decrease in nuclear shift of SREBP-2, KO 
mice should display lowered cholesterogenic enzyme expression levels as compared 
to WT and the effect ought to be detected in all 7 of the enzymes tested. As this 
was not the case, the observed statistical differences are more likely a result of 
biological variability than a depiction of the effect of SIRT2 depletion. 
 
4.9. Acute inhibition of SIRT2 has no effect on the levels of cholesterol 
biosynthesis enzymes in WT or R6/2 mice 
The lack of effect of SIRT2 knock-out on tubulin and H4K16 acetylation, and on 
cholesterogenic enzyme expression could be due to compensation. With a 
traditional knock-out, as is the case here, SIRT2 protein is constantly reduced or 
absent from Sirt2HET or Sirt2KO mice, respectively, allowing the organism time to 
adjust and compensate. In contrast, previous studies were performed in a cell 
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culture setting, where SIRT2 was acutely inhibited, thereby limiting the time for the 
same compensatory mechanisms to be employed by the system (Luthi-Carter et al., 
2010).  
To investigate whether the lack of observed effects in the Sirt2KO mice could be 
due to compensation, wild type and R6/2 mice at 12 weeks of age were given a 
single low (1 mg/kg) or high (3mg/kg) dose of a dual SIRT1/SIRT2 inhibitor CHDI-
00194500-0000-0005 (CHDI194500). The doses have been chosen based on 
pharmacokinetic data and in vitro inhibition assays (Appendix 2). Tissues were 
harvested either 4 or 8 h post dosing. RNA was extracted from the cortex and the 
expression of cholesterogenic enzymes was measured with Taqman qPCR assays. In 
line with previous reports and data from this work, expression of all 
cholesterogenic enzymes was diminished in R6/2 vehicle treated mice as compared 
to WT vehicle treated mice (Fig 4.14) (Valenza et al., 2007).  However, neither dose 
of CHDI194500 affected the expression of cholesterogenic enzymes at 4 or 8 h post 
dosing in both WT and R6/2 mice. Although a decrease in the expression of Hmgcr 
can be observed in WT mice 8 h post dosing (Fig. 4.14 B), the fact that none of the 
other enzymes’ expression was changed and that Hmgcr expression after 3 mg/kg 
dose was comparable to vehicle strongly suggests that this observation is a result of 
experimental variation rather than a real biological effect. These data strongly 
suggest that either SIRT2 inhibition does not modulate the expression levels of 
cholesterol biosynthesis enzymes or SIRT2 inhibition was not achieved with 
CDHI194500.  
 




Figure 4.14. Expression of cholesterogenic enzymes in wild type and R6/2 mice 
after an acute dose of CHDI194500 SIRT1/SIRT2 inhibitor. 
Expression of cholesterogenic enzymes in the cortex of 12 week old wild type (WT) 
and R6/2 mice (A) 4 h and (B) 8h after an acute dose of the CHDI194500 
SIRT1/SIRT2 inhibitor or vehicle. Values were normalised to the housekeeping 
genes Atp5b and Canx and expressed as fold change of WT Vehicle ± SEM. 
n≥7/genotype/treatment group.  
 
4.9.1. Measurement of SIRT2 activity with Fluor de Lys assay 
In order to measure the activity of SIRT2 after inhibition with CHDI194500, it was 
attempted to adapt the Fluor de Lys SIRT2 in vitro activity assay kit to measuring 
SIRT2 activity in tissue lysates. Firstly, different amounts of total protein extracted 
in Fluor de Lys Assay Buffer from WT and Sirt2KO mouse cortices were incubated 
with or without the SIRT2 cofactor NAD+ and the SIRT2 acetylated substrate. The 
SIRT2 substrate is a tetrapeptide corresponding to amino acids 317-320 of human 
p53, acetylated at position 320 and modified in such a way that deacetylation 
sensitizes it to produce a fluorophore when incubated with the Developer solution. 
The signal detected after incubation with the Developer solution was proportional 
Chapter 4 Genetic reduction of SIRT2 in R6/2 mice 
151 
 
to the amount of protein added to the substrate, except for when 100 µg of total 
protein was used, for which the signal was only slightly higher than with 50 µg of 
protein (Fig. 4.15 A). This indicates that the substrate was consumed and 100 µg 
contains an excess of deacetylase. At the same time it was noted that although all 
samples were pre-incubated at 37°C to allow all internal NAD+ to be used up, the 
enzyme activity in the reactions to which no NAD+ was added was considerable and 
indistinguishable from reactions with external NAD+ when 50 or 100 µg of protein 
were used. The largest difference between signals obtained with and without 
external NAD+ was seen with 5 µg of total protein. Most importantly however, no 
difference in activity between lysates obtained from WT or Sirt2KO mice could be 
detected (Fig. 4.15 A). This was not surprising, given that the acetylated substrate is 
based on p53, which is also a client of SIRT1 and above all, is an artificial short 
peptide, and could therefore be deacetylated by any of the other Sirtuins or by a 
yet unidentified deacetylase.  
In order to investigate whether extending the 10 min pre-incubation time at 37°C 
could decrease the signal obtained from reactions where no external NAD+ was 
added, so that concentration of NAD+ could be controlled better by relying mostly 
on externally added NAD+, Fluor de Lys was performed on samples containing 5 µg 
of total protein that were pre-incubated for 20, 40 or 60 min at 37°C. To find out 
whether the deacetylase activity observed in the Sirt2KO samples arises from 
nuclear Sirtuins, only cytoplasmic fractions were used. Unfortunately, in this 
experiment the signal obtained from samples without externally added NAD+ was 
stronger for all pre-incubation times tested (Fig. 4.15 B).  
There was still no difference in signal between the samples obtained from WT and 
Sirt2KO mice, suggesting, that the activity observed in Sirt2KO samples was not due 
to the presence of nuclei (and therefore SIRT1) in the lysates (Fig. 4.15 B).  
Although no differences could be detected with the Flour de Lys assay between WT 
and Sirt2KO tissues, it was still possible that this was due to compensation 
occurring in the Sirt2KO animals. In a final attempt to measure SIRT2 activity using 
the Fluor de Lys kit, cortical samples from WT mice acutely dosed with CHDI194500 
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were extracted and examined with the Flour de Lys assay. Unfortunately, the assay 
did not reveal differences between vehicle, 1 mg/kg and 3 mg/kg treated groups. 
Equally, there was no effect of adding exogenous NAD+ to any of the samples (Fig. 
4.15 C).  
This suggests that either internal NAD+ was not used up before the assay was 
commenced or that the enzymatic activity towards the acetylated substrate is NAD+ 
independent. In any case, all data points to the acetylated substrate not being 
specific to SIRT2 and clearly shows that the Flour de Lys SIRT2 activity assay is not 











Figure 4.15. Measuring SIRT2 activity with the Flour de Lys SIRT2 activity assay.  
(A) Fluorescence signal obtained after different amounts of total protein from wild 
type (WT) or Sirt2KO (KO) mice were incubated with the acetylated substrate and 
with or without NAD+(NAD). n=4/genotype, values ± SEM. (B) Fluorescence signal 
obtained after different pre-incubation times were applied to samples from WT or 
KO mice incubated with the acetylated substrate and with or without NAD+(NAD). 
n=3/genotype, values ± SEM (where possible). (C) Fluorescence signal obtained 
from vehicle, 1 mg/kg or 3 mg/kg CHDI194500 treated WT mice dissected 4 or 8 h 
post-dosing. Samples were incubated with the acetylated substrate and with or 
without NAD+(NAD). n=6/treatment group, values ± SEM. 
 
 
4.9.2. Measurement of the effects of CHDI194500 acute dosing on Ac-p53 and Ac-
FOXO1 
After efforts to adapt the Flour de Lys SIRT2 activity assay to measure SIRT2 activity 
in tissue lysates failed, one option to detect a pharmacodynamic effect of 
CHDI194500 was to assess the levels of acetylated in p53 and FOXO1. These 
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transcription factors have both been found to be substrates of both SIRT1 and 
SIRT2 (Peck et al., 2010; Wang et al., 2011). Therefore, as CHDI194500 inhibits both 
SIRT1 and SIRT2, exposure to CHDI194500 should in theory result in increased levels 
of acetylated p53 (Ac-p53) and acetylated FOXO1 (Ac-FOXO1). Cortical protein 
lysates from the acute CHDI194500 dosing study were prepared and western 
blotted with antibodies against Ac-p53 (expected to resolve at 53 kDa) and Ac-
FOXO1 (expected to resolve at 70 kDa). Unfortunately, the antibodies commercially 
used to detect Ac-p53 and Ac-FOXO1 gave very weak signals even when applied in 
low dilution (1:100) (Fig. 4.16). Additionally, it was evident that the high amount of 
protein (60 µg), that was required to detect Ac-p53 and Ac-FOXO1, caused 
unevenness across the gels during electrophoresis and western transfer.  Although 
it appeared that there was no difference in the acetylation status of either Ac-p53 
or Ac-FOXO1 between vehicle, 1 mg/kg or 3 mg/kg dosed mice, the western 
blotting signal was not quantifiable and therefore, this conclusion cannot be drawn 
with certainty.  
  
 
Figure 4.16. Western blotting and immunodetection of Ac-p53 and Ac-FOXO1 in 
mice acutely dosed with CHDI194500. 
Western blots of Ac-p53 (upper panel) or Ac-FOXO1 (lower panel) from cortices of 
12 week old wild type (WT) and R6/2 mice acutely dosed with vehicle (Veh), 1 
mg/kg (Low) or 3 mg/kg (High) of CHDI194500 and dissected 4 or 8 h post dosing. 
Image representative of n=4/genotype/treatment group.  
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4.9.3. Pharmacokinetic analysis reveals presence of CHDI194500 in the brains of 
dosed mice. 
CHDI194500 has already been demonstrated to be brain penetrant (Appendix 2). 
LC/MS/MS analysis of brain tissue from mice dosed with CHDI194500 revealed that 
at 4 h post dosing, CHDI194500 was present in both WT and R6/2 mice at 
concentrations above its IC50 for SIRT2 (560 nM) (Fig. 4.17 and Appendix 2). 
Although at 8 h post dosing the concentration was below the IC50 for all groups 
except WT treated with 3 mg/kg, it could be expected that the downstream effects 
of SIRT2 inhibition should still be detectable at this time point. Interestingly, a 
difference in CHDI194500 brain concentration can be observed between WT and 
R6/2 at 8 h post dosing, indicating that the drug is metabolised quicker in R6/2 
mice, a phenomenon not previously reported for these mice. Ultimately however, 
no differences were found in cholesterol enzyme expression between CHDI194500 
and vehicle treated mice in either WT or R6/2 groups at 4 h post-dosing, where the 
compound was present in both groups at the same level. This suggests that lack of 
effects in cholesterol biosynthesis pathway observed in SIRT2 knock-out mice is not 
due to genetic compensation.  
 
Figure 4.17. CHDI194500 is present in the brain of dosed mice after one acute 
dose of 1 mg/kg or 3 mg/kg at 4 and 8 hours post dosing 
Pharmacokinetic analysis was performed by LC/MS/MS on rest of brain samples 
(brain except cortex, striatum, hippocampus, cerebellum, and brain stem) from 
mice dosed with vehicle, 1 mg/kg or 3 mg/kg of CHDI194500. No compound was 
detected in mice dosed with vehicle alone. Black line denotes the SIRT2 IC50 
concentration of 560 nM for CHDI194500 as determined in in vitro assays (Appendix 
2). n≥8/genotype/dose/time point. 
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4.10. Final conclusions 
To conclude, the data presented here show that genetic manipulation causing an 
approximately 50% reduction in SIRT2 protein levels or total ablation of the SIRT2 
protein has no effect on disease progression in the R6/2 mouse. Moreover, 
reduction or removal of the SIRT2 protein has no effect on the levels of acetylated 
tubulin, acetylated H4K16 or on the expression of enzymes involved in cholesterol 
biosynthesis. Additionally, it has been demonstrated that compensation has not 
occurred in the regulation of the cholesterogenic enzyme expression as no changes 
have been observed after acute inhibition of SIRT2. Though it was not possible to 
find an appropriate pharmacodynamic readout of SIRT2 activity after inhibition with 
CDHI194500, the pharmacokinetic data showed that CHDI194500 was successfully 
introduced into the brain of dosed mice at 0.5 - 2 µM levels, greater than the IC50 of 
0.56 µM for SIRT2. Overall, this signifies that the roles of SIRT2 in the regulation of 
cholesterol biosynthesis and as a possible therapeutic target for HD do not translate 

















5.1. Tubulin hyperacetylation is observed after genetic depletion of HDAC6 but 
not SIRT2 
 
The significance of tubulin acetylation in cell function and human disease has 
gradually emerged since the identification of this modification almost 30 years ago 
(L'Hernault and Rosenbaum, 1983). HDAC6 and SIRT2 are the only known tubulin 
deacetylating enzymes (Hubbert et al., 2002; North et al., 2003). As acetylation of 
α-tubulin has been suggested to modify microtubule stability and dynamics 
(Matsuyama et al., 2002), influence protein-microtubule binding (Giustiniani et al., 
2009), and play a role in numerous biological processes (Perdiz et al., 2011), it was 
surprising to discover that both Hdac6KO and Sirt2KO mice were viable and did not 
shown any overt phenotypes. Nevertheless, the observation that Hdac6KO mice 
displayed a deficit in their immunological response to infection (Zhang et al., 2008) 
argues for the possibility that both Hdac6KO and Sirt2KO mice could exhibit other 
subtle phenotypes or alternatively, only present with a phenotype when challenged 
with stressful conditions.  
Thorough investigation of acetylated tubulin levels revealed that tubulin is 
hyperacetylated throughout the brain of Hdac6KO mice (Experimental Paper – Fig. 
2 A and C). This finding was surprising as the Hdac6KO mice that were used in this 
study have previously been shown to possess hyperacetylated tubulin in peripheral 
tissues but not in the brain (Zhang et al., 2008). However, tubulin hyperacetylation 
has been observed in the brain of a different line of Hdac6KO mice (Gao et al., 
2007). An absence of tubulin hyperacetylation in brain tissue in the experiments 
performed by Zhang and colleagues, was attributed to constitutively high levels of 
acetylated tubulin in the brain of wild type mice (Zhang et al., 2008). This 
discrepancy may be due to differences in tubulin acetylation within the brain during 
ageing. Zhang and colleagues characterised mice at 12-26 weeks of age (Zhang et 
al., 2008), whereas the work presented here was performed in mice that were 15 
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weeks of age or younger. Interestingly, tubulin hyperacetylation was found to be 
highest at 4 and 9 weeks of age and decreased by 15 weeks of age in Hdac6KO 
brain tissue. This effect appears to be due to an increase in tubulin acetylation in 
wild type mice at 15 weeks of age. Given that mice older than 15 weeks have not 
been examined here and assuming that tubulin acetylation continues to increase 
with age it is possible that the effects of HDAC6 depletion are not detectable in 
mice older than 15 weeks. However, as no specification as to the age of mice tested 
in the study by Zhang et al was given (Zhang et al., 2008), it is not possible to 
determine if this explanation could apply. A minimal decrease in Hdac6 mRNA 
expression level was observed between 4 and 9 weeks of age in the cortex, but not 
in the striatum or cerebellum of wild type mice (Experimental Paper – Fig. 1C). It is 
possible that this could account for the increase in tubulin acetylation observed at 
15 weeks of age. Alternatively, this phenomenon could be a result of changes in the 
expression or activity of recently identified tubulin acetylatransferases αTAT 
(previously MEC-17) and the elongator complex (Akella et al., 2010; Creppe et al., 
2009). Although these experiments are beyond the scope of this project, it would 
be interesting to investigate which factors regulate tubulin acetylation in the brain. 
Like HDAC6, SIRT2 has been shown to deacetylate tubulin in vitro and in cell culture 
experiments. Given the dramatic changes in tubulin acetylation in Hdac6KO mice, it 
was expected that a similar change would be observed in Sirt2KO mice. Surprisingly, 
no differences could be observed in the levels of acetylated tubulin between brains 
of Sirt2KO mice and those of wild type mice. It is unlikely that an age related change 
in SIRT2 levels is the explanation for these observations as SIRT2 levels in the brain 
were found to be higher at 4 than at 15 weeks of age, which is consistent with 
previous studies (Werner et al., 2007). The data obtained in this study suggest that 
either SIRT2 is not critical for tubulin deacetylation or that a chronic loss of SIRT2 is 
compensated for in Sirt2KO mice.  
It is possible that SIRT2, though shown to be capable of tubulin deacetylation in 
vitro and in cell culture after acute RNAi mediated SIRT2 knock-down, is not a bona 
fide tubulin deacetylase in vivo. Previous studies could not detect changes to levels 
of acetylated tubulin in mouse embryonic fibroblasts derived from Sirt2KO mice 
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(Zhang et al., 2008). At the same time, double mutant Hdac6KOxSirt2KO mice are 
viable and do not display any overt phenotypes up to 4 weeks of age, arguing for 
non-redundant roles for HDAC6 and SIRT2 (unpublished observations). Therefore, it 
is possible that previous findings on the function of SIRT2 as a tubulin deacetylase 
do not translate to the mammalian system. 
Structural and functional similarity implies that increases in either SIRT1 or HDAC6 
activity could compensate for SIRT2 loss. However, neither Hdac6 nor Sirt1 levels 
were found to be changed in Sirt2KO mice implying that SIRT2 loss is not 
compensated for by changes in the expression of HDAC6 or SIRT1. Nevertheless, it 
remains possible that increases in HDAC6 or SIRT1 activity could occur 
independently of changes in expression upon SIRT2 loss. As such, it would be 
interesting to investigate whether compensation occurs via changes in enzymatic 
activity of HDAC6, SIRT1 or another deacetylase. However, the tools required to 
address this question are not currently available. Though the mechanism regulating 
tubulin acetylation was not the focus of this work, further investigation assessing 
the levels and activity of tubulin acetyltrasferases and histone deacetylases upon 
SIRT2 depletion may be interesting. 
 
5.2. SIRT2 loss does not affect histone 4 lysine 16 acetylation 
 
In addition to tubulin, SIRT2 has been proposed to regulate the acetylation status of 
several other clients. Although cytoplasmic in nature, SIRT2 has been shown to 
regulate cell cycle progression through deacetylation of lysine 16 of histone 4 
(H4K16) (Vaquero et al., 2006). Interestingly, no change in the levels of acetylated 
H4K16 were observed in brain and liver tissue from Sirt2KO mice. 
The absence of change in levels of acetylated H4K16 between wild type and Sirt2KO 
mice was not due to the fact that the brain contains fewer dividing cells than other 
organs, as the same observation was also made in the liver, which contains a high 
number of dividing cells. It is equally unlikely that the antibody used in this work 
was not specific enough to detect changes in this particular modification of H4, as 
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this antibody has been extensively characterised through the modENCODE project 
(Egelhofer et al., 2011). Together with the fact that Sirt2KO mice develop normally 
and do not show any phenotypes it appears that cell cycle progression is not 
impaired in these mice. 
In accordance with previously published data (Vaquero et al., 2006), SIRT2 was 
found to be predominantly cytoplasmic with little SIRT2 being found in nuclear 
fractions isolated from mouse brain. This could indicate that SIRT2 is only important 
for cell cycle regulation under specific conditions, as has been suggested by some, 
but not all, previous studies (Dryden et al., 2003; Inoue et al., 2007; Pandithage et 
al., 2008; Vaquero et al., 2006). Equally, in addition to its role in cell cycle 
progression, acetylation of H4K16 has been reported to be important for cellular 
processes such as maintenance of active chromatin for transcription or DNA repair 
(Vaquero et al., 2007). Given the fundamental importance of these pathways, it is 
highly likely that compensatory mechanisms to maintain proper H4K16 acetylation 
levels exist and could be responsible for the inability to detect differences in H4K16 
acetylation between wild type and Sirt2KO mice.  
 
 
5.3. SIRT2 ablation has no effect on the expression of cholesterol biosynthesis 
enzymes 
 
Cholesterol is vital to the proper functioning of neurons through its involvement in 
myelin formation, neurite outgrowth, synaptogenesis and proper clustering of 
membrane proteins such as ion channels and neurotransmitter receptors (Valenza 
and Cattaneo, 2011). Defects in cholesterol biosynthesis can lead to malfunctioning 
of the central nervous system, as is the case in Smith-Lemli-Opitz syndrome 
(Waterham et al., 1998). Changes in cholesterol levels have also been observed in 
HD patients as well as in all HD models investigated (Valenza and Cattaneo, 2011). 
However, therapeutic interventions aimed at correcting cholesterol levels in HD 
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have not yet been investigated in HD mouse models or patients. Equally, as the 
contribution of cholesterol dys-homeostasis to HD pathology is unknown, finding a 
strategy for studying the effects of varying cholesterol levels on HD progression 
might shed light on the potential benefits of this unexplored therapeutic avenue. 
Consistent with previous reports, the expression of cholesterol enzymes Hmgcr, 
Hmgcs1, Dhcr7, Fdft1, Fdps, Idi1 and Sqle was reduced at 12 weeks of age in vehicle 
treated R6/2 mice that were part of the CHDI 00194500-0000-005 (CHDI194500) 
acute dosing study. This reduction has been proposed to contribute to altered 
cholesterol levels in HD and may be due to aberrant interaction of mHTT with 
SREBP-2 – a transcription factor that controls the expression of cholesterol 
biosynthesis enzymes. Surprisingly, expression of cholesterol enzymes Hmgcs1, 
Dhcr7 and Sqle was not reduced in R6/2 mice at 15 weeks of age. However, in 
contrast to the mice treated with CHDI1945 vehicle, these mice were included in 
the Sirt2KOxR6/2 phenotyping study and would have been subjected to forced 
regular exercise. Though the effect of exercise on brain cholesterol is unknown, 
physical exercise correlates with changes in cholesterol levels in the liver and in 
blood. Therefore, differential effects of exercise on the expression of Hmgcs1, 
Dhcr7 and Sqle between wild type and R6/2 mice could explain the discrepancies 
observed. 
A role of SIRT2 in modulation of cholesterol content was suggested after acute 
inhibition of SIRT2 ameliorated mHTT toxicity in worm, fly and cell culture HD 
models (Luthi-Carter et al., 2010). This effect was attributed to SIRT2 inhibition 
decreasing cholesterol synthesis via cytoplasmic retention of SREBP-2 (Luthi-Carter 
et al., 2010). Therefore, genetically depleting SIRT2 in mice was expected to lead to 
a decrease in the expression of cholesterol synthesis enzymes that are targets of 
SREBP-2. Surprisingly, the expression of 7 enzymes of the cholesterol biosynthesis 
pathway, 6 of which were confirmed targets of SREBP-2 (Horton et al., 2002), was 
found to be unaltered in Sirt2KO mice. Absence of an effect upon SIRT2 depletion 
was not due to focusing on a specific time point, brain region or tissue as the same 
observations were made in the cortex at 4 and 9 weeks of age, and in the brain 
stem and liver at 4 weeks of age. Equally, expression of cholesterogenic enzymes 
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was not affected by Sirt2 knock-out at 15 weeks of age, when Sirt2HET and Sirt2KO 
mice were included in the analysis of cholesterogenic enzymes expression in double 
mutant Sirt2KOxR6/2 mice.  
One straightforward reason for the lack of changes in the expression of cholesterol 
biosynthesis enzymes detected after SIRT2 depletion is that SIRT2 does not play a 
role in cholesterol synthesis in the mouse.  Previous work linking SIRT2 to 
cholesterol synthesis was performed with inhibitors that could have multiple off-
target effects. Although changes in the expression of Fdft1, Hgmcs1 and Hmgcr 
were also detected after over-expression of a catalytically dead SIRT2 (Luthi-Carter 
et al., 2010), these changes could be due to viral transduction being stressful to 
cells.  
On the other hand, it is possible that SIRT2 does promote SREBP-2 nuclear 
localisation and the fact that no changes in the expression of cholesterol 
biosynthesis enzymes were detected in the brains of Sirt2KO mice could be a result 
of compensatory mechanisms, which may also account for an absence of changes in 
tubulin and H4K16 acetylation. Therefore, it was important to attempt to verify 
whether acute SIRT2 inhibition would decrease the expression levels of cholesterol 
biosynthesis enzymes. The CHDI compound 00194500-0000-005 (CHDI194500) is 
brain penetrant when administered by gavage and inhibits SIRT1 and SIRT2 in in 
vitro assays (Appendix 2). Unfortunately, attempts in adapting an in vitro SIRT2 
activity kit to measuring SIRT2 activity in brain lysates were unsuccessful, most 
likely due to the design of the assay and presence of other proteins with 
deacetylase activity in the lysate. Future experiments with probes specific for SIRT2 
activity would be more apt at answering the question of SIRT2 inhibition.   
As it was not feasible to ascertain that SIRT2 activity was reduced after dosing with 
CHDI194500, there was a possibility that although CHDI1945 was found in the 
brains of dosed mice, it might not have inhibited SIRT2. Overall, it is not possible to 
definitely rule out compensatory mechanisms, however, taken together, these data 
suggest that the changes previously observed upon SIRT2 inhibition in cell culture 
do not translate to the mammalian brain. 
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5.4. Tubulin acetylation is not altered in R6/2 brains 
 
Given that histone acetyltransferase and deacetylase activity has been shown to be 
altered in HD, it was possible that this imbalance could have effects on targets 
other than histone proteins such as tubulin. On the other hand, neither Hdac6 nor 
Sirt2 expression was found to be dysregulated in R6/2 mice (Experimental Paper – 
Fig. 1 D). Interestingly, a thorough characterisation of tubulin acetylation levels in 
R6/2 brain tissue revealed that tubulin acetylation is not affected by disease 
progression at any age tested (Experimental Paper – Fig. 2 B and D). This is in 
accordance with another study published during the timeframe of this work, which 
also found no differences in acetylation of tubulin in the CAG140 knock-in mice or 
in the cortex from HD patients (Quinti et al., 2010). In contrast, a more limited 
study using a smaller number of samples reported that tubulin acetylation is 
reduced in the striatum of HD patient brains (Dompierre et al., 2007). Considering 
the pronounced variability in tubulin acetylation levels observed in the cortex of HD 
patients (Quinti et al., 2010), and the fact that only 2 biological replicates were used 
to measure tubulin acetylation in the striatum (Dompierre et al., 2007), it is possible 
that this finding is not an accurate reflection of the state of striatal tubulin 
acetylation in HD. Nevertheless, it would be very interesting to find out whether 
these findings represent a discrepancy between the methods used to detect tubulin 
acetylation or a real biological phenomenon, whereby tubulin acetylation is 
reduced in the striatum, but not in the cortex during HD. 
 
5.5. Knock-out of HDAC6 has no effect on physiological or behavioural 
phenotypes in R6/2 mice 
 
Previous studies in cell culture and D.melanogaster models of polyglutamine 
disease indicated that modulation of HDAC6 levels could affect polyglutamine-
related toxicity (Dompierre et al., 2007; Iwata et al., 2005; Pandey et al., 2007). 
However, to date only one study has also investigated the effect of HDAC6 genetic 
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depletion on behavioural phenotypes in the context of neurodegenerative disease. 
Flies deficient in HDAC6 have been found to have a significantly greater impairment 
in climbing assay in a D.melanogaster model of Parkinson’s Disease (PD) (Du et al., 
2010). However, the work presented in this thesis showed that the depletion of 
HDAC6 did not modify the R6/2 phenotype in rotarod performance, grip strength or 
spontaneous exploratory activity (Experimental Paper – Fig. 3 C-E and Fig. S1). 
Concomitantly, HDAC6 loss did not affect body or brain weight loss in R6/2 mice at 
any age tested (Experimental Paper – Fig B and F). The discrepancy between these 
findings and previous studies can possibly best be explained by the differences in 
the models used and diseases investigated. Equally, a decrease in polyglutamine 
mediated toxicity and rescue of neurodegeneration measured with cell viability and 
ommatidial degeneration assays respectively, might not necessarily translate into 
changes in behavioural outputs. The data presented here clearly suggest that 
genetic ablation of HDAC6 has no effect on behavioural or physiological 
dysfunctions observed in R6/2 mice and previous findings on HDAC6 depletion do 
not translate to the mammalian system. On the other hand, effects of HDAC6 
depletion might only manifest in the context of full length mHTT and/or with age. 
Nevertheless, though the investigation of the behaviour of HdhQ150 knock-in mice 
with HDAC6 depletion would be valuable, such an endeavour is very impractical as 
the end point in these mice is 22 months of age. 
Given that HDAC6 has been reported to be necessary for HSP90 mediated 
glucocorticoid receptor (GR) maturation (Kovacs et al., 2005) and disruptions in GR 
signalling have been linked to both loss of anxiety and depressive-like behaviours 
(Urani and Gass, 2003), it was interesting to find that Hdac6KO mice showed no 
change in spontaneous exploratory activity. Nevertheless, it has also been reported 
that mice with a forebrain specific knock-out of GR in the mature CNS do not 
display altered anxiety or activity unless placed under stress (Boyle et al., 2006). As 
the mice examined in this work have not been placed under stressful conditions, it 
is not possible to determine whether depletion of HDAC6 affects the GR signalling 
in a manner similar to that observed after GR loss. Equally, although it has been 
ascertained that compensatory mechanisms in Hdac6KO mice did not occur for 
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tubulin acetylation, the acetylation of HSP90 has not been assessed and therefore 
further investigation would be required to address the question of the role of 
HDAC6 in GR mediated anxiety and depressive-like behaviour. 
 
5.6. Knock-out of SIRT2 increases body weight, but has no effect on brain weight 
or behavioural phenotypes in R6/2 mice 
 
Rescue of mHTT toxicity after genetic knock-down or pharmacological inhibition of 
SIRT2 has been observed in D.melanogaster models of HD and PD (Luthi-Carter et 
al., 2010; Outeiro et al., 2007; Pallos et al., 2008). Although the question of how 
SIRT2 inhibition affects behaviour in the context of HD has not been previously 
addressed, one study demonstrated an improvement in the phenotype of R6/1 
mice upon treatment with nicotinamide (NAM), a pan-sirtuin inhibitor (Hathorn et 
al., 2011). In contrast, thorough phenotypical characterisation performed in this 
work revealed that SIRT2 genetic depletion did not modulate rotarod performance, 
grip strength or spontaneous exploratory activity and had no effect on the brain 
weight in wild type or in R6/2 mice. These data suggest that the use of a pan-sirtuin 
inhibitor is not directly comparable to a genetic depletion of a single sirtuin. 
Additionally, off-target effects of NAM, which is an element of cellular energy 
metabolism and therefore also a possible substrate, activator or inhibitor of other 
enzymes, cannot be excluded. Equally, although both studies were performed in a 
fragment HD mouse model, slower disease progression in R6/1 mice could account 
for manifestation of an effect.  Thus, the effects seen in the study of Hathorn and 
colleagues (Hathorn et al., 2011), are not in conflict with the data presented here, 
but rather indicate that combinatorial sirtuin inhibition could be a more effective 
therapeutic strategy for HD. 
Interestingly, both reduction and depletion of SIRT2 caused a significant increase in 
body weight that was observed in both wild type and R6/2 mice, indicating that this 
effect is independent of disease progression. No effect on body weight was 
observed when mice were treated with nicotinamide, suggesting that this 
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phenotype depends not only on loss of SIRT2 activity but also on the activity of 
other sirtuins (Hathorn et al., 2011). The question of how SIRT2 loss causes body 
weight gain can be approached from different angles. Firstly, SIRT2 has been shown 
to inhibit adipocyte differentiation by deacetylation of FOXO1 and by engagement 
and inhibition of PPARγ controlled promoters (Jing et al., 2007; Wang and Tong, 
2009). SIRT2 knock-down causes cytoplasmic retention of FOXO1, and increased 
adipocyte differentiation (Jing et al., 2007). Therefore, Sirt2KO mice could have an 
increased potential for adipogenesis that could have a significant influence on body 
weight. Bearing in mind that mice are maintained on a diet enriched in protein and 
fat, it is plausible to expect that increased adipogenesis could occur and translate 
into an increased body weight in mice with reduced or depleted SIRT2. Additionally, 
it has been suggested that knock-down of SIRT2 decreases intracellular ATP levels in 
PC12 cells (Nie et al., 2011). Although the validity of this observation in the context 
of the mouse is unknown, decreased ATP levels in Sirt2Het or Sirt2KO mice could 
lead to activation of the AMPK (Adenosine monophosphate activated protein 
kinase) pathway (Hardie, 2007). This in turn has been shown to affect multiple 
downstream events, including hypothalamic increase in cellular NAD+ levels and 
SIRT1 activation, which leads to FOXO1 deacetylation, inhibition of POMC 
(proopiomelanocortin), activation of  NPY (neuropeptide Y)/AgRP (Agouti-related 
protein) and increase in food intake (Cakir et al., 2009; Canto et al., 2009; Hardie, 
2007). A role for SIRT1 in mediating effects of SIRT2 depletion could explain why no 
changes in body weight were observed upon NAM treatment. Whether any of these 
speculative explanations could account for the phenotype observed requires 
further investigation. Nevertheless, it would be very interesting to elucidate the 
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5.7. Knock-out of HDAC6 or SIRT2 does not affect aggregate load or levels of 
soluble mutant huntingtin 
 
Aggregates of mHTT are formed in HD patient brains and all known mouse models 
and their appearance correlates with disease progression. Genetic depletion of 
either HDAC6 or SIRT2 did not affect aggregate load or levels of soluble mHTT in the 
R6/2 brain at any age examined.  
These findings were very surprising given that previous studies have identified 
HDAC6 as indispensable for the formation of the aggresome and its subsequent 
autophagic degradation (Iwata et al., 2005). Aggresome formation has been 
suggested to occur in the context of misfolded protein accumulation, whereby 
small dispersed aggregates become ubiquitinated, recognised by HDAC6 via its 
ubiquitin binding domain and transported to a peri-nuclear localisation by dynein, 
which can also interact with HDAC6 through the p150glued protein (Iwata et al., 
2005; Johnston et al., 2002; Johnston et al., 1998; Kawaguchi et al., 2003). This 
process was hypothesized to result in neuroprotection by allowing cells to dispose 
of an excess of misfolded proteins. In keeping with that assumption, overexpression 
of HDAC6 has been demonstrated to rescue neurodegeneration in the 
D.melanogaster SBMA model in an autophagy dependent manner (Pandey et al., 
2007). The reason why an absence of HDAC6 does not increase aggregate load in 
R6/2 mice is unknown but could include compensatory mechanisms, differences in 
aggregate handling between lower organisms/cell culture systems and mice (as 
evidenced by differences in disruption to of the UPS in cell and mouse models of 
HD) or the effects being too subtle to be detected.  
Given that impairment of the UPS has been reported to be localised to the synapses 
in mouse models of HD (Wang et al., 2008), it is unlikely that changes in 
proteasome function upon HDAC6 depletion account for an absence of detectable 
changes in aggregate load. However, accumulation of K48 and K63 ubiquitin linked 
chains has been reported in R6/2 mice (Bennett et al., 2007). It is possible that 
HDAC6 modulates aggregation through its ubiquitin binding domain and a specific 
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species of ubiquitin conjugate. Therefore, it is conceivable that a lack of a particular 
species of ubiquitin such as K63 in R6/2 mice could prevent HDAC6 from affecting 
aggregate load. 
Alternatively, constitutive knock-out of HDAC6 could have allowed compensation to 
occur during development. However, the fact that both an intact microtubule 
network and HDAC6 catalytic activity are required for aggresome formation (Iwata 
et al., 2005), together with the observation that tubulin is hyperacetylated in 
Hdac6KO mice, strongly suggest that compensation has not occurred. On the other 
hand, it has been suggested that HDAC6 is found in a complex with the p97/VCP 
(valosin containing protein) chaperone, which possesses segregase activity and has 
been implicated to be important for proteasomal clearance of ubiquitinated 
proteins (Richly et al., 2005; Rumpf and Jentsch, 2006; Seigneurin-Berny et al., 
2001). Interestingly, it has been shown that the fate of ubiquitinated proteins is 
determined by the balance between HDAC6 and p97/VCP, whereby an excess of 
p97/VCP causes dissociation of ubiquitinated proteins from HDAC6 and their 
subsequent proteasomal degradation, whereas excess of HDAC6 promotes 
aggresome formation (Boyault et al., 2006). At the same time, p97/VCP has been 
shown to suppress aggregate formation in a C.elegans mHTT exon 1 HD model 
(Nishikori et al., 2008). It is also possible that in the absence of HDAC6,  altered 
p97/VCP activity, which has been demonstrated to interact with several E3 
ubiquitin ligases (Halawani and Latterich, 2006), affects ubiquitination of mHTT.  
Given that impairment of the proteasome could not be demonstrated in R6/2 mice, 
it is possible that HDAC6 genetic depletion stimulates compensatory mechanisms 
that involve p97/VCP and result in an overall comparable level of aggregate load 
between R6/2 and Hdac6KOxR6/2 mice. Further investigation of the activity of 
p97/VCP and its association with ubiquitinated proteins in R6/2 and Hdac6KOxR6/2 
mice is necessary to address this issue. 
An alternative reason for not observing a change in aggregate load upon HDAC6 
ablation is that the effect was too subtle to be detected. With 8 mice, the Seprion 
ELISA technique has 80% power to detect a 30-50% change between 4 and 8 weeks 
of age, and a 20-40% change between 4 and 12 weeks of age in the R6/2 brain, 
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depending on the region examined (Sathasivam et al., 2010). Nevertheless, genetic 
knock-down of HDAC6 in a mHTT-exon 1 cell culture model of HD led to an 
approximately 3-fold increase in aggregate load and a 2-fold increase in inclusion 
number (Iwata et al., 2005). This indicates that even if genetic depletion of HDAC6 
leads to a subtle and undetectable increase in aggregate load, handling of 
misfolded mHTT exon-1 fragment is different between invertebrates/cell culture 
systems and the mouse brain, as previously discussed (Experimental Paper – 
Discussion).  
Lack of effect of SIRT2 loss on aggregate load or levels of soluble mHTT was equally 
interesting. SIRT2 pharmacological inhibition was found to reduce mHTT inclusion 
number in primary striatal neurons, but over-expression of a catalytically dead 
SIRT2, that was suggested to diminish activity of endogenous SIRT2, had little effect 
on mHTT inclusion number in the same model (Luthi-Carter et al., 2010). 
Additionally, SIRT2 knock-down rescued α-synuclein mediated toxicity in human 
neuroglioma cells but SIRT2 inhibition led to a decrease in number and increase in 
size of inclusions in the same model of PD (Outeiro et al., 2007). No changes in 
inclusion size were observed when the same SIRT2 inhibitors were used on primary 
striatal HD neurons (Luthi-Carter et al., 2010). Interestingly, HDAC6 has also been 
implicated in the rescue of α-synuclein toxicity by promoting large inclusion 
formation in a D.melanogaster PD model (Du et al., 2010). On the other hand, 
though not a specific SIRT2 inhibitor, NAM treatment had no effect on inclusion 
number in R6/1 mice (Hathorn et al., 2011). Considering previously published 
findings and data obtained in this study it appears that not only could mechanisms 
of aggregate formation be quite different for α-synuclein and mHTT but also that 
mHTT aggregate formation and handling is dependent on the cellular and 
organismal context. Further work that directly compares aggregate formation 
between different model systems is necessary to shed more light on these 
intriguing observations. 
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5.8. Rate of soluble mHTT level reduction but not aggregate load increase during 
disease progression is not homogeneous throughout the brain 
 
Intriguingly, though aggregated and soluble mHTT levels were unaltered by SIRT2 
depletion, TR-FRET and Mezoscale Discovery (MSD) assays revealed that the rate at 
which soluble mHTT levels decrease is dependent on the brain region examined. On 
the other hand, the rate of aggregate formation was similar across brain regions, a 
result that is in accordance with previous observations where aggregate load was 
measured by Seprion ELISA (Sathasivam et al., 2010). This suggests that aggregation 
proceeds through the formation of a population of mHTT that is an intermediate 
between soluble and aggregated mHTT, and which is not detected by either of the 
two antibody combinations employed in the MSD assay or by TR-FRET analysis. 
Based on the data obtained, it is also likely that the kinetics and/or mechanisms 
that govern the formation of such a population depend on the expression of either 
mHTT or other brain region specific factors. For example, it is well documented that 
the expression of the proteostasis machinery components, a system with many 
links to aggregate formation, is not homogeneous throughout the mouse brain 
(Powers et al., 2009; Tebbenkamp and Borchelt, 2010). The existence of differences 
in kinetics/mechanisms of mHTT aggregation throughout the brain could account 
for the fact that some therapeutic interventions are effective at reducing the 
aggregate load in some brain regions but not others (Mielcarek et al., 2011). 
Further experiments examining the existence, nature, and mechanisms of 
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5.9. HDAC6 depletion has no effect on the efficiency of BDNF cortico-striatal 
transport 
 
Although several studies have argued for a role of HDAC6 in aggregate clearance, 
there was also rationale to think that HDAC6 could be beneficial in HD 
independently of aggregation (Dompierre et al., 2007). Reduced levels of the 
neurotrophin BDNF have been implicated in HD pathology and increasing levels of 
BDNF has been proposed to be beneficial in models of HD (Cho et al., 2007; 
Gharami et al., 2008; Xie et al., 2010). HDAC6 has been proposed to negatively 
regulate the transport of BDNF from the cortex to the striatum and therefore, 
inhibition of HDAC6 might be expected to increase striatal BDNF delivery and 
improve behavioural phenotypes in HD mice (Dompierre et al., 2007). In 
accordance with previous findings Bdnf mRNA was found to be highly expressed in 
the cortex and hippocampus, but not striatum (Schmidt-Kastner et al., 1996). In 
contrast, BDNF protein levels between cortex, striatum and hippocampus were 
highly comparable (Experimental paper - Fig S4). These data are consistent with an 
existing model whereby BDNF is synthesized in the cortex and then transported to 
the striatum (Altar et al., 1997). Therefore, measuring BDNF levels in the striatum is 
a good indicator of the efficiency of BDNF cortico-striatal transport. 
Interestingly, although Bdnf mRNA expression was found to be decreased in the 
cortex of 9 week old R6/2 mice, no changes in the levels of BDNF protein could be 
detected in the cortex or striatum of R6/2 mice at this age. This was especially 
surprising given that tubulin was hyperacetylated in both the cortex and the 
striatum at this age, and that the proposed mechanism of increased BDNF cortico-
striatal transport involves faster movement of microtubule cargo as a consequence 
of reduced kinesin-1 pausing on acetylated microtubules (Dompierre et al., 2007; 
Gauthier et al., 2004; Reed et al., 2006). It is conceivable that the method employed 
for detection of BDNF protein levels was not sensitive enough to detect subtle 
changes in BDNF. However, the fact that levels of cortical BDNF were not decreased 
in R6/2 mice is contrary to some, though not all, previous studies, indicating that 
sample preparation, mouse husbandry or even the ELISA assay itself could carry 
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considerable variability between groups (Apostol et al., 2008; Cepeda et al., 2010; 
Seo et al., 2008). The effects of environmental enrichment on R6/2 phenotype and 
BDNF levels are well documented (Ickes et al., 2000; Spires et al., 2004; Zhu et al., 
2006). Although unable to detect changes in BDNF with disease progression, the 
method employed was able to detect a significant difference between brain tissues 
and liver (Experimental Paper – Fig. S4 B) indicating that any dramatic changes in 
BDNF levels could be identified. Therefore, the data presented here strongly 
indicate that while HDAC6 depletion induces tubulin hyperacetylation, BDNF 
cortico-striatal transport efficiency and behavioural phenotypes are unaffected.  
 
5.10. Compensation for HDAC6 or SIRT2 in conventional knock-out mice 
 
Generation and use of constitutive knock-out mice has been instrumental to the 
elucidation of functional importance of many proteins, including huntingtin. 
However, this tool has a serious limitation in that both compensatory mechanisms 
as well as pleiotropic effects resulting from compensation can be mistakenly 
interpreted as a direct consequence (or lack thereof) of deleting a certain protein 
(Gerlai, 2001). Examples include lack of phenotype in MyoD knock-out mice that 
became apparent when double knock-out mice for MyoD and Myf-5 were created 
(Rudnicki et al., 1993) or up-regulation of HDAC1 in Hdac2 knock-out mice 
(unpublished data from our lab).  
The finding that Hdac6KO mice were viable was surprising, given the multiple 
proposed roles of HDAC6. Importantly, compensation for HDAC6 has not occurred 
in the acetylation of tubulin, as these mice show hyperacetylated tubulin 
throughout the brain and the periphery (Zhang et al., 2008), (Experimental Paper – 
Fig. 2A and C), suggesting that cells can tolerate high levels of acetylated tubulin. 
Whether this is because hyperacetylation of tubulin is not detrimental to cellular 
functions or downstream compensatory mechanisms have occurred remains to be 
investigated. In any instance, changes to BDNF transport efficiency were reported 
to be a direct effect of increased tubulin acetylation (Dompierre et al., 2007), and 
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therefore, Hdac6KO mice were the appropriate model with which to investigate this 
process. At the same time, HDAC6 dependent aggresome formation required both 
its catalytic activity and ubiquitin binding domain (Kawaguchi et al., 2003). The 
combination of these two properties has not yet been detected on any other 
protein. Therefore, if compensatory mechanisms have occurred, they would need 
to involve at least two proteins, which is possible, although unlikely.  
It was even more interesting to find that genetic depletion of SIRT2 did not affect 
tubulin acetylation or H4K16 acetylation. Both of these substrates have been well 
characterised in in vitro SIRT2 assays and cell culture studies of SIRT2 over-
expression, knock-down, or knock-out. It is therefore impossible to quickly 
determine whether SIRT2 does not deacetylate tubulin or H4K16 in vivo or whether 
compensatory mechanisms have occurred. Although expression of other 
deacetylases was not modified in Sirt2KO mice, compensation could occur on the 
level of protein expression, its activity or sub-cellular localisation. Unfortunately, 
though it would be interesting to test all of these possibilities, tools to address 
these questions are largely unavailable for mouse tissue studies. 
The reported role of SIRT2 in cholesterol biosynthesis could also not be reproduced 
in Sirt2KO mice. However, the rationale for a SIRT2 involvement in this process was 
derived from two studies where SIRT2 was pharmacologically inhibited (Luthi-
Carter et al., 2010; Taylor et al., 2011). The on-target effect of the inhibitors used 
was supported by the observation of reduced levels of Hmgcr, Hmgcs1 and Fdft1 
after the over-expression of a catalytically dead SIRT2 (SIRT2H150Y) (Luthi-Carter et 
al., 2010). Interestingly, in the same study, over-expression of SIRT2H150Y did not 
have the same effect on mHTT inclusion number reduction as did the SIRT2 
inhibitors used (Luthi-Carter et al., 2010). This implies that these results should be 
approached with caution. Compounds can have many off target effects and the 
over-expression of a protein can also evoke compensatory mechanisms or aberrant 
interactions within cells, especially when the expressed protein is a mutant version 
of the endogenous one. It would have been interesting to examine the effects of 
shRNA mediated SIRT2 knock-down in the primary striatal cells used in the study by 
Luthi-Carter and colleagues (Luthi-Carter et al., 2010), to determine whether this 
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approach complimented their findings from over-expression of SIRT2H150Y and 
pharmacological inhibition of SIRT2. 
No changes in the expression of cholesterol biosynthesis enzymes have been 
observed in wild type or R6/2 mice after acute inhibition of SIRT2 with the 
CHDI194500 compound. Although a pharmacodynamic read-out was not available, 
the potency of CHDI194500 to inhibit SIRT2 in an in vitro activity assay and the 
presence of the drug in the brain of the dosed mice suggests that SIRT2 was 
inhibited by CHDI194500. Nevertheless, there is a possibility that CHDI194500 was 
not active in the context of mouse tissue and thus, SIRT2 inhibition was not 
achieved. Although it would be interesting to directly compare the brain specific 
effects of CHDI194500 with those of the inhibitors used in primary striatal neurons 
(Luthi-Carter et al., 2010), the blood-brain-barrier permeability has only so far been 
established for AK-7, a weak SIRT2 inhibitor (Taylor et al., 2011), which has not 
been previously examined for the SIRT2 inhibition mediated effect on cholesterol 
enzyme expression.  
Overall, there is strong indication that SIRT2 does not play a role in cholesterol 
biosynthesis and the previously observed findings are a result of off-target effects 
of the inhibitors used or of the differences between primary cell culture and mouse 
models. However, until appropriate tools to confirm SIRT2 inhibition after acute 
dosing become available, compensatory mechanisms cannot be excluded. 
 
5.11. Limitation in tools for studying protein activity and modification in mouse 
tissues 
 
Robust molecular read-outs are necessary to ascertain that the intended genetic or 
pharmacological disruption to the protein’s function has taken place. Otherwise, it 
is impossible to determine whether the intervention was successful. Hdac6KO mice 
have hyperacetylated tubulin throughout the brain, clearly demonstrating that 
absence of the HDAC6 protein translates into a molecular phenotype. In contrast, 
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though the SIRT2 protein is absent in Sirt2KO mice, they have not displayed any 
difference in acetylated tubulin or H4K16 levels. Other reported SIRT2 substrates 
are acetylated p53 (Ac-p53), acetylated FOXO1 (Ac-FOXO1), and acetylated FOXO3a 
(Ac-FOXO3a) (Peck et al., 2010; Wang et al., 2007; Wang and Tong, 2009). 
Regrettably, when western blotting against those substrates was attempted, the 
antibodies against Ac-p53 or Ac-FOXO1 (reported to also cross-react with Ac-
FOXO3a) proved to be inadequate for this purpose. Bands corresponding to the 
expected size of these proteins could not be detected unless a very low dilution of 
the antibody and a large amount of protein were used in the experiment. 
Unfortunately, during SDS-PAGE the large protein amount of the protein loaded 
caused the electrophoresis and the transfer to run unevenly across the gel. The 
resulting signal was not only weak and hardly detectable, but also impossible to 
quantify and interpret. It would have been very interesting to be able to accurately 
measure the levels of Ac-p53, Ac-FOXO1 and Ac-FOXO3a in both the Sirt2KO and 
CHDI194500 treated mice.  
The failure to detect differences in SIRT2 activity between wild type and Sirt2KO 
brain lysates with the Fluor de Lys SIRT2 activity assay was perhaps unsurprising. 
The fluorogenic substrate used in this assay is an acetylated tetrapeptide which in 
theory could be deacetylated by any of the 17 deacetylases other than SIRT2. 
Although the Zn2+ dependent HDACs were inhibited by Trichostatin A, 6 sirtuins 
were still present in the Sirt2KO brain lysates. At the same time, the finding that the 
signal detection was not enhanced by addition of extracellular NAD+ suggests that 
efforts to deplete intracellular NAD+ may have been unsuccessful. However, even 
when conditions well in excess (1h of incubation at 37°C) of those previously 
reported to be sufficient (10 min of incubation at 37°C) (Escande et al., 2010) were 
used, no effect of external NAD+ addition could be observed. Therefore, it is likely 
that the fluorescent signal detected was due to an NAD+ independent activity, 
perhaps not resulting from a deacetylation event but from an unknown mechanism. 
Overall, it was unfortunate that the Flour de Lys activity assay could not successfully 
be adapted to measure SIRT2 activity in mouse tissue lysates.  
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An absence of appropriate molecular tools to measure SIRT2 activity in mouse 
tissue constituted a major obstacle in determining whether acute treatment of 
mice with CHDI194500 resulted in SIRT2 inhibition, and in turn, whether a lack of 
differences in cholesterogenic enzyme expression between vehicle and CHDI194500 
treated mice supports data from Sirt2KO mice that SIRT2 does not play a role in 
cholesterol biosynthesis as has been reported previously. 
 
5.12. Genetic depletion of tubulin deacetylases HDAC6 or SIRT2 does not modify 
disease progression in the R6/2 mouse model of HD 
 
The rapid onset of behavioural, physiological and molecular phenotypes that 
deteriorate with disease progression makes the R6/2 mouse model a useful tool to 
study the validity of therapeutic targets and drug treatments. Studies reporting 
both beneficial and detrimental effects in these mice have been published 
(Hernandez-Espinosa and Morton, 2006; Labbadia et al., 2011), strongly suggesting 
that when no effects on phenotype are observed it is not due to an inability of 
these mice to deteriorate further or to improve.  
In this study the R6/2 phenotype was not altered by genetic depletion of either 
HDAC6 or SIRT2. Compensatory mechanisms have been partly excluded for HDAC6 
dependent activities and it can therefore be assumed that HDAC6 inhibition in R6/2 
mice would not result in altered phenotype. No changes to HD progression in the 
R6/2 mice were observed after SIRT2 loss, except for an increase in body weight, 
which was however, not specific to the HD phenotype. Pharmacological SIRT2 
inhibition was only partially confirmed, and though there were no changes to the 
R6/2 phenotype after chronic treatment with CHDI194500 (unpublished data – 
CHDI foundation), lack of appropriate pharmacodynamic readouts does not allow 
for conclusive interpretation of these data. Therefore, though the data presented 
here do not support SIRT2 as a modifier of R6/2 phenotype, inability to exclude 
compensatory mechanisms only allows for the conclusion that constitutive knock-
out and knock-down of SIRT2 have no effect on disease progression in R6/2 mice.  
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5.13. Validity of tubulin deacetylases HDAC6 and SIRT2 as therapeutic targets in 
HD 
 
The finding that depletion of neither HDAC6 nor SIRT2 exerted any changes on HD 
progression in R6/2 mice was surprising. Previously published reports on the roles 
of HDAC6 and SIRT2 as modifiers of neurodegenerative disease clearly provided a 
rationale for conducting a phenotypic study in a mouse model of HD. However, 
R6/2 mice are not a genetically precise HD model and thus the lack of phenotypic 
modulation observed could be due to the necessity of placing the knock-out 
mutations in the context of full length mHTT. On the other hand, involvement of 
HDAC6 in the aggresome pathway and of SIRT2 in cholesterol biosynthesis were 
studied in cells expressing N-terminal fragments of mHTT (Iwata et al., 2005; Luthi-
Carter et al., 2010), which would suggest that the R6/2 mouse is an ideal system to 
study those findings in the context of a mammalian brain. Although the role for 
HDAC6 in modulation of BDNF cortico-striatal transport was elucidated in cells 
derived from knock-in mice (HdhQ109), this consequence of HDAC6 inhibition was 
shown to be a direct result of increased tubulin acetylation and reported to be 
independent of disease context (Dompierre et al., 2007). The finding that an 
increase in the efficiency of BDNF cortico-striatal transport could not be 
demonstrated in Hdac6KO mice, strongly suggests that this process is regulated 
differently in the context of the mouse brain than in cell culture. Nevertheless, the 
short lifespan of R6/2 mice prevents detection of any changes that could be 
associated with ageing. HdhQ150 mice are not only a genetically precise model of 
HD, but their normal life-span also allows the study of treatments in the context of 
an ageing organism. However, given that the rate limiting step in disease 
progression in knock-in mice is likely to be the formation of an N-terminal fragment 
of mHTT (Graham et al., 2006; Landles et al., 2010), it is highly unlikely that genetic 
depletion of HDAC6 and SIRT2 would modify phenotype in the HdhQ150 knock-in 
mouse model of HD. Moreover, the time and resources required to perform these 
experiments are considerable and therefore, efforts should be prioritised to 
address more pertinent questions first.  
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Given the devastating nature of HD and the lack of disease modifying treatments, 
considerable effort has been invested in the search for, and validation of, 
therapeutic strategies. However, the ethical considerations and cost of clinical trials 
require therapeutic targets to be prioritised according to their probability of 
yielding promising treatments for HD during pre-clinical assessment. Pan HDAC and 
sirtuin inhibitors such as SAHA and nicotinamide have been shown to ameliorate 
disease phenotype in HD mice but are also associated with significant toxic effects. 
In order to divorce the toxic and beneficial effects of HDAC inhibition, considerable 
efforts have been made to determine which HDAC(s) and sirtuin(s) are key 
modifiers of disease progression. Genetic knock-down or knock-out of HDAC3, 5, 7 
and 9 has shown no benefit in R6/2 mice whereas genetic knock-down of HDAC4 
resulted in a marked improvement in R6/2 behavioural and molecular phenotypes 
((Benn et al., 2009) and unpublished data from our lab). This suggests, that the 
positive effects of general HDAC inhibitors are mediated at least in part through 
HDAC4 inhibition. 
This study demonstrates that like HDAC3,5,7 and 9, HDAC6 and SIRT2 do not modify 
disease progression in R6/2 mice and should not be prioritised as therapeutic 
targets in HD. As a consequence, further work should be focused on investigating 
the effects of the remaining HDACs and sirtuins on disease progression whilst 
attempting to uncover efficient ways to target and inhibit HDAC4 in mouse brain 
tissue. 
In conclusion, the purpose of this work was to perform a pre-clinical validation of 
HDAC6 and SIRT2 tubulin deacetylase inhibition as a therapeutic target in HD using 
the R6/2 mouse model. The data collected strongly suggest that neither HDAC6 nor 
SIRT2 inhibition would modify HD progression and therefore, HDAC6 and SIRT2 
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Genomic sequence of the mouse Sirt2 gene with the position and sequence of the 
mutation as present in the Sirt2KO mice. The inserted sequence (mutation) is 
highlighted in yellow. The mouse Sirt2 genomic sequence was obtained from NCBI 




     1 TTCTTGTTTC CGCTGCCGTC ACGGGACAGA GCAGTCGGTG ACAGTCCCGA 
    51 GGGCCCCCAC CCCGTTCCCA TGGCCGAGCC GGACCGTGAG TTAGGGGCCC 
   101 TGTTGGGAGG GTGGGAGGGT CGGGCCGCGC CGGGGCCTGG CTTTGGGCTG 
   151 CAGGCCCCGG GGCCCGAGGG TAGGCTCGGT GGGGCGGGAG ACAGGATCTA 
   201 CCTGAAGGGA GTGGGATTCG GAGGGGTGTT GCTAAGTGGT CCGTATTACT 
   251 AGGTTGGTTG GTTTCTGGAT TGTGAAATGT AAGGGTCCGA TTGTCAAGTT 
   301 CTTAATGATC GCATTTCTCG TACTTTGGCT GCTGAGGACC CTCGTTGCTA 
   351 AGGACCAAAG TTACCACTAT CCCGGTTGCT AAGGTTGTCT GTTGTTAAGG 
   401 GCAACTGTAG GATGGGTTCC GGGGACCCCT GTGGCCCCTT ACTATCTCAT 
   451 TCCTTCAGTT CTTGTGCCTC TCCTAAACCT CCTACCTTCA CTGCATCTCC 
   501 TCTCCCACAC TCAACTCTCA GCAGAAGTAT CCCTACTTAC GTCTCTTGAA 
   551 AAACTTAGCC CTCCCTCATT CTCTCGACTC GCACATGCTA CCATATCCTG 
   601 CTTAACTCTG AAACCTTCCT TCAGTCCAGT CTCGCCTGCT TTCTCCTCCT 
   651 AAAGATTCCC CTCCTCAGCC TTTTCACGTC ACACATACCT CCACTCTAAA 
   701 ATATGCCTTT TCCCATCTCC GATAGTTTTA CTACCATCCC TGACTCTGAA 
   751 ATAATTAGGT TGGTGGGTCC TCTTGTCCTC CACCATTGTG AGCCCTTCTG 
   801 CTTAACTCTT TCCCCGCACT GTAACCACGT CTGCTCCCCT CCTCCCCAGC 
   851 CTCTGACCCT CTGGAGACCC AGGCAGGGAA GGTGCAGGAG GCTCAGGTGA 
   901 GATGGGGAAG GGGTGGAGGG AAGGAGAGAC TTGGTTCCAC GTGCCGCACT 
   951 GGGGGGAGGT GGCAAGGGAA GGCTTTTACC CAAGGGCCCT TGGCTTATGG 
  1001 CCCTGATCCC CAAGCCCATC TGGGGATTAG TACAATCTCC TGGGAGAATG 
  1051 GTGGCTTCTT GGGACTGTCA AGGAAAATGT ATAGCCTCAA CCCCTGGTTC 
  1101 CCTTCCATAT CGTCCTCGTT TCCTACTGTT GCCCATCCCA TCCTCAGCCC 
  1151 CTTCTGAACC TCATTTGTGC TGGACCTGAA AGAGACGGTT TTCCAGTTCA 
  1201 ATCCGCAAAC TCAGATCCTA TGAGGTGGGG GAAAGGACCC TATAGGGCAC 
  1251 GTTATAAAAG TATCGAAGCT GGGTGTGGTG CCAGCCCCCT GTAATGCCAG 
  1301 CACATGGGGG GGGGCAGGGG AGGGGGGAAG TGAGGTAGGA GGATGGAGAA 
  1351 AGGAGAGGCA GCTTGGGCCA TATGGTGAGA CCCAGTCTCA AAAAAGGAGG 
  1401 GAGGAAGGGA GAGAGCATAC CCCTGGAGTA CCGGGCAAAC TCTGTGGGTC 
  1451 AGAGATTATA GAAGATTCTA GCCAAACTCT CCCCTGGTGG AACCCACAAG 
  1501 CTGATCTAGG AACAAGACCA AGATATAGTC ACAGTGTCGT ATAAGTGAAG 
  1551 TGATAAGGGA TTTTCTTAAA TGAGATCGGA GGTGGTGTTC CATGCAGGGT 
  1601 ACAGGCCTGA GAGCACGAAG GGATAGTAGA TGTTTCAGTA GTTGGGTTGC 
  1651 TGGCGTGGTC ATTTATTGAT ACTCTGCCTG AATTTTAATG TACATGACTT 
  1701 CATTTAATCT TTGCAGCATC CCAGTGAAGG GAAGGCCTCT CATGGCTGTG 
  1751 TTACAGATGA GCAGCTTACT TGGTGAAAAC TGTTAACCCC TGTGTTCTTT 
  1801 GGGTAGAAAG GAAAGGGCTT GAAACTTATG GGGAAATGGG CTCCGAAAGA 
  1851 TGCTGCAGCT TCAGTGGAGT GTAGATGAGC CATCTCAAAG ATGTTTGAAG 
  1901 ACACGTGCCA AGGCCTCCGG TTCCCCCAGA GGCCAGGTTG TCCTCATATA 
  1951 CTCGAGGAGT GGTTCTCAAT CTTCCTAATG CTGCAACCTT TTAATGTAGC 
  2001 TCCAACGGTG TGGTGTCCCT CCAACCATAA AATTATTTTG TTACTACTTC 
  2051 ATAACTGTCC TTTTGCTACT GTTATGAACT ATAATGTAAA TATCAGATAT 
  2101 GTAGGATATC TGATATGGGA CCCCCCCCCC AAGAGAGGGT CGCTTGATCC 
  2151 CTAAAGGGAT TGTGTCCCAC AGGTTGGGAA ACAGTGTACT GGACCATGCC 
  2201 TACAACCACT GAATGCCAGC ATGCTCATCC TATGAGACCA CACTTCGAAG 
  2251 GGAGGCAGGT GCAGAAGCTG TGGTCAACAA TACCCCCATA AGAGCTGTGA 
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  2301 CAGCCTGCTG TGGGTCTCTA GTCTCTTACT TGTCTGGCTC CCAAATGAAG 
  2351 GCTTAATGCC AGACTAAAAA AGGGTTTCAC AGTCAAAAGG GGTTCTCAGT 
  2401 GGCCAAGAAG ATGTGGGGTG TCAATTGCAG CATTATCCAG ATGGGGCAAC 
  2451 GCTAGCAGCA GCCTCAGTGG CTGTCAGGAG AGGGAGTCAA TGAACCACGG 
  2501 TTCATCATAC AATGTGTTAC TATGGAGCCA CAATAAAGAA TGAGGTGGGG 
  2551 GCTGGAGAGA TGGCTCAGTG GTTAAGAATT CTATTCCAGA GAACCTGAGT 
  2601 TCCATGTACC AGGCGCTCAC AAGTGACTAT AACTCCAGTC CCAGGGGATC 
  2651 TGACTCTATG GAGACTTGCA CACACATGCA CATATTCACA TAACTAAAAT 
  2701 AAACTAAAGA GAATGATGTA GGTCTGTGAA ACATTGTGCA GTATCTTACT 
  2751 CTGGCAAGAC CCAGTTCTAT AATAATGAGC AAATGCGCAA AACCTCACGC 
  2801 CGAGAAACCA CGTAGAGTTA TCTCTGTTTA ACTGTTGCTT GGTTTTGCTT 
  2851 TGGTGTTTGT TCGTTATCCA GGCTCAGGAG GCCGAAGGGG GAGGATTAGG 
  2901 AGTTGGAAGC CATCTTAGGT AAAACAGTAA GACTTGGACA GGCTCTTTTT 
  2951 AAAGCTTTTA TCTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTAGTTTCA 
  3001 TGTGCATTGG CATTTTGCCT GCGTGTGTGT CTGTGTGAGC GTGTCACATC 
  3051 CCCTAGAACT GGGGTTACAG GCAGCTCTGA TCTGCCATGT GGGTGCTGGG 
  3101 AATTGAAGCA GTCAGTGCTC GTAACCACTG AGCCATCTCT CCAGACCCTC 
  3151 TTTTTAAAAT TTTACACCTA GTTTGTTTTG TGTGTGTGTG TGTGTGTGTG 
  3201 TGTGTGTGTG TGTGTGTGTT TAGGATACAC ACGCCACAGT ATATGTATGG 
  3251 TGATCTGAGG ACAGCTATCG TCTCCTCCCA CCATGTGGGG CCTGGGAATC 
  3301 AAACGCAGAT TGTCAGGCTT AGCAGGCAGC CCCTTCCCCT GGTGACCCAT 
  3351 CATGCCAACT TATGTCATTT TTTAATATCA GTGAAGAATC ATTCTAGAGT 
  3401 CAGGCATGAT GGTGATGCAA TCCTGTAATC CTAGCACCTA AAACAATAAA 
  3451 AATAGATGGG TCAGGAATTC AAGTTCACCC TCACGTACAT ACAAGTTAGA 
  3501 GCCAGCCTGG GCTATGTCGG ACCCTGTCTT AAAACAATAA CAACAGAAGA 
  3551 ATCTTTAAAA ATAATTTAGA AAGGAGATTT GGAAGCAGAG TGTGGAAGGG 
  3601 AAGGTCTGGG GGCCTTTGAG CAGGGAGTTG ACTGTACTGG TCAGACTGTG 
  3651 TGGCATCTGC TGCAAGGCCA GCCCTGGGCT GGCCCCAGTC GGCATGTGTT 
  3701 GAGTGGTAGA TGGTTCTGGA AGTCCTGTTA TCTAGGCTGG GCAGTAAGCA 
  3751 GTAAACGTAA TGTCCCTGCC CTTGTGTGGC TGATATTGTG GCACTCAGTA 
  3801 GATGTTTGTG ATTTGGGGAC GGGGGAAGGA TTAAAGAAGA GAGAGGTGGA 
  3851 CTGTCCTCAA CAGGCCATCA TATGATCTAA GACAGAAACT GAGTCAAGGA 
  3901 GGCCAGGGCA GGACCCCAGG AGAGAACACG TTGAACCAGG TGGAGCTCTA 
  3951 GGGTTGGGAG AGGGAGTCAG TGGAAGGATG TCAGGAGGCT GGCATCCCAG 
  4001 TGGGTACACT GGGAATTGGC ATGAGGGTGG TGAGGTAGGG AAGCCAATGA 
  4051 AGGGACAGGG AGGCCACTTA GTATGGGGAC TGGGAGCAGG AGCTGGTTTG 
  4101 GGGAGATTCT GAGGCCACTT TGGAACATGG TTGGAGCAAG GTGGGGTCGC 
  4151 CCTGAGAGGC TCATGTCCGG TGTCAGAGAA GTGGCATCAC CAATGACTAG 
  4201 GCTGTGGTAT AGCCAGCCGA GGCACCTAGG GGCTCGCTGC TCGGCTTCAC 
  4251 AGCAACCTCT GAGCTATATG GACAAGTTGC GGCCCATGGG CTTGGAGGTC 
  4301 TATCTCGAGG TCACCTAGCA TGCATGAAGC CATGGCTTCA GGCCCTAGCA 
  4351 TCTTGTCAGG CTGTGATGGC CAACTGGGTA GAGTGTTGGA TGTGCTCCCA 
  4401 ACATCATGCC CGTAATCCCA GCTTTAGAGG GGTGGAGACA GGAAGATCAG 
  4451 AAGTTCAAGT TACAAAGACT TCATAGCAAG TTTGAAGCCA GCCTGGGCTA 
  4501 CATAAAACCC TAACTCAAAA AGCAAGCTAG GCATGGTGGC ATATGCCTTT 
  4551 AATCCTAGCA GTCAGAGAGA GGCAAGTGGT AATCTAGTCT ACATAGTGAG 
  4601 TTCTAGGCCA GCTAGGGATA TATAAAGTGA GACTCTGTCA GAAGAAAAAA 
  4651 GATGGGACAA GCATGCAGGT GCATGCCTTT AAACCCAGGC CACAGATCCA 
  4701 GGCAGATCTT CAGGAATTCC AGGTCAGCCT GGTCTGTGTA GTAAGTTTTA 
  4751 GGCCAGCCAG AGAGACCCCA TCTTGAAAGA AAGATAAGGC CTAGAGGAGA 
  4801 GCCAGGTCCT CTCTCTAAAG CAACCTTTCC CAGAGTCCTT ACACTGGCCC 
  4851 TGTACTTCTT CAGGGCACCT CCCAGTCAGA GCCCTACTGT ATTTGAACCA 
  4901 GGTTGTCACC CTTCCCATCC CTTCCCTTCC CTTCCCTTCC CTTCCCTTCC 
  4951 CTTCCCTTCC CTTCCCTTCC CTTCCCTTCC CCGCTAACCC CACTTCTTGG 
  5001 GCTTGGCCAT CCCACCCACC CCTTCCAGGA TTCAGACTCG GACACTGAGG 
  5051 GAGGAGCCAC TGGTGGAGAG GCAGAGAGTA AGTGTCGTCC TGGAGGAGGG 
  5101 CAGGGAGGTG ATCTGGGGTC TGGGATTAGA GGATGGGATT CTGGGGAGAC 
  5151 CCCCTCCAAG CTACCGGAGT GATAGGCAAA GCATGTAACA ATGGTTTGGG 
  5201 ACTGGATGCT GCTGTCTGTG GGAGACATTG GGAGTTGAGA TGTGGGAGGA 
  5251 GAGTGTGTGC TTGGGCCCTG GCTCGATGCC CACCTGGCGC TGTCTCTCTT 
  5301 GTTGTTGGCC AGTGGACTTC CTGAGGAATT TATTCACCCA GACCCTGGGC 
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  5351 CTGGGTTCCC AAAAGGAGCG TCTTCTAGAC GAGCTGACCC TCGAAGGAGT 
  5401 GACACGCTAC ATGCAGAGCG AGCGCTGTGA GTCCCCAATT GCTTGGCCGC 
  5451 TTCTCCCATT CCTGGCCCCA GTTGACTCCA TATTTTGGGG GGTAGGAGTA 
  5501 GTAAGAAAGC CTGCTGTATA CACCTGTAAT CCCAAACTCT GAGCAGATTG 
  5551 GGAAAGGACC AGCATTTCAA GTTAGCCTCT GCTAGACTGT GTGTGTGAGG 
  5601 CTACCCTGAG CTACATGGGA AGTTTTCCTA AAATTCAGAA AGAAAAAAGA 
  5651 TGGAGGAAAC CCAACTCTTG GGATGGAGAG ATGGTTTAGT AGTTAAGAGC 
  5701 ACTAGCTGTT TTCCCAAAAG ACCTAGGTTG GGTTCCCAGG ACTCACATGA 
  5751 TGGCTTACAA CCATCTGTAA CTCCAGTTTC AGGGGATCCT ACTTATGGCC 
  5801 ACCATGGGCA TCAGGCATGC ATGTAGCACA CAACATTCAC GAAGGAAAAC 
  5851 ACCCATGTAG TTAAGAAAAA AAACAAAAAA CTCAGCTTGC TGGGGGGGGG 
  5901 GGTGGTGAAC GCCTTTTACC CCAGCACTCG GGAGGCAGAG GCAGGCAGAT 
  5951 TTCTATAGTT TGAGGCCAGC CTGGTCTGCA GAGTGAGTTC CAGGAGGTGA 
  6001 CTGAAGCCAG AAGATCATGA GTTTGAGGGT AACATGTGCT ACATAAGATT 
  6051 GTTAACTCAA AGAAAGAAAA GAGAAAGACA AGAAACCAGA ACTCTAGCCA 
  6101 AAAACAATAA AAAGGAGCAT GCAGACTCTT AAGCATTAAA TGTGATGGAG 
  6151 CCAGGCTCGA GGACATTGTT AGGACATTGT TCTCAGGCCT CACAAGTCTG 
  6201 TCTGCGTAGG GTGAAGGAAA GTCCAGCAGG CGGCTCCTGC TTGGGAGGGT 
  6251 ACCTTTGCAC TTAAGAACAA GGCCACATTG GCCCAGAAGC CCCCCCCCCC 
  6301 CCCCCCCGGA TGGAACTCAG CCCCTACACT CACACACCAC GCTAGGCAGG 
  6351 CACTCTGTCA TTGAGCTACA GCCCCAGCCC TTCCTTTCCT ACTGTTTTAT 
  6401 TTTGAACGCC CTGAATTTAC CCTCTAGTCC CTGAAGGTCG ATCCTCTTAC 
  6451 CTCAGCCTCC CACATAGCTG GGAGTACAGA GTAGCACCAC TAGGCCTGCC 
  6501 TTTGGGTCAC TTCCCTAGTG AATCTATTAC TGTCTTCTGA TGGGCCAGGC 
  6551 CTATGCCCTA GACTGGAAGT GATCAAAGCT CTGGGGTGAC TCAGGTGAGG 
  6601 CTAAGGAAAT TGCCACATGC TGAGCATACA TATGCTCAGC ATGCCGAGCT 
  6651 CATCTGCAGG CCCAGCCACT CTGGAAGCTG AGGCTAGAGC ATGTGAATTC 
  6701 AGAGGCAGCC TGGACTACAG AAAAAAGAGG GAAATGGAAT GATGATGGTG 
  6751 GCCCACACCT TTAATCCCAG CAGAGGCAGG GGGATTTCTG AGTTTGAGAT 
  6801 CTGCCTGGTC TACAGAGTGA GTTCCGGGAA AGCCAGGGTT ACACAGAGAA 
  6851 ACCCTGTCTC AAAACACGAG AGAGAGACAG AGAGAGACAG AGAGAGAGAG 
  6901 ACAAAGAGAG ACAGAGAGAG AGAGACAGAG AGAGAGACAG AGAGAGACAG 
  6951 AGAGAGACAG AGAGACTTAG GAGATTATCT CAGTCCATTA AGTGCTGGCA 
  7001 GCTCCCACAC AAGCAGCTCA CAAGTGCTTG TAATTCCCGG GCTGGGGAGG 
  7051 CAGAGGCAGG AGCCAAGCTC AGGTCCCCAT GAGACTCGTG AGACCCTGCC 
  7101 TTAAAATCCG TGATGGCACC AGTTGTCCTC TCACTTCCTT CCACATGTTT 
  7151 GCTGTGAAAT ACACGCACAA AGAGATGTGT GCACACCACC AAACAAACAA 
  7201 ATAACAGCCC ATATACACAC TAGGTGGATG GCCCTGGAGA AATACACACA 
  7251 CACACACACA CACACACACA CACACACACA CACTCGAGAG ATAAGTGATT 
  7301 AGAACAGGAC CCGATCTCTT GAGAGATACA GAAGTGTTTG CCATGGTATT 
  7351 ATTACAGGAA GCTTGTCTCA GACGTGCTGT TTAGAAGCCA GCTAGCTGGG 
  7401 TCACCGTGAA ATTGATATTT CTTGCTGAGG TCGAGTCACC GAAGTCTGAG 
  7451 AACCCAGGCC CTCGCAGTCC CCGTTGGGAA CAATGCAGCT TTGAGGGTCC 
  7501 TGAACAGCCC TTTGTTGAGG CCATCTTCTC CAGTTTCCCC TTGGCCCAGC 
  7551 TGCTCAGCGC CCTCCTTGGC AGCCGGGATG GCAGCTGAAC CTCCCTCTCC 
  7601 TGCCACAGGC TGGGCAGCCG GCCGCCTACA GAGCATACCC ACACAGTGGC 
  7651 CAGGCGACAC TGGTCCTCCC TCTTACACTC AGATCTGAGA GTCCCTGGCC 
  7701 CATAGGGTGC TGGTGTGGGA CGTGACATAA ATATCAACTA AGCAGACCCT 
  7751 TGCTGTTCGC CAGGCTCTGG GCTAAGTAGC TCACCAAGCA TCCTTGAACC 
  7801 TAATTATCAC GCAATAGCTG TGAGGTCTTT CTAGAAGTGA GCTGAACAGA 
  7851 AGAGGAAACT GAGGCACGGA GAGGTTGTGA CTTGGTGTGA ACATATGCAA 
  7901 GGGGCACAGT CAGGGCCCTT GAAGCTCGGT CTTGTTCTGT AGCTGTGGCA 
  7951 AGCTTTGAAT TTAAGATTTT CTTGCCTCAG TCTCTGGAGT TTTGGTATTA 
  8001 CAGTGTTACC ACACCCAGTC TCAATGCCTA CGATCTCCAG CCAGACTTGG 
  8051 GCCAGTAACA TCCTAAAGAA GCTGAGTGCA TAGACTGTAG CAGGCTCTCT 
  8101 GCTGTCATTT GTTTTTGGTT TGGTTTGGTT TTTTTTTTTT TTTTTTCTAT 
  8151 GTAACAGACC TTGCTGGTCT GCAATTCACT TTATAGACCA CACTGGCCTC 
  8201 AAACTCACAG AGATCCTCCT GCCTCTGCTT CCCAAGTTCT GGGAATAAAC 
  8251 ACATACGCCA CCATGCCTGG TTTAAACATT ATCTTTGAGT GTGTGTGCTG 
  8301 GGGGTGGGTG GGTGATGTGG GCATTACTGT AGGTGCATGC ATGCTACTGT 
  8351 GTTTGCCAGG GGACATCTTT GAGGAGTTAT TTTTCTCGTT CTACCGTGTA 
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  8401 GTTTCCGGGA ATCAGGCTTA GCAGCAAGTG CCTTTACCCA CTGAGCCATC 
  8451 TCGCCAGCCC CGATGGCAGA CTGACTTCTG TTCACACGTG TCCCTTAAAC 
  8501 AGAACACCCC AGGGGTGCCC AATTCATGGG ATACCACACT TGTGTCTGCC 
  8551 CATCAGCTGA CAGACAGATG TCGGGGCTCT GTGTGGCTGG GCTGTAGGCC 
  8601 AGCCAGCAGC TGGGGCAGCA ATAGGGCCAT TTCTTCTCAG CTCTGTGCCT 
  8651 GTGAATGGAT TCAATCCTAT CACCCCCTAA TAGTTCTTTA AAAACCAAGA 
  8701 ACAAAGCCCC CATAAGAGTA TGAACCATGG ATCTGAAGAA GCATAATACA 
  8751 CCGGAGGGGC TGGGGGCTCG GCTTGGCTCG GTTGGTGGAG TGCTTGCTTA 
  8801 GTGCACAGGC CCCTAGAGTC AGTCTCCTGC ACCACACACA ACAACGGGCA 
  8851 TAGCAAGGCT TGGTGGCACC CACTCCTCCC AACGCTTGCA AGGTCACTGC 
  8901 GAGTTCTCAT GCTGAGACCC TGTCTCAAAG AAAGAAAAGA AAAGCTGGGC 
  8951 ATGATGGCAA TGCTGGGCAC TTAAAGATGG AAGCAGGGTG ATTGGAAGTT 
  9001 CAAGGTGATC CTTGGCTGGC TGCACAGTGA ATTTAATGCT TGCCTGACGT 
  9051 CCATGAGATC CTGTCCAAAA CAAACAAACA AAAAAACCGT TATTTAGTGC 
  9101 AATTGACTCA AAGGAGCAGA CTTTAGGCTT TTGTGTGAAC AAAGCAGGAT 
  9151 GGTGAAGGGA TGTGTACAGC TAGAAACAGG TCCTAGCCAG TCATTGGAGC 
  9201 TCCTGGGAGG CTGAGGAGGG AGGTACAGGA TTCCAGGCCA GCCCAGGGTA 
  9251 CATAGGGAGG CACTGACTCA AAACCAGAGA AACCAGCAGA CATGCTGGTG 
  9301 CACACCACAA CACCAGCACC CAAGAGGTGG AGCCAGGAGG CTCCGAAGTT 
  9351 CAAGGTCAGC CTTAGCTACA TAGAAGGCTC AAGGTCAGCC TTGGCTATAT 
  9401 GAAACCTTGT CTCAAATTTT CTTTTTTAAG TGTGTGTGTG TGTGTGTGTG 
  9451 TGTGTGTGTA TAAGCATGAG TGTAGATGTA CAGATGCCCT CAAAGGTCAG 
  9501 AGGCACAGGA TCCATGGAGC TGGAGTTAAC AGGTGGCTGT GAGCTCTGCC 
  9551 TGACAGGGGT GCTGGAAATT GAACTCAGGA CCTCTGGAAA AGGAGGAGGT 
  9601 GTTCTACCCA CTGAGCCATC TATGTAGCCC TCATCTGTGT GTGTGTGTGT 
  9651 GTGTGTTTTG AACAAGGTTT CTCTGTGTGT CTTTGGCTGT CTTGAAACTC 
  9701 ACTCTGTAGA CCAGGCTGGC CTCAAACCCA CAGAAATCTG TCTGCCTCTG 
  9751 CCTCCCGAGT GCTTGGATTA AAGGTGTACA CAACTACCTT CTGACCCAAA 
  9801 AGTAATTTTT TTGAAGTCTT ACAGTATTGT ACCTAGAAGA TTAGTCATTG 
  9851 TCAGAATTTG GTTTGGATTG ATTGTCAAGG ACTCAAACTA GCCGTCTCTG 
  9901 TACTGCCGAA CTTTGCAAGG CGTCCCCACC TCACCCCACC CCCCATCCCT 
  9951 CTCCCTTCTC CTGGGTGGCT GTGTCTCCTC ACCTGAAATG TGAGGTTGCC 
 10001 AATGCCATCC TGCCCGGCAC CAGCAGTACG TCTAGGAGGG AAACCTTAGC 
 10051 ATGTGCCATC AATCCTCTGT TCCAGGCCGC AAGGTCATCT GTTTGGTGGG 
 10101 AGCCGGAATC TCCACGTGTA AGTTCCCCGT CCTTCAGCCA CTCCTGGGGC 
 10151 TGGGGGAGGC TGGAGGGGTT CGTGCACACG TGGGCAGAGC CTCTGACTGC 
 10201 GTTGCCTTCC TAGCCGCGGG TATCCCTGAC TTCCGCTCCC CGTCCACTGG 
 10251 CCTCTATGCA AACCTGGAGA AGTACCACCT TCCTTACCCA GAGGCCATCT 
 10301 TTGAGATCAG CTACTTCAAG GTAGACGGCT AAGATGAGGG GAGGTGGCTC 
 10351 CCAACTCCAG TCCTTGTCTT ACCTGGGACA TGTGGCCCTC TGCTCCTCTC 
 10401 TCCCACAGAA ACATCCGGAA CCCTTCTTTG CCCTTGCCAA GGAGCTCTAT 
 10451 CCCGGGCAGT TCAAGGTGAG GTCATCTTCT GCAGGGAGCC TGGGAAGAGT 
 10501 AGGCATGGAA GCAGGCTCTT TATAGGCCCT CCAGGCAAGC ATAACATGAT 
 10551 TAAGAACCTA GCTTCTGGGG CCAGCAGGAT GGTTCCATGG GTAAAGGTGC 
 10601 TTGCTACCAA ACCTAATGAC CTGAGTTCAA TCCCTGGAAT CCTCATGACT 
 10651 GAAGGAGAGA ACTGACTCCA TCATATTCTC TGACCTCCAC ATGTGCACTG 
 10701 TGGCAAGTGC ATATCCCCAG GTAGATGGTT GGATGGAGGG AGAGACAGAT 
 10751 GGGTGGGTAG GTAGATAGAT GGATGGATGG ATAGATGGAT GGATGGTGGG 
 10801 TAGATAGATG GATGGATGAT AGATAGATAG ATAGATAGAT AGATAGATAG 
 10851 ATAGATAGAT AGACAGATAG GTAGATGGGT AGATGGGTAG ATAGAGATAT 
 10901 TGTTAAAGAA AAAAGAAAAG AATTACATAA GTTCTGGCCA GATTTGATAG 
 10951 TTCATCCCCA TAACTGTAGC ATTTGGGAGG CAGAGACAGG AAACTTTCAA 
 11001 ATGCAAGGTC AGCCAAAACT ACCTATCTCA AAAGTAAAAA AAAAAATAAA 
 11051 AATTAAAGAT GAAAGAGGTG AAAGTGGGAG AGATGGCTCA GGGTAAAAGA 
 11101 GCAGATAGTA CTCTTCCAGA GGACCTGGGT TCAATTCCCA GGACCCACAT 
 11151 CAGGATGTTC ATAGCCCCCT GTAACTACAG CTCCGGGGAG CCTGACACCT 
 11201 CTGGCCTCTG TGGGCACTAG AACTCACCTC CATATACCAA CAGAGACCCA 
 11251 CACACATATC TGTAACTAAA AATAATTGGA ATGGTAGCTT AGCAGTTCAG 
 11301 TGCACTGGCT CCTCTTCCAG AGGACCTGGG TTCAATTCCC AGACCCACAT 
 11351 GGCAGCCTAC AGCTATCTGT AACTCCAGTT CCAGGGGATC TGACACACAC 
 11401 ACACACACAT GCAGACAAAA CACCAGTCAA TGCACATAAA ATAAAAATAA 
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 11451 ATAAATCATT TAAAAAATTC CAGCTCGGGG GCCGGGCGGT GGTGGTGCAG 
 11501 GCCTTTAATC TCAGCACTTG GAAGGCAGAG GCAGGCAGGT TTCCGAGATC 
 11551 GAGGCCAGCC TGGTCTACAG AGTGAGTTCC AGGACAGCCA GGGCTATACA 
 11601 GAGAAACCCT GACTCGAAAA CAAACAAGCA AACAAACAAA CAAACAAACA 
 11651 AAAACAAGAA ACAAAACAAA AAAGAAAACA AACAAAAAAA TCCAGCTCTT 
 11701 GGTGAGAGGC AGGAAGATTT CTGTGAGTTT GAGGCTAGCC AATTCCAGGC 
 11751 TTACCTAGAG AGACCCTATC TCAAAAACCA AAAAAATAAA TAAATAGTAA 
 11801 AATAAACAAT TTTAAGAAAT TAAAAGAAAG GAGGAGTGGG TTGCCTGGCC 
 11851 CCTCGTCTCT TTATCCTGTG GCTCTGGGCC TCAGTTTACC CAACTCTAAG 
 11901 AAAGCTGCTG AGACTATCAG GAAGGGCTGA GACTGAAGCC TGGCTGTGAG 
 11951 CCTGACTCTG CAGTTTACCT ATTGGTGATG CCAAAAAGCC GCCACCATGC 
 12001 CCTTGCCTGG GTCTCCTCAT TTGTGGTACG GGAGAAGGCA GGCTCACCCT 
 12051 CACTGGGCCA CTGAGATGGG GCCATGGGGC AGAATGGGCC CACAGCATGG 
 12101 CCTGGGACAT TCACATCAGC ACTGTTACTC TTCTCTCAGC CAACCATCTG 
 12151 CCACTACTTC ATCCGCCTGC TGAAGGAGAA GGGGCTGCTG CTGCGCTGCT 
 12201 ACACGCAGGT AGGCGGGGCC ACGGGCAGGT GTGACCATGG GTAGGCAGGA 
 12251 CCTTGGGCAA GCGTGACCTT GGGTGGCAGG GCTCGAGGGC AGTAGGCCAG 
 12301 ATGGGTCTTG GAACACTCGG TCAGAGCTGG GCTAACACAG GCAGGCACAG 
 12351 GACCAGGGCT CAGCTAATTA TAGTGAATGA CCTACAATGG GCCACTTCCT 
 12401 CTTGGCCTCA GTTTCCCCTT TGTAAAATAG GGGACGGAAA CAGGATAGAT 
 12451 TGGTACTCAT TGGAATCAGG AGAAAGGTCA GAAATTCAAG GTTGCTGGAT 
 12501 GGTAGTGGCA TATGCCTTTA ATTCCAGTAC TCAAAAGGCA GATGCATGCA 
 12551 GATCTCTGTG AGTTTGAGGT CAGCCTGGTC TACATAGAAA GTTCTAGAAG 
 12601 AGCCAGGGCT ACACAGAGAA ACCCTGTCTT GAAAGACCAA AAAAAAAAAA 
 12651 ACCCAAACAA CAACAAAAAC CAAAGAAAGG TTATCATTGG CTACAAAATG 
 12701 AGTTTAAGGC CAACCTTCAG GATGTGAGAC TGTATCTCTA AATTAATTGA 
 12751 TTAGTCGATT AATTACAATA TAAACTAATA GAAGAATGTT TAAATATAAA 
 12801 GAAGTCAGAA CAGCTTCAAG CCCTCTCAAG TCTGCTGTGA GGTGACAGGT 
 12851 GACAGGACAT CCCAGACTTA CTGCAAAAGG CCTCTGTATC TGAGGGGACA 
 12901 CCGTCCATAC CACAGCCACT CCAAATCAGG AAAGTGACAC TGTATCGTAA 
 12951 GGAAGGTGGG CTTCTTATTC ATACACTTCT GAGCCTGGCC TTGGATACGG 
 13001 TGGCTAATGG GACACTGTGG CCACACTGAG GTTCAGACGG ATGTTCAGGC 
 13051 TGCTGGCTTC TATGTGTCTC TGTGCGTTTT GTGGATGTGT TGAAGTTCAG 
 13101 ACTGCTCTGT GTATACATGT GTGCTAAAAA ATTGTCTCAG AATACAAAGT 
 13151 GGCCATTACA TTACACACTT GTTATCCCAG TGCTTGGGAA GCCGAGGAAG 
 13201 GAGCTGGTCA TGAGTTCAAG GCCAGCCTGG GCTAATAGTG GATTTAAGGT 
 13251 CAGACTGGCT CCATAGCAAA CAATCTCCCC CGCCCCCCGC CCCCTCCCCC 
 13301 GCCCTGCCCA AGAAGAAAAA GTTAGAAAGG AAAAAGAGAG AACTCCAAAT 
 13351 TGTACAGAAG AGTTAATGCT TGAATACAAA TAGGTTTGAA GCTCTTGCAA 
 13401 TGTCAGAAAT GGCCACCAGG GGGAGGATGG GTTCAAACTT TTGGGTCCAG 
 13451 ATGGCTGGAG GCCCCAGCTG GGGAAGAGAC AGCTTAGTCC TTCCAGGCAC 
 13501 CGCCCAAGCT CAGAGTCAGC CTCATTCACA GAAAGAGGCT CAGGCCTGAT 
 13551 ACTAACAGCT TCCTTGAAGC CCCATACTTC CTGCTTGTTG TTGCATGTCC 
 13601 CTCCTGCACC CTTGTTTGCT GGCCTCTATG ACAACAGGTG TCCACCCAAG 
 13651 TACCAGGCCC TACCAGTGAG CCAAGCAGAC ACCGCTGCCC TCCTGGTGCC 
 13701 AATTCATGTG TGTGACAAGA ACAAGAGGGA CGATGAGTCA TAGACCTAGG 
 13751 GTGTCAGATG GGGCTGAGAC CAGCCTGAAG TTTGGAAGTC AGAGGACAAG 
 13801 GTGCAGGAGT CAGTCCTTCC TTTCCATCGT GTGGGTCTCA GGGATGGAGC 
 13851 TCAGGTCATC AGGCTTGGTG GCCTTTACCT GAGCATCTCA CTGGCTCCAC 
 13901 ACATAAACTT TAAAGGGAGA TTTATTTTTA TTTCATGTTT ATGGATGTTC 
 13951 TTCCTGCTTG TATGTCCATG ACCTATGTGT ATGCAGTGCC CACAGTAGCC 
 14001 AAGAGAGGCT TTAACAGATG TGTGCTGCCA TGTGGGCGCT GGGTCCCAAC 
 14051 CCGGGGTCTT CTGGGAGAGC ATCCAACACT CTTAACTGCT GAGCCATCCC 
 14101 TCCAGCCCCC ACACGTACAT TTTTGTAAAA TATCTGAAGG TGGAAAAAAA 
 14151 TGTTCCACTT GCCCCCTTTG TGGTCAGCTT TTTTTCCTTC GTGGCCTCTT 
 14201 CTCCTCAGTC ACCGTTTGAA TCACTGACCC ACTTTCTGGA ACACAGTGAC 
 14251 TCCGCCTCTG AGTTGTGCCG ACACAGCATC TTTGAAGCTG TGGTGCTGTT 
 14301 TTTAGCTCTG CACAGGAACC CATCGCTCAA GCCACTGTGG TCCCCACAGA 
 14351 AGAGTGGCTA TAGACCTTCA AGTTGCATAC ATGAAATTCA CCCTCCAGGA 
 14401 AGTTCTCTGT ATGCCCCAAA CCCAGCCTCT TGTCTGGGGA CCCCTCGATA 
 14451 CTCACACCAT AGAGCAGCAC CATGCTTTTT AAAATCGAAG AGTAGTCTTT 
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 14501 TTCTTTTTTT CTTTTTCCTT TTATTTTGGG TGTGTGTCTG CTGCGTTAGT 
 14551 TATATAGGCC GCAGGGCTTC CGGCATGCTG GGGAAGTGCT CTACCACTGA 
 14601 GCCACACCCC CAGCCCAGGC AAGACCTGAG TTTGTAATCT TCTGTCTCAC 
 14651 CCTCCTGTAG CTGAGGTTAC AGGCTTGCTC TGCTAGCCCA GCTCTACTGT 
 14701 GCAGGCATTG GGTACAGGCG GCAGCCTACC ACGTCATCAT GAGGGGAAAC 
 14751 TGCAAACTTA CATCAGTGAT GTGCAGTAGG GTAGGTGTCA GAGGCCTGCT 
 14801 CCACTCAGGG TAGACCCAAC TCACGGTGGG CTTATGAGGA CAGAGCCCCA 
 14851 TTGCAAGGGA AGGAGCGTGT CTGTGGATAT AATCCAACAT GATCAGAGAT 
 14901 CTCAGGCATC TCCCTCCACC CTAGACTATG TTTCCTTTGA TCACAGAGGC 
 14951 TGCCGGAGGT AATTCTGTGA TCCCTTAGTT AGCTGTTTGT GTGTGTGTGT 
 15001 GCTGCTCACT CTCCAATGAA GGGCTTGGTA GACTGAGCCA GCGACAAAGC 
 15051 AGATGCAGAG TGCGGGGTGT GGCAGTGCTC CCCTGTCATC CTGGCACTCT 
 15101 GGAGGGAGGT TCTCCAGTTT GAGGCAGTCT CAAAAAATCA TATCCCCCCC 
 15151 CAAAGAAACA AATAAGTCAT TCTCTTGTTT TATTTATTCA TATTACATTA 
 15201 TTTAGTGTGT GTAAAGTTCA GCTGACAACT GAAGGAAGGC GTTTGCTTCT 
 15251 ACCATGTGAT GTCTGGGGCC CAAAGCCACG TTGCTATGTT GGTAGCAAGG 
 15301 ACCATTGTCA GCTGAGCCAT CTTGTCAGCC CTTACTGTGG CTTTTCCAGA 
 15351 CAGGTGCTAG TCTTGTCCCA GCTTGCCTGA ATCTCACCCT GTTCCTCAGG 
 15401 CTAGCCTCAC CTTTACAGCA GTCTAGAATT ATAGGCATGG CCTACCATGC 
 15451 CTGGCTTTAT TTACTTATTG CTTATTTATT TCACTTTTTT GAGGCAGGTC 
 15501 TTCCCATGTA GCCCTGGCTG GCCTGACATT AGCTATGTAG CCTCAGCTGA 
 15551 CTTTAAACTT AAAGCAGTCC TCCTACCTCA GCCTCTAATT GCAGGGCTTA 
 15601 TAGGCAGTCA CCACCACTGC TGACCTGATT CAGTTTATTT ATGTTAATGC 
 15651 TTGGCCAGAG CTGTCACATA CAAGCTACTC AGGTGGGATC CCCACAAGGA 
 15701 TGCCACATCT GAGGGAGACG CTGAAGATAG GTACATTTAT TGCAATAAAT 
 15751 GTGTGGCAAA TGGAGGGACT GTGCGTGGCT CTCTAACAAA AGAACTTCTC 
 15801 TGAAAATTAG AGGCAGTGAC CCAAGTTTGT AGAAGAATAT CCCATGGGCA 
 15851 TCCTTTAGCA ACCTTCTGTG GCCCCACTGG GGAAGCGGGC ACTTTCCATA 
 15901 TATCCTCACC CTTCCTCATC CCCCGCAATG CCACTTCTCA GAGCCACCAG 
 15951 GGCTGGCTGT CTTCCTGACC TCCCCTCCCC CTCCAGAACA TAGACACGCT 
 16001 GGAACGAGTG GCGGGGCTGG AGCCCCAGGA CCTGGTGGAG GCCCACGGCA 
 16051 CCTTCTACAC ATCACACTGT GTCAACACCT CCTGCAGAAA AGAATACACG 
 16101 ATGGGCTGGA TGAAAGGTGA GGCTGGACTC TGCGGGCAGG CAGGCCTCGG 
 16151 GCAGGCCAGG GGGAGGTAGG GGGTGGGGGG CTCTCACTGC TTGCCTGCCA 
 16201 TAGCCAGCCT CCAAGGGCTG GGCCCCAGTG CAGTCTGCTC CATTCTTTGG 
 16251 CTCTTGCTAG TCAGTGAGTT GGTTGGTTTC CACTGAGGCT AGGCTTCCCT 
 16301 ATGTAGCCCA GGCTGGCCTG GAGCTTGCAC TTCTGCCTCA GCCTCTCTAG 
 16351 TACTGAGGTT GCTTGCAGGC GTGCACTACG GTACCCAGCT GTCTTGCTTT 
 16401 TTATGGTAGC TGTAGAAGCC TCAAGGATTC AAGGTGACAG CAGGTCTTTG 
 16451 CTCCCATGCC ACCCCTCTGC TGGGCTGTCA TCCATATGAA CCGCAGAGCA 
 16501 CGGCCAGCCA CGTGTGGACT CCGTGTAGAC TCACGTCCTC AACGGTCACA 
 16551 CAGCCTGTGT CTCTGAGGTG TTTACTATCT ATCTTACATG GCAAACACGG 
 16601 CTACCTTCTG AGGAAGGCAT TGCACAGTGG AACCTTCCGA GACGAGGAGG 
 16651 CCTGTGTCTA CGTCCAACAT GGCTCCACTT GCCCCATGTG CCTACTGAAG 
 16701 CAAAGTGTCT AACCTCTGCT GCCACCATGT GGGTCCCAGG AACTGGACTC 
 16751 AGGCGCTCAG GCTTGAGGAT GGACCACCTC GCTGGCCCAG AACAGTTTAA 
 16801 TTTTTATTAT ATTTTTTAAA GATAGGGTCT CTAATTTCAT TAAGTTCTTG 
 16851 TTGGTTTAAG TTGTAGAAGT CGCAGGAGGA ACCATGGTAC ATGCCTATTA 
 16901 GCCTATTGCT TGGGAGAGGC AAGAGGATCA GGAGTTCAGG GTTAGCCTTG 
 16951 GCTACATACT AAGTTCCAGG TCAGCCTGGG CTACATGACA ACATGAAAAT 
 17001 AAAAACTAAT AAATTTTATA TAAGTCTTAT GTAGCTCAGC CTTCCATGTT 
 17051 GGACAGTGCA GCAGGAGCCT GTGGAGAGGG AAGCTGGGTG CTGTGCTGGG 
 17101 TAAGACAAGT GCTGGAGACA CACATGGTAG CTCACGGCTG TCACTGCTGT 
 17151 CACTGTCCTC ATTCATGTGA GGACACAGCA ACTGAGAGGA CAGCTAGTCC 
 17201 CCGCGCCTGG GTGCCAGCAC CAGTCTGTTC TGGCAGCCAT TGTGCTGAGC 
 17251 CTGAAGCTGC TGTGTCAACT GTGGGAATCC ATTTCTGTAT TCTTTATGCT 
 17301 GACTTCACAA AGCCTCTGGT GTCCCCTTGA GATCAGGACA GCTGTGGCCT 
 17351 TTATAGCAGG ACCCTGGAAG GTAGCTCTTC TGACAGAATG CCAGCCAGCT 
 17401 GCCCCCAGAC TGAGGGTTCC TGAGCAGCCC ATGTGTGCAC AGCTGGGGGT 
 17451 GACGGACAAT GGACATCACC CCCTTTATGT CCCTGTGGAA TCGCATCTTC 
 17501 CACCCACAGA ATAGCATATT TGTGCAGAAA TACCTCAGCA GCAGCCGTTA 
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 17551 AAGCTTCGCC CTGTGACTGG CTGTATGAGT GGCTGGCGGA GTGAGCTCCA 
 17601 GTCCTGTGGG CTGCATGTGG CAGATGTGCT TTCAGACTCC GTGATCCATA 
 17651 AGTAAGAAGG AGTGTGACTT TCATAAGGGT GGTCTGTCCC ATAAGGAGTC 
 17701 TGTCACAGAA TCCGAGAGTG GGAAACAGTT GGGCTTGAGG TTTGATCCAA 
 17751 CCCAAGGCTA TCTGTATGTC CTTTCCTGAC CCAGGGCAGA TAGGACTGTC 
 17801 CCCAGGACCC ATTGGATGAC TCCCATTCCC CAGATGGGGG TCTGGTGGAG 
 17851 TCCAGGGGCA CCTGTCTGGG GCAGATGGGT TTGCCCCTGT ATATGCCCTT 
 17901 TCACTCACTA GCTGTGGTGC TGCCAGCCAC CCCTGGATGC CTGGAGGTGA 
 17951 AGGGGACGGC TCTCTAAGAA GGGAGCTCCT CTCTGTGAAG CAGGAAAGAC 
 18001 CACTCAGGAA ATGCCTGAGT AGTGAGCTGT GCTGTTTGTT TTGTGGCGCT 
 18051 GCGGATCAGA CTAGGGGACT CGGGCATTCG AGGTCAGAGG CTCTTCCACT 
 18101 GGGCCACACC CACAGCCCCC ATACTGGGAG ACTCAAAGCA GGCATCTCCT 
 18151 GCTGAGTCGT GCCCAAGCCC TCTTGGTTCC ACCGCTGAGC TAGCCTAGCT 
 18201 CTTGGGGTTT GTGTGCGCAT GTGTGTAGGT GTGCACATGG CATAGCATGC 
 18251 GTGTGCATGT CAGGGCCATC TGCAGGAGCT GCTTCTCTCC TTTTAGCATG 
 18301 TGGGATCTGG GGACGGAACT CAGGCCACCA GGCTTGGCAG CAGGTCCCTT 
 18351 TACACACTGA GCCACCTTGA AGCCTCAGCT CTTATTTTTT TGAGATGTGG 
 18401 TTTTGTTGTG TAGCCAAGGC TGGCCTCAAA CTCACAATTC TCCTGTTTAA 
 18451 TTCTCCCCCA AGCAGGCTTG CGGCATGCAC CACTGCCACC TGCCTGGGAT 
 18501 GCATTTCTGT TGACAGGAGG GAGGGGCAGA AGAGGGCTTC TCCAGCAGCC 
 18551 CTTGGGGGAG CCTCACAACT CACCCCCCCT TCCTCTTTCC CACTCAGAGA 
 18601 AGATCTTCTC AGAAGCAACT CCCAGGTGTG AGCAGTGTCA GAGTGTGGTA 
 18651 AAGCCTGGTG AGTCCTGGGC CCGGGGCTGG AGCTGGGACC CCTTCCTCCA 
 18701 CGGCCTCACC CCCCAATCTG GCCACTCTGC CACCTGGCCC GTCCCCTACT 
 18751 GTTCAGCAGA GGGTGCCCCG CCCCCCAAGC CTCAGTTGGG CCCCTGACTC 
 18801 CTGACTGTTC TAGCTCTGTC TCCCATATCT CCTGTCCTCT GTCCCTCTGT 
 18851 CCCTCTGTCC CTCTGTCTGT GTCTACCGCA GATCTGAAGC TTCTGATGGA 
 18901 ATTAGAACTT GGCAAAACAA TACTGAGAAT GAAGTGTATG TGGAACAGAG 
 18951 GCTGCTGATC TCGTTCTTCA GGCTATGAAA CTGACACATT TGGAAACCAC 
 19001 AGTACTTAGA ACCACAAAGT GGGAATCAAG AGAAAAACAA TGATCCCACG 
 19051 AGAGATCTAT AGATCTATAG ATCATGAGTG GGAGGAATGA GCTGGCCCTT 
 19101 AATTTGGTTT TGCTTGTTTA AATTATGATA TCCAACTATG AAACATTATC 
 19151 ATAAAGCAAT AGTAAAGAGC CTTCAGTAAA GAGCAGGCAT TTATCTAATC 
 19201 CCACCCCACC CCCACCCCCG TAGCTCCAAT CCTTCCATTC AAAATGTAGG 
 19251 TACTCTGTTC TCACCCTTCT TAACAAAGTA TGACAGGAAA AACTTCCATT 
 19301 TTAGTGGACA TCTTTATTGT TTAATAGATC ATCAATTTCG ATCCGCTCCT 
 19351 GGGCACCGAA CTGCGCCGCG TGTTCAGCAG GGTCGGCGTG TTCGGTGTGT 
 19401 CCCCCGCGGT GGGCCTCGGG GGCGGGTGCG GGGTCGGCGG GGCCGCCCCG 
 19451 GGTGGCTTCG GTCGGAGCCA TGGGGTCGTG CGCTCCTTTC GGTCGGGCGC 
 19501 TGCGGGTCGT GGGGCGGGCG TCAGGCACCG GGCTTGCGGG TCATGCACCA 
 19551 GGTGCGCGGT CCTTCGGGCA CCTCGACGTC GGCGGTGACG GTGAAGCCGA 
 19601 GCCGCTCGTA GAAGGGGAGG TTGCGGGGCG CGGAGGTCTC CAGGAAGGCG 
 19651 GGCACCCCGG CGCGCTCGGC CGCCTCCACT CCGGGGAGCA CGACGGCGCT 
 19701 GCCCAGACCC TTGCCCTGGT GGTCGGGCGA GACGCCGACG GTGGCCAGGA 
 19751 ACCACGCGGG CTCCTTGGGC CGGTGCGGCG CCAGGAGGCC TTCCATCTGT 
 19801 TGCTGCGCGG CCAGCCGGGA ACCGCTCAAC TCGGCCATGC GCGGGCCGAT 
 19851 CTCGGCGAAC ACCGCCCCCG CTTCGACGCT CTCCGGCGTG GTCCAGACCG 
 19901 CCACCGCGGC GCCGTCGTCC GCGACCCACA CCTTGCCGAT GTCGAGCCCG 
 19951 ACGCGCGTGA GGAAGAGTTC TTGCAGCTCG GTGACCCGCT CGATGTGGCG 
 20001 GTCCGGGTCG ACGGTGTGGC GCGTGGCGGG GTAGTCGGCG AACGCGGCGG 
 20051 CGAGGGTGCG TACGGCCCGG GGGACGTCGT CGCGGGTGGC GAGGCGCACC 
 20101 GTGGGCTTGT ACTCGGTCAT GGTGGCGGCT GGATCGGTCG AAAGGCCCGG 
 20151 AGATGAGGAA GAGGAGAACA GCGCGGCAGA CGTGCGCTTT TGAAGCGTGC 
 20201 AGAATGCCGG GCCTCCGGAG GACCTTCGGG CGCCCGCCCC GCCCCTGAGC 
 20251 CCGCCCCTGA GCCCGCCCCC GGACCCACCC CTTCCCAGCC TCTGAGCCCA 
 20301 GAAAGCGAAG GAGCAAAGCT GCTATTGGCC GCTGCCCCAA AGGCCTACCC 
 20351 GCTTCCATTG CTCAGCGGTG CTGTCCATCT GCACGAGACT AGTGAGACGT 
 20401 GCTACTTCCA TTTGTCACGT CCTGCACGAC GCGAGCTGCG GGGCGGGGGG 
 20451 GAACTTCCTG ACTAGGGGAG GAGTAGAAGG TGGCGCGAAG GGGCCACCAA 
 20501 AGAACGGAGC CGGTTGGCGC CTACCGGTGG ATGTGGAATG TGTGAGGCCA 
 20551 GAGGCCACTT GTGTAGCGCC AAGTGCCCAG CGGGGCTGCT AAAGCGCATG 
Appendix   
223 
 
 20601 CTCCAGACTG CCTTGGGAAA AGCGCCTCCC CTACCCGGTA GAATATCGTG 
 20651 TTTTTCGGTG AGAACCTTCC ATCGCGCTTC TTCTCCTGCA TGCAGTCAGT 
 20701 AAGTGTCCAC TCTGGGCTGG GCCCATGTGA GGGGGACAAA GCCAGAGTAG 
 20751 TGGGGTCCAA GGCCTTCCTG GTTACTCCCC GCAGGACTTC TCCAAGGTGG 
 20801 ACCTCCTCAT CATCATGGGC ACCTCCCTGC AGGTGCAGCC CTTCGCCTCC 
 20851 CTCATCAGCA AGTAGGTTGA GGAGGATGGG ACTGGGTGTC AGCTCGGGAC 
 20901 AGGGCACTAG GGCAGATCCT GAATCTCAGC TCCCCCTTCC CAGGGCACCA 
 20951 CTAGCCACCC CACGGCTGCT CATTAACAAG GAAAAGACAG GCCAGGTAAG 
 21001 TCTGCCTCAG CTTCCCTCCC CCTCTCCTCC CCCCCTCCTT CCCTGTCCCC 
 21051 CTCCCCCTCC CTCCACTTTC TTTGCCCCCT TCCTCATTTG GCCACTTCCT 
 21101 CAGGGGACAG GGCAGGTCTC TGTCCCACCT GGAAAGCACC AGATCCTTAG 
 21151 ACTTGCCAGT TCAGTCAGGA GAACATGGGA GCTGGCCTGT GCACTGGGCC 
 21201 TCTGTCATTC TAGACTCCAC TGAGCACAGA ACAGAACCGT GCCTTGAACC 
 21251 TGCTGAAGCC CAAGTGCTTC CCCGGACCCA GGAGACAGTC CAGACACTAC 
 21301 CATTCTAGTG CCCTCTCACA TATCAAAATC TGGGGACCCT CAAGTCCCTC 
 21351 CTATGAAGTG GCAGAGTGTT TATATAGAGC AATCTCTGAA GATGCTAAGC 
 21401 TGTGTCTCCG TGACGTGTGC GATACCATGT GAACTCAGGA GACAGGCTCC 
 21451 CATGCCCCCC TGCCCTCTCA GACACGCCAC GGAATTTAAG ATGACCTTGA 
 21501 ACTCCTAGTC CTCCTGCCTC TGCCTTCCAA GTTCTGGCAT GACAAGCCTG 
 21551 TGCCACCACT CCTGGCTGTG TTGTTGTTTG TTTAGCAGAA GGATAAGTTG 
 21601 CTTGCCACGC ATGCACTAGG TCCCGAGTTT AACTGCTTGC ACCCACATAA 
 21651 AAATCCAGGC ATGGTGTTTG TAGTCCCACA CTGGAGAGGC AAAGATTAGT 
 21701 GGGTCCCTGG GGCTCACCGG GTAGCCAGTC TCACATAATC CTGAATTCCA 
 21751 GGCCAGTTGA GCAATGTCTC AGAAAGAATG TGTCTGGGCC GAGGCTGTAA 
 21801 CTCAGCGGCA GTGCTTGCCT GGCGTATGCG CGGCCCTGAG TTCAATCCTC 
 21851 AGCACCACCA AAGACGAAGA CGGTTATTAG TTTTGGACTA GAGAGATGGT 
 21901 TTACTGATTA AGACCTTCTG TCCCCAGCAC CCATGTCAGG TGGCTCACAA 
 21951 CTGCCTTTAA CCCCGGCTCC TGGGCATCTG ACGCCTCTCA GTCCTCTGAG 
 22001 CACTCACACA TAGAGAGCAC ACATGCAGTC AGATAAAAAG AAGCCAAGTG 
 22051 GTGGTGGTGC ACACTTTAAT TCCAGCACTT GGGAGACAGA GGCAGGTGAA 
 22101 TCTGAGTTTG AGACCAGCCT GGTCTCCTTA GTAAATTCCA TATTAGTCAG 
 22151 GACTATATAC ATATAGACAC CATCTAATCA ATCAATCAAT AACAAGTTGG 
 22201 CTAACTTCTA AGAAACAGTA ATTATGGTTG GCCTCTTGGT TGACCTCTAG 
 22251 CCTGACCTCC AGGTCCACAT GTGTACAAAT ATAGACACAT AGCCCACTAC 
 22301 CATACACACA CACACACACA CACACACACA CACACACTAA TTAGTAAATA 
 22351 GGAAAATAAG GCTAGGTATG GTGGTGCACA TCTTTTATCC CAGCACTGAG 
 22401 GAGGCAGAGG AAAGGTGGAT CTTTGTGAGT TCAAGGCCAG CCTGGTCTAC 
 22451 AGAGCAAGCC CCAGGACAGC CAGGGCTCCA CAGAGAGACC CTGTTTTAGA 
 22501 AATAAGCATA AGGCAGGTCT GCTGGCTCAG GGCTGTGCCC TTAGCTGTCT 
 22551 TCTCCCCACA GACGGACCCC TTCCTGGGCA TGATGATGGG CCTGGGAGGT 
 22601 GGCATGGATT TTGACTCCAA GAAGGCTTAC AGGTGAGGCT GGGCCTGGGT 
 22651 GAGCAGCTCG AGAAGGGTGG GTGAGGAGGG AGAGAAGACA GAAGGCCGGC 
 22701 TGGTCCTCAG CCTGTTCTCT TACTCCTGCT CACCCTGCAG GGACGTGGCC 
 22751 TGGCTGGGTG ACTGTGATCA AGGCTGCCTG GCTCTCGCTG ACCTCCTCGG 
 22801 ATGGAAGGTG AGGAGCTGGG CCACCCCAGC CCACCCTGAG CCCAGGCCCA 
 22851 TGGGGTTTAC GGTAACCTGA CTTGCGTCAA CTTTGCCCCC TACAGAAGGA 
 22901 ACTGGAAGAC CTTGTCCGGA GGGAGCATGC CAACATAGAT GCCCAGTCAG 
 22951 GGTCACAGGC CCCCAACCCC AGCACTACCA TCTCCCCTGG AAAGTCCCCA 
 23001 CCGCCTGCCA AGGAGGCGGC CAGGACCAAA GAGAAAGAGG AACAGCAGTA 
 23051 ACAGTAACCA TGACCTCCCG CAGGACAGCG GAGCCCGGCC AGCACTGGGC 
 23101 CCTCTTAACA TGCAGCTTGT GTGAGCTCAA AGACCCTTCG TTCTTTAACC 
 23151 ACGTTCTTGA AATCAGGGTC CCCAACTCAA TCCCAGAAAA GCCTAATATA 
 23201 CCTAGGGGCT GAGGCCTGTG CAGTCTGTAG CTGGGGCCTC TAACCACCAT 
 23251 AGCCTCTAAC CACCATAGCC TCTAACCACC ATAGCCTCTA ACCACCCAGG 
 23301 CAAGAAGCAG CCTTCCCTAA CTTCTAATTA TTCCCAGACA ACAGGCTACC 
 23351 CCAAAACCCC TAACAGTGCC AGAATAAGGC ATTTCTCTAT TGTTTTCAGG 
 23401 GGGCCTATGG CTAAATCAAA TTAACCTACC CCGCATAGGG GCTGGACTCT 
 23451 ACAAATAGAA CTTCACCCAA GGGGGTGGGG CCTTGTGGGA TCTCTGAGCC 
 23501 TGAAGGCCTG CCAACTCTCT GCCTCCAACA AAGTGGGTAC TAGGCTCCCT 
 23551 TTCCTGGGGA CCCACTTGCC AGCTGTTGGT GGATGAGCAA GAGACCTTGC 
 23601 TTATTAGAAA CAAATTAAAA AACAAAACAA AGCAACTAA 






Brain penetrance of CHDI194500 as assessed by Pharmidex Pharmaceutical Services 
Ltd. Reproduced with permission from the CHDI Foundation: 
 
 
Brain penetrance of CHDI194500 following intravenous (IV), subcutaneous (SC) or 
oral gavage (PO). Male, 6-7 weeks old C57Bl6 mice were dosed with 5 mg/kg (IV) or 
10 mg/kg (SC and PO) of CHDI194500 and brains were harvested at 0.5, 2, 8 and 24 
h after compound administration. Concentration of CHDI194500 in the brain was 
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Determination of SIRT2 IC50 value CHDI194500 in an in vitro assay performed by 
Cerep. Reproduced with permission from the CHDI Foundation. 
 
Dose-response curve showing activity of recombinant human SIRT2 towards a 
fluorogenic substrate in presence of increasing CHDI19500 concentrations. 50% 
inhibition (IC50) was achieved at concentration of 560 nM for SIRT2. Data obtained 










Determination of SIRT1 IC50 value CHDI194500 in an in vitro assay performed by 
Cerep. Reproduced with permission from the CHDI Foundation. 
 
   
     
 























Dose-response curve showing activity of recombinant human SIRT1 towards a 
fluorogenic substrate in presence of increasing CHDI19500 concentrations. 50% 
inhibition (IC50) was achieved at concentration of 530 nM for SIRT1. Data obtained 
from CHDI Foundation in a report dated to 06/08/2009. 
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